Optimization of Surgical Technique by Objective Quantification and Reconstruction of Adipose Tissue Volume

Albaraa Aljerian Department of Experimental Surgery McGill University, Montreal

April 2020

A manuscript-based thesis submitted in partial fulfillment of the requirements of the degree of Master of Science in Experimental Surgery

© Albaraa Aljerian, 2020

Table of Contents

Abstra						
Resun	ne					
Acknowledgments						
Contri	butions7					
Introd	uction					
Comp	lications of Aesthetic Liposuction					
• Abstract						
0	Background12					
0	Methods					
0	Results					
0	Discussion					
0	Conclusion					
0	References					
0	Tables and Figures					
Bridging text						
Complications in Brachioplasty						
0	Abstract					
0	Background					
0	Methods62					
0	Results					
0	Discussion					
0	Conclusion71					
0	References					
0	Tables and Figures76					
Discus	ssion					
Final conclusion and future directions						
References						

Abstract

Background: Adipose tissue plays a vital and continuously expanding role within the field of Plastic and Reconstructive surgery for both cosmetic and reconstructive purposes. Its utilization ranges from simple extraction (i.e. liposuction), to transfer as is the case with tissue flap-based reconstruction and fat grafting. Therefore, the introduction of a standardized and objective quantification method of subcutaneous adipose tissue is of great value. Currently, procedures directed at adipose-tissue manipulation carry a certain degree of subjectivity. Taking liposuction as our primary focus, being a particularly common procedure done worldwide, the primary guide of the surgeon is a tactile sense of the underlying subcutaneous adipose tissue fullness, or lack thereof, as a measure dictating the need to continue or cease aspiration at any given site. A practice commonly resulting in over or under resection (i.e. contour irregularities). We seek to utilize and standardize ultrasound imaging as a quick, inexpensive, safe, reliable and readily available modality to objectively assess subcutaneous adipose tissue volume and distribution. this will serve to potentially decrease certain complications, facilitate preoperative discussion, goal setting and expectations, as well as postoperative confirmation and evaluation of results. Our aim is to equip surgeons with specific measured aims, as well as provide the patient with improved outcomes. As such, we intend on commencing with an elaboration on the rate and consequences of complications in liposuction, and liposuction-associated procedures with an emphasis on contour irregularities.

Methods: In the current phase of the study (current thesis), two systematic reviews and metaanalyses of common complications associated with liposuction and liposuction-associated body contouring procedures were done. The first meta-analysis quantitatively synthesizes complications in liposuction done exclusively, aimed at establishing the rate of contour irregularities, among other complications. The second manuscript extensively reviews and synthesizes complications and revision rates associated with a rapidly expanding liposuctionassociated body contouring procedure, brachioplasty. **Results:** Our effort in recognizing the incidence of complications in these procedures serves as the first quantitative synthesis in the literature. Meta-analysis revealed contour irregularities to be one of the most common complications following liposuction, at a rate of 2%. Contour irregularities were a component and a common cause for reoperation in brachioplasty procedures at an encompassing rate of 7.46%. Other complications and an elaboration on the state of the literature is investigated and elaborated on, as well.

Conclusion: Objective, prompt and safe quantification of adipose tissue has a potentially considerable role to play in the surgeon's armamentarium. The high incidence of contour irregularities and revision rates associated with it establishes the need for stronger efforts to tackle these complications. This novel application of a recognized technology may alleviate certain complications and reoperation rates in specific cohorts, allowing for improved patient care and outcomes. The next phase of the study will address further developing, validating and refining a software and ultrasound protocol, whereby the volume and distribution of subcutaneous adipose tissue can be displayed. We aim to study the software's effects on aiding the reconstructive or aesthetic surgeon in surgical planning, as well as its effects on decreasing the rate of contour irregularities as a predominant complication.

Résumé

Contexte: Le tissu adipeux joue un rôle essentiel dans le domaine de la chirurgie plastique, surtout les chirugie esthétiques et cas reconstructives. La manipulation du tissue graisseuse est impliqué dans le liposuccion simple et durant le transfert des greffes de gras. Par conséquance, l'introduction d'une méthode d'évaluer d'un forme objective du tissu adipeux sous-cutané est necessaire. Actuellement, les procédures visant la manipulation du tissu graisseus comportent un certain degré de subjectivité. Pour la liposuccion, le seul guide du chirurgien est son sens tactile de la degré du tissu adipeux sous-cutané, ou son absence, comme mesure pour decider la nécessité de continuer ou d'arrêter. Sa ve dire q'un chirugien peut enlever sois trop ou pas assez. Nous cherchons à utiliser et à standardiser l'echographie comme une modalité rapide, économique, fiable et facilement disponible pour évaluer objectivement le volume et la distribution du tissu adipeux sous-cutané. Notre objectif est d'équiper les chirurgiens avec des des mesures objectifs spécifiques, ainsi que de assures les patients ont les meilleurs résultats et réduire les complications. Le plan s'agit de revoir dégree de complications de la liposuccion en mettant l'accent sur les irrégularités de contour.

Méthodes: Deux revues systématiques et méta-analyses des complications associées à la liposuccion et aux procédures qui utilise la liposuccion ont été réalisées. La première métaanalyse évalue quantitativement les complications de la liposuccion, en esperant d'établir le prévalance d'irrégularités de contour, ansi que des autres complications. Le deuxième manuscrit examine et évalue en profondeur les complications et nombre de révision associés à une procédure de brachioplastie.

Résultats: Les irrégularités de contour se sont l'une des complications les plus commun après une liposuccion, à 2%. Les irrégularités de contour étaient un composant et une cause fréquente de réintervention dans les procédures de brachioplastie à 7,46%.

Conclusion: Une quantification objective, rapide et facile du tissu adipeux a un rôle à jouer dans l'arsenal du chirurgien. L'incidence élevée des irrégularités de contour et de révision démontre la

nécessité de augmenter les efforts pour adresse ces complications. Cette nouvelle application de l'échographie peut atténuer certaines complications et le risque de réopération, ce qui permet d'améliorer les soins aux patients et les résultats. La prochaine phase de l'étude visera à développer, valider et affiner un logiciel et un protocole d'échographie permettant d'afficher le volume et la distribution du tissu adipeux sous-cutané.

Acknowledgments

I would like to extend my appreciation and gratitude to Dr. Mirko Gilardino and Dr. Thomas Hemmerling for their constant guidance, support and motivation.

I would also like to thank my colleagues in the lab, as well as my co-authors on the respective reviews and meta-analyses for their invaluable work. Finally, the members of the research advisory committee for their time, valuable feedback and support.

Contributions

Albaraa Aljerian: was responsible for the systematic review literature search, data collection, as well as writing and revising the manuscripts. He was responsible for writing and revising the thesis.

Dr. Mirko Gilardino & Dr. Thomas Hemmerling: responsible for supervising and reviewing the manuscripts

Jad Abirafeh: aided in systematic review data collection and manuscript writing.

José Ramirez-GarciaLuna: performed statistical analysis associated with meta-analysis.

Introduction

Adipose tissue plays a vital role in the discipline of plastic and reconstructive surgery. Its utilization ranges from transfer in cases of fat grafting or tissue flap-based reconstruction for the correction of deformities following trauma, congenital defects or oncologic resection, to removal in cases of body contouring procedures (e.g. liposuction)¹⁻³. Due to the subjective nature of perioperative subcutaneous adipose tissue (SAT) assessment (i.e. tactile feedback or a 'pinch test') commonly utilized in the aforementioned procedures, adequate SAT assessment can be flawed, leading to miscalculation, or contour irregularities in the case of liposuction (i.e. under or over resection). As such, the objective quantification of subcutaneous adipose tissue poses a value especially when evaluating appropriate donor sites and performing optimal harvest of the desired amount/layer of the tissue in question, as well as assessment of contour irregularities and facilitation of pre and post-operative patient discussion.

Multiple studies have demonstrated the use of ultrasound to objectively quantify subcutaneous fat depth, and these have been conducted for a variety of reasons, which include correlation with metabolic disease, assessment prior and post cosmetic procedures and to study of the effects of certain diets, disease states or bariatric surgery on abdominal fat distribution⁴. the accuracy of US as compared to other imaging methods (e.g. Computed Tomography) has also been studied, showing US to be accurate and reproducible, without the associated radiation and resources required⁵.

Liposuction, and liposuction-associated body contouring procedures serve as an excellent prospect to study the feasibility and effects of ultrasound-guided evaluation of SAT volume and distribution. Liposuction, specifically, continues to be one of the most popular plastic surgery procedures world-wide, and is overwhelmed with contour irregularities as a prevalent complication². Brachioplasty is an example of a body contouring procedure that commonly employs liposuction and is currently experiencing a dramatic surge in popularity⁶. Yet, a quantitative synthesis of the overall rate of contour irregularities and other complications remains lacking in the literature. Therefore, in our aim to ultimately develop a standardized objective

method of subcutaneous adipose tissue measurement and distribution using ultrasound, we first commence on establishing the incidence of contour irregularities and its detriment in this cohort, effectively shedding light on the need for more robust methods of evaluation.

Complications of Aesthetic Liposuction: A Systematic Review and Meta-Analysis

Author List:

Albaraa Aljerian, MD, MSc^{1,2}, Jad Abi-Rafeh, MSc³, Thomas Hemmerling, MD, MSc,^{2,4}, and Mirko Gilardino, MD, MSc, FACS, FRCSC^{1,2}

- Division of Plastic and Reconstructive Surgery, McGill University, Montreal, Quebec, Canada
- 2) Division of Experimental Surgery, McGill University, Montreal, Quebec, Canada
- 3) Faculty of Medicine, McGill University, Montreal, Quebec, Canada
- 4) Department of Anesthesia, McGill University, Montreal, Quebec, Canada

Corresponding Author:

Mirko S. Gilardino, MD, MSc, FACS, FRCSC

Chief, Division of Plastic and Reconstructive Surgery

Associate Professor of Surgery

McGill University Health Centre

Montreal General Hospital

1650 Cedar Avenue

Montreal, Qc, Canada

H3G 1A4

mirko.gilardino@muhc.mcgill.ca

ABSTRACT

Background: Aesthetic liposuction represents one of the most commonly performed cosmetic procedures worldwide. The purpose of this article is to examine and synthesize reported complication rates and explore the analytical prospect of possible patient or procedure-related predictive factors associated with specific complications.

Methods: A systematic review was performed using the Pubmed, Cochrane and Embase databases in line with specific criteria set to ensure an accurate assessment of complication rates; extracted data was synthesized through a random-effects model and meta-analysis of proportions.

Results: A total of 60 studies were included in the meta-analysis, representing 21,776 patients undergoing aesthetic liposuction. Most studies followed an observational design. The overall complication rate was 12% [95%-CI 8%; 16%]. When stratifying according to specific complications, the incidence of contour irregularities was determined to be 2% [95%-CI 1%;2%], seroma 2% [95%-CI 1%; 2%], hematoma 1% [95%-CI 0%; 1%], surgical site infection 1% [95%-CI 1%; 2%], fibrosis or induration 1% [95%-CI 1%; 2%], and pigmentary changes 1% [95%-CI 1%; 1%], among others. A meta-regression to identify patient- or procedure-related factors associated with greater complication rates proved infeasible given the nature of the available data.

Conclusion: Overall, liposuction demonstrated a relatively low complication rate with contour deformities and seroma formation being the most prevalent; however, a considerable degree of heterogeneity exists within the examined literature preventing the recognition of predictive risk factors. While this calls for efforts to establish consensus on unified methods of outcomes reporting, the present meta-analysis can serve to provide practitioners with an evidence-based reference to improve informed consent and inform clinical guidelines, specifically pertaining to the incidence of commonly encountered complications in aesthetic liposuction, of which presently available survey studies and database queries remain devoid.

Background:

Since Illouz's landmark presentation in 1982 during the American Society of Plastic Surgery meeting, liposuction has experienced a remarkable rise.¹⁻⁴ Today, liposuction represents one of the most commonly performed aesthetic procedures with a 31.9% rise in frequency from 2014, and approximately 1 billion dollars spent annually in United States alone.⁵ Throughout its evolution, suction-lipoplasty has undergone a variety of modifications and additions as newer technologies, knowledge of anatomy, fluid dynamics, instruments, and techniques continue to evolve.⁶

Although generally seen as a relatively benign intervention, the procedure is not without its complications. Multiple publications, each with their respective focus, design, and limitations, have provided unique insight on adverse events associated with liposuction, including a host of minor and major complications, both local and systemic, and procedure-specific or anesthesiarelated.⁷ A database inquiry of 4534 patients undergoing liposuction reported a total complication rate of 1.5%.8 In contrast, a survey study encompassing 1,249 procedures reported on an overall complication rate of 9.3%,⁹ while a retrospective analysis of 655 patients reports on an overall complication rate of 22.3%,¹⁰ with no major complications when liposuction was performed alone. While such large-scale primary studies can shed valuable insight onto the rate of major complications and adverse sequalae encountered in aesthetic liposuction, by nature of study design and publication bias, these efforts may fall short in providing accurate insight onto the rate of common complications frequently encountered in aesthetic surgery practice. The objective of this study is thus to quantify the reported rate of relatively common complications associated with aesthetic liposuction through a meta-analysis of published primary clinical studies, with an emphasis on local cosmetic-related adverse events, and to address any inherent limitations in the evaluated literature which may pose a challenge to this effort.

Methods:

Search strategy:

A systematic review and subsequent meta-analysis was carried out in full accordance with the Cochrane Handbook for Systematic Reviews of Interventions¹¹, as well as the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.¹² The MEDLINE via Pubmed, Embase, and The Cochrane Central Register of Controlled Trials (CENTRAL) databases were queried. The following keywords were used: ("Liposuction" or "suction lipectomy" or "lipoplasty") in combination with ("complications" or "adverse events"). A manual citation search followed through relevant retrieved articles and key journals to supplement the initial protocolized search.

Primary screening was conducted based on title and abstract review, and relevant articles subsequently underwent full-text review. Screening was performed by two independent reviewers. The authors resolved eligibility disagreements by means of consensus. Data extraction was carried out by two reviewers for analysis. Key data, such as study design, nature of intervention, sample size and patient factors, perioperative setting, anesthesia protocol, mean lipoaspirate volume and proportion of patients with outcomes of interest were extracted (i.e. contour irregularities, seroma, hematoma, infection, tissue loss or necrosis, pigmentary changes, as well as other complications in addition to the total number of patients with complications), when available.

Eligibility criteria:

Original primary research articles, including experimental and observational designs, containing patient cohorts that underwent exclusive aesthetic liposuction of anybody site (including liposuction-only breast interventions), utilizing any invasive modality, with sufficient, extractable, unambiguous reporting on complications, published in the English language after the year 2000 were included. Publications were excluded if substantial data was missing, or if the patient cohort underwent liposuction for non-aesthetic purposes, liposuction with co-interventions, or the pooling of outcomes with concomitant procedures was done. Case-reports, reviews, surveys, background and database articles were also excluded, as were publications with less than 1 month of follow-up. If a study contained multiple arms, data from only those

that fit the inclusion criteria was extracted. Cohorts containing patients selected based on a specific outcome were excluded, as were cohorts with less than 10 patients to avoid publication bias and over-reporting on complication rates, respectively (**Table 1**).

Defining complications:

Major complications were aggregated and defined mainly as a systemic adverse event that may potentially be life-threatening or require urgent pharmaceutical or surgical intervention. Included as well were "organ-threatening" complications, for example. direct visceral organ injury, optic neuropathy or named major nerve-sectioning (**Table 2**).

Minor complications were reported on separately, when statistically feasible. These were defined as local adverse events that may or may not require surgical intervention on a non-urgent basis (**Table 2**). Pain, or "recurrence" of the condition was not considered a complication given the subjective nature of this outcome and heterogeneity in reporting strategies employed. Infections were considered minor if they were deemed localized and did not require surgical drainage of an abscess.

Undesirable entry site complications were defined as unsightly scar formation (e.g. hypertrophic or widened scars) or dehiscence of a primarily approximated incision site. Paresthesia was defined as any sensory change (i.e. hypo or hyperalgesia, dysesthesia) of the treated sites, including temporary changes. If complete sensory loss or pain was attributed to a direct nerve injury, this was added to the major complication incidence. Skin loss was defined as tissue necrosis, not due to a thermal injury, that is directly associated with the procedure (i.e. separate from pressure-related ulceration). A designation of overcorrection, as well as asymmetry, were added to the contour irregularity category. Suction-assisted and power-assisted liposuction cohorts were excluded from analysis of thermal injury incidence in order to avoid underestimation of incidence, given that this complication is unique to laser- and ultrasound-assisted liposuction. Infrequent complications were not reported on separately, however, were still included in the calculation of the overall complication rate. The overall complication rate was calculated as the total number of complications (as per the author's criteria) as a weighted proportion of the total number of patients within each cohort.

Statistical analysis

Meta-analyses were performed using the aggregated data. Proportions were calculated as the ratio of the number of affected patients to the total sample size. Proportions are provided with the corresponding 95% confidence intervals (CI). For all studies, a meta-analysis was performed for each outcome. Combined with the inspection of forest plots, the I² index, and the τ^2 statistic were utilized to investigate statistical heterogeneity. Heterogeneity based on the I² statistic was defined as: Low (25%), moderate (50%), and high (75%). Given the high degree of heterogeneity, the authors proceeded with a random-effects model for overall complications with a logit transformation. Studies from which a specific complication rate was not extractable with confidence were excluded from subgroup analysis of that particular outcome. Publication bias was not statistically pursued given the substantial heterogeneity in addition to the design of a meta-analysis of proportions. Meta-analyses and sub-analyses were performed using the R software (The R Project for Statistical Computing, R version 3.2.1).¹³

Results:

A total of 3768 papers were retrieved after the removal of duplicates; 60 papers were included in the final synthesis following abstract and full-text review. An elaboration on the search strategy, as well as the inclusion and exclusion process, is presented in **figure 1**. **Table 3** provides a summary of all primary articles included in the meta-analysis^{6,14-74}. Most studies were of an observational design. Within included cohorts, the majority of procedures utilized either suction-assisted liposuction (SAL) or laser-assisted liposuction (LAL), followed by ultrasound-assisted liposuction (UAL), radiofrequency-assisted liposuction (RFAL), and power-assisted liposuction (PAL). Among studies that provided sufficient procedural and patient demographic data, the overwhelming majority performed low to moderate volume aspiration (<5 L) and female patients constituted the vast majority of included subjects. Twelve studies strictly used general anesthesia (GA) for all patients, while the majority used a combination tumescent anesthesia with or without sedation, and 7 cohorts were variable.

Overall Complications: The rate of total complications (including major and minor complications) was 12% [95%-CI 8%; 16%]. When the incidence of ecchymosis and edema were removed from the analysis, the total rate was reduced to 6% [95%-CI 4%; 8%]. In accordance to the definitions set for the present study, the total major complication rate was 1% [95%-CI 0%; 1%] and the total minor complication rate was 5% [95%-CI 4%; 8%]. (**Table 2**) Forest plots are presented in **Figures 2-4**, and **Supplementary Figure 1**.

Specific complications: The reported rate of ecchymosis was established to be 3% [95%-CI 1%; 7%]; swelling as 2% [95%-CI 1%; 3%], contour irregularity as 2% [95%-CI 1%; 2%]; seroma 1% [95%-CI 1%; 2%]; hematoma 1% [95%-CI 0%; 1%]; surgical site infection 1% [95%-CI 1%; 2%]; and thermal injury as 1% [95%-CI 1%; 2%]. Naturally, no patients in the SAL or PAL groups suffered any thermal injury, in contrast to 7 out of 2809 patients in the LAL group (0.25%), 22 out of 4092 in the UAL group (0.54%), 4 out of 250 patients in the RFAL (1.6%) affected. Pigmentary changes occurred at a rate of 1% [95%-CI 1%; 1%], with no incidence in the RFAL treatment group. Paresthesia occurred at rate of 1% [95%-CI 0%; 2%]; fibrosis, nodularity and induration at 1% [95%-CI 1%; 2%]; skin loss at 1% [95%-CI 1%; 2%]; and

undesirable entry site complication at 1%, as per the definition established in the current study [95%-CI 1%; 1%] (**Supplementary Figures 2-13**; **table 4**). No deaths were reported; 1 case of thrombophlebitis was acknowledged with no embolic event.⁷⁴ Other infrequent complications not included in specific outcome analysis are summarized in **table 5**.

Discussion:

This study seeks to provide further insight into the complication profile associated with aesthetic liposuction and aid clinicians in providing full disclosure within the spirit of informed consent, as well as explore the present state of the literature to identify procedure- and patient-specific factors associated with higher complications. Given the high degree of heterogeneity identified, the results of this meta-analysis should be interpreted in consideration of complication rates established in previous reports, all the while acknowledging the contrast between authors and centers, and potential subjectivity as to what constitutes a complication, as opposed to an undesirable aesthetic result, or an inevitable consequence of the operation (in the case of ecchymosis or edema, for example).

As alluded to by Matarasso¹, the lack of a central registry impairs exact reporting on complications associated with liposuction. Indeed, the published complication rate of certain adverse events may display a dramatic variability⁸. Nevertheless, the underlying factor common to many published cohorts, is that liposuction tends to be a safe procedure when performed by trained hands^{10,75}. In a database inquiry of 4534 patients who underwent liposuction, Chow et al. reported a total complication rate of 1.5%.⁸ Contrasted to 9.3% in a survey encompassing 1,249 procedures,⁹ to 22.3% in a retrospective analysis¹⁰ of 655 patients, with no major complications when liposuction was performed alone. The results of this study, including major, minor and overall complications are within range of reported rates in the literature.

As noted, the exclusion of edema and ecchymosis from aggregated analyses stems from the nature of included data; while some authors may mention that *all* patients experienced some degree of edema or bruising, culminating in 100% "complication rate", others may disregard these as being an inevitable consequence of the operation, and not a complication per se (unless severe enough or persistent beyond a certain subjective limit). Thereby, the inclusion or exclusion of these complications may effectively inflate, or deflate the results, respectively, depending on the surgeon's point of view. The rate of complications associated with the different liposuction modalities was not included given the notable difference in the number of studies and patients related to each group, precluding reliable interpretation.

Contour irregularities have been cited as the most common complication in suction lipectomy^{76,77}. In a large database study, Matarasso et al.⁷⁷ demonstrated a 9.2% rate of irregularities, while another large survey study maintained a rate of 0.26%⁷⁸. Cardenas-Camarena¹⁰ reported a palpable irregularity rate of 7.36% and a visible irregularity rate of 3.25% (although some patients within the cohort underwent concomitant abdominoplasty).

In a commonly cited survey, Pitman and Teimourian⁹ reported results of 612 plastic surgeons (1249 liposuction procedures) with the following rates: hypoesthesia (2.6%), seroma (1.6%), edema (1.4%), pigmentation (1%), hematoma (0.8%), infection (0.6%), and skin slough (0.2%). The previously mentioned rates are by no means an exhaustive coverage of all published figures. They do, however, serve to demonstrate the tangible discrepancy within the literature, as well as the fact that although subject to heterogeneity, the results of this study are not anomalous. Finally, it remains pertinent to consider that while these complications are reported on in terms of prevalence, the severity of these complications, measures necessary for their rectification, and their financial burden, in addition to patient-specific perception of these complications and their detriment on patient satisfaction and quality of life were all not taken into account. These factors remain essential aspects to consider alongside the incidence data presented in order to adequately assess the risk-benefit profile of this procedure on a patient-by-patient basis.

Limitations

In order to appreciate and adequately infer the results of this study, a thorough elaboration of its limitations should be noted. The inclusion and exclusion criteria chosen will undoubtedly introduce bias, such as limiting results to the English language, for example. Due to the set limitation on follow-up time (as the primary aim of the study was to look for aesthetic and local outcomes), some cohorts were excluded, effectively eliminating certain studies with shorter follow-up which may have provided more complete insight on intraoperative or immediate post-operative outcomes such as blood loss, need for transfusion, metabolic derangements, anesthetic-related events or immediate postoperative pain, for example.

The current state of literature on this specific topic, with a relative lack of randomized-controlled trails (RCTs) and a general dominance of lower quality studies dictates the quality of evidence

and nature of pooled analysis characteristics. Given the type of desired outcome, namely complications, and the relative deficiency in experimental designs in this domain, it was not feasible to restrict study designs to RCTs alone, or even case-control designs. A substantial portion of our data set was retrieved from retrospective or prospective cohorts and case series, which, by design, are better-equipped to capture the incidence of complications among a patient population. However, these studies tend to carry biases inherent to their designs (e.g. under-reporting or information bias, publication bias), besides the frequent occurrence of incomplete data. In fact, multiple cohorts were excluded due to incomplete date, but could have been included should further (presumably readily available) data would have been provided. While this provision may not necessary pertain to the corresponding research question or study objective at hand, generally speaking, this might be beneficial to other researchers in improving the synthesis of data.

The decision to exclude case reports rests within the fact that these, albeit valuable in providing insight into rare, possibly catastrophic events, cannot be used to estimate proportional data. The detriment, however, is that rare adverse events: massive infections, visceral perforation, anesthetic complications and fatalities, among others, will be invariably missed or understated. This accentuates the importance of interpreting the findings of the present study in consideration of data provided by previous reports using different strategies, such as database queries or large-scale surveys, which may better-capture these complications. On the other hand, owing to the method of calculation of proportions with the available data, a certain amount of inflation will likely occur, considering that while some patients will have more than one complication, the total number of complications was still calculated out of a proportion of the total sample size. Surveys and database studies were excluded to limit duplication, and subsequent overstating, of complication rate, which again was detrimental to the major complication rate.

Studies conducted prior to the year 2000 were excluded; the rationale being an attempt to add a sense of homogeneity given the differences in techniques, instruments, technologies, and operative protocols that have evolved and changed over the years. Yet the authors recognize that although some studies were published after the year 2000, multiple included cohorts did in fact encompass patients that underwent surgery as far back as 1994.

The main challenge faced in the present study was the inconsistency pertaining to what constitutes a true complication according to the primary articles assessed. While some authors might mention a detailed summary of undesirable outcomes and proportions of which, others would acknowledge the presence of adverse events with broad, non-specific descriptions. Data from latter cases was avoided. Moreover, some may consider a complication exclusively as an undesirable outcome that requires a corrective intervention, operative or otherwise. Some publications did not provide numeric, prevalence data concerning specific complications, rather, provided measures of central tendency concerning visual analogue or Likert scales. Data from these studies was not considered since no insight on incidence could be provided for the meta-analysis.

Finally, the authors acknowledge the heterogeneity pertaining to within-cohort and betweencohort differences in patient characteristics (e.g. age, body mass index, gender or race), perioperative protocols (e.g. anesthetic medications and techniques, warming, antibiotics, chemical or mechanical venous thromboembolism prophylaxis), intraoperative technique or site involved (e.g. breast vs abdomen) and amount of aspirate (low-volume vs. high-volume), employed modality of ultrasound, settings of which (hospital or private practice), in addition to instruments as well as differences in the amount and constituents of wetting solutions. All of which coalesce, culminating in a state of heterogeneity that cannot be ignored when interpreting the results of this study; a variability that has been elaborated on by other authors as well.⁷⁹Due to these limitations, the authors were unable to confidently proceed with a meta-regression to explore possible predictive factors of certain or overall complications such as the amount of aspirated fat, type of anesthesia, facility, modality of liposuction or specific patient demographics, among others.

Conclusion:

In experienced hands, liposuction continues to be a safe aesthetic procedure; the overall complication rate was determined to be 12% in the present study by means of a meta-analysis of primary clinical studies. Special attention to full-disclosure in operative consent is paramount for maintaining a solid physician-patient relationship and to appropriately manage patient expectations. Plastic surgeons should continue to probe the most recent evidence and employ appropriate judgment regarding patient selection, operative protocols, and technologies. Substantial heterogeneity in outcome reporting for liposuction exists which may impair reliable data synthesis. Although not always feasible, further large-scale, robust, and collaborative efforts are needed to clearly define and establish complication rates, as well as predisposing patient- and procedure-specific factors, which may require further attention in order to continue improving the safety profile of this procedure.

References

1. Matarasso A, Hutchinson OH. Liposuction. JAMA. 2001;285(3):266-268.

2. Illouz YG. History and current concepts of lipoplasty. Clin Plast Surg. 1996;23(4):721-730.

3. Lewis CM. Early history of lipoplasty in the United States. *Aesthetic Plast Surg*. 1990;14(2):123-126.

4. Teimourian B, Adham MN. A national survey of complications associated with suction lipectomy: what we did then and what we do now. *Plast Reconstr Surg.* 2000;105(5):1881-1884.

5. https://www.surgery.org/media/news-releases/the-american-society-for-aesthetic-plasticsurgery-reports-americans-spent-largest-amount-on-cosmetic-surger. Accessed June, 2019. ASfAPSAsocsAa.

 Stephan PJ, Kenkel JM. Updates and advances in liposuction. *Aesthet Surg J.* 2010;30(1):83-97; quiz 98-100.

7. Chia CT, Neinstein RM, Theodorou SJ. Evidence-Based Medicine: Liposuction. *Plast Reconstr Surg.* 2017;139(1):267e-274e.

8. Chow I, Alghoul MS, Khavanin N, et al. Is There a Safe Lipoaspirate Volume? A Risk Assessment Model of Liposuction Volume as a Function of Body Mass Index. *Plast Reconstr Surg.* 2015;136(3):474-483.

9. Pitman GH, Teimourian B. Suction lipectomy: complications and results by survey. *Plast Reconstr Surg.* 1985;76(1):65-72.

10. Cardenas-Camarena L. Lipoaspiration and its complications: a safe operation. *Plast Reconstr Surg.* 2003;112(5):1435-1441; discussion 1442-1433.

11. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: *The Cochrane Collaboration*.2011: <u>www.handbook.cochrane.org</u>.

12. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4:1.

13. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing V, Austria. URL <u>http://www.R-project.org/</u>.

14. Alexiades-Armenakas M. Combination laser-assisted liposuction and minimally invasive skin tightening with temperature feedback for treatment of the submentum and neck.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 2012;38(6):871-881.

15. Blugerman G, Schavelzon D, Paul MD. A safety and feasibility study of a novel radiofrequency-assisted liposuction technique. *Plast Reconstr Surg.* 2010;125(3):998-1006.

16. Boeni R. Safety of tumescent liposuction under local anesthesia in a series of 4,380 patients. *Dermatology (Basel, Switzerland)*. 2011;222(3):278-281.

17. Boni R. Tumescent power liposuction in the treatment of the enlarged male breast. *Dermatology (Basel, Switzerland).* 2006;213(2):140-143.

18. Branas EB, Moraga JM. Laser lipolysis using a 924- and 975-nm laser diode in the lower extremities. *Aesthetic Plast Surg.* 2013;37(2):246-253.

 Chia CT, Theodorou SJ. 1,000 consecutive cases of laser-assisted liposuction and suctionassisted lipectomy managed with local anesthesia. *Aesthetic Plast Surg.* 2012;36(4):795-802.
 Cohen SR, Weiss ET, Brightman LA, et al. Quantitation of the results of abdominal liposuction. *Aesthet Surg J.* 2012;32(5):593-600.

21. Commons GW, Halperin B, Chang CC. Large-volume liposuction: a review of 631 consecutive cases over 12 years. *Plast Reconstr Surg.* 2001;108(6):1753-1763; discussion 1764-1757.

22. Duncan DI. Improving outcomes in upper arm liposuction: adding radiofrequency-assisted liposuction to induce skin contraction. *Aesthet Surg J.* 2012;32(1):84-95.

23. Fulton Jr JE, Rahimi AD, Abuzeni P. Breast reduction with tumescent liposuction. *The American Journal of Cosmetic Surgery*. 2001;18(1):15-20.

24. Giugliano G, Nicoletti G, Grella E, et al. Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. *British journal of plastic surgery*.
2004;57(3):190-194.

25. Goldman A. Submental Nd:Yag laser-assisted liposuction. *Lasers in surgery and medicine*. 2006;38(3):181-184.

26. Habbema L. Breast reduction using liposuction with tumescent local anesthesia and powered cannulas. *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]*. 2009;35(1):41-50; discussion 50-42.

27. Habbema L. Safety of liposuction using exclusively tumescent local anesthesia in 3,240 consecutive cases. *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]*. 2009;35(11):1728-1735.

28. Hodgson EL, Fruhstorfer BH, Malata CM. Ultrasonic liposuction in the treatment of gynecomastia. *Plast Reconstr Surg.* 2005;116(2):646-653; discussion 654-645.

29. Hong YG, Sim HB, Lee MY, et al. Three-dimensional circumferential liposuction of the overweight or obese upper arm. *Aesthetic Plast Surg.* 2012;36(3):497-503.

30. Hurwitz D, Smith D. Treatment of overweight patients by radiofrequency-assisted liposuction (RFAL) for aesthetic reshaping and skin tightening. *Aesthetic Plast Surg.* 2012;36(1):62-71.

31. Innocenti A, Andretto Amodeo C, Ciancio F. Wide-undermining neck liposuction: tips and tricks for good results. *Aesthetic Plast Surg.* 2014;38(4):662-669.

32. Ion L, Raveendran SS, Fu B. Body-contouring with radiofrequency-assisted liposuction. *Journal of plastic surgery and hand surgery*. 2011;45(6):286-293.

33. Irvine Duncan D. Nonexcisional tissue tightening: creating skin surface area reduction during abdominal liposuction by adding radiofrequency heating. *Aesthet Surg J.* 2013;33(8):1154-1166.

34. Jacob CI, Berkes BJ, Kaminer MS. Liposuction and surgical recontouring of the neck: a retrospective analysis. *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]*. 2000;26(7):625-632.

35. Katz B, McBean J. Laser-assisted lipolysis: a report on complications. *Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.* 2008;10(4):231-233.

36. Katz BE, Bruck MC, Felsenfeld L, Frew KE. Power liposuction: a report on complications. *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]*. 2003;29(9):925-927; discussion 927.

37. Keramidas E, Rodopoulou S. Radiofrequency-assisted Liposuction for Neck and Lower Face Adipodermal Remodeling and Contouring. *Plastic and reconstructive surgery Global open*.
2016;4(8):e850.

38. Kim YH, Cha SM, Naidu S, Hwang WJ. Analysis of postoperative complications for superficial liposuction: a review of 2398 cases. *Plast Reconstr Surg.* 2011;127(2):863-871.

39. Leclere FM, Alcolea JM, Vogt P, et al. Laser-assisted lipolysis for arm contouring in Teimourian grades I and II: a prospective study of 45 patients. *Lasers in medical science*. 2015;30(3):1053-1059.

40. Leclère FM, Alcolea JM, Vogt PM, et al. Laser-assisted lipolysis for arm contouring in Teimourian grades III and IV: a prospective study involving 22 patients. *Plastic Surgery*. 2016;24(1):35-40.

41. Leclere FM, Moreno-Moraga J, Alcolea JM, et al. Laser assisted lipolysis for neck and submental remodeling in Rohrich type I to III aging neck: a prospective study in 30 patients. *Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology*. 2014;16(6):284-289.

42. Leclere FM, Moreno-Moraga J, Mordon S, et al. Laser-assisted lipolysis for cankle remodelling: a prospective study in 30 patients. *Lasers in medical science*. 2014;29(1):131-136.
43. Leclere FM, Trelles M, Moreno-Moraga J, Servell P, Unglaub F, Mordon SR. 980-nm laser lipolysis (LAL): About 674 procedures in 359 patients. *Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology*. 2012;14(2):67-73.

44. Leclere FM, Vogt PM, Moreno-Moraga J, et al. Laser-assisted lipolysis for neck and submental remodeling in Rohrich type IV patients: fact or fiction? *Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology*. 2015;17(1):31-36.
45. Licata G, Agostini T, Fanelli G, et al. Lipolysis using a new 1540-nm diode laser: a retrospective analysis of 230 consecutive procedures. *Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology*. 2013;15(4):184-192.
46. McBean JC, Katz BE. A pilot study of the efficacy of a 1,064 and 1,320 nm sequentially firing Nd:YAG laser device for lipolysis and skin tightening. *Lasers in surgery and medicine*.

2009;41(10):779-784.

47. Mellul SD, Dryden RM, Remigio DJ, Wulc AE. Breast reduction performed by liposuction. *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]*. 2006;32(9):1124-1133.

48. Moreno-Moraga J, Trelles MA, Mordon S, et al. Laser-assisted lipolysis for knee remodelling: a prospective study in 30 patients. *Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology*. 2012;14(2):59-66.

49. Moskovitz MJ, Baxt SA, Jain AK, Hausman RE. Liposuction breast reduction: a prospective trial in African American women. *Plast Reconstr Surg.* 2007;119(2):718-726; discussion 727-718.

50. Omranifard M. Ultrasonic liposuction versus surgical lipectomy. *Aesthetic Plast Surg.* 2003;27(2):143-145.

51. Paul M, Blugerman G, Kreindel M, Mulholland RS. Three-dimensional radiofrequency tissue tightening: a proposed mechanism and applications for body contouring. *Aesthetic Plast Surg.* 2011;35(1):87-95.

52. Paul M, Mulholland RS. A new approach for adipose tissue treatment and body contouring using radiofrequency-assisted liposuction. *Aesthetic Plast Surg.* 2009;33(5):687-694.

53. Perez JA, van Tetering JP. Ultrasound-assisted lipoplasty: a review of over 350 consecutive cases using a two-stage technique. *Aesthetic Plast Surg.* 2003;27(1):68-76.

54. Petty PM, Solomon M, Buchel EW, Tran NV. Gynecomastia: evolving paradigm of management and comparison of techniques. *Plast Reconstr Surg.* 2010;125(5):1301-1308.

55. Reynaud JP, Skibinski M, Wassmer B, Rochon P, Mordon S. Lipolysis using a 980-nm diode laser: a retrospective analysis of 534 procedures. *Aesthetic Plast Surg.* 2009;33(1):28-36.

56. Roland B. Safety of liposuction of the neck using tumescent local anesthesia: experience in 320 cases. *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]*. 2012;38(11):1812-1815.

57. Roustaei N, Masoumi Lari SJ, Chalian M, Chalian H, Bakhshandeh H. Safety of ultrasoundassisted liposuction: a survey of 660 operations. *Aesthetic Plast Surg.* 2009;33(2):213-218.

58. Saariniemi KM, Salmi AM, Peltoniemi HH, Charpentier P, Kuokkanen HO. Does

Liposuction Improve Body Image and Symptoms of Eating Disorders? *Plastic and reconstructive surgery Global open.* 2015;3(7):e461.

59. Sadove R. New observations in liposuction-only breast reduction. *Aesthetic Plast Surg.* 2005;29(1):28-31.

60. Saleh Y, El-Oteify M, Abd-El-Salam AE, Tohamy A, Abd-Elsayed AA. Safety and benefits of large-volume liposuction: a single center experience. *International archives of medicine*. 2009;2(1):4.

61. Sasaki GH. Early clinical experience with the 1440-nm wavelength internal pulsed laser in facial rejuvenation: two-year follow-up. *Clin Plast Surg.* 2012;39(4):409-417.

62. Scuderi N, Paolini G, Grippaudo FR, Tenna S. Comparative evaluation of traditional, ultrasonic, and pneumatic assisted lipoplasty: analysis of local and systemic effects, efficacy, and costs of these methods. *Aesthetic Plast Surg.* 2000;24(6):395-400.

63. Song YN, Wang YB, Huang R, et al. Surgical treatment of gynecomastia: mastectomy compared to liposuction technique. *Annals of plastic surgery*. 2014;73(3):275-278.

64. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283(15):2008-2012.

65. Sun Y, Wu SF, Yan S, Shi HY, Chen D, Chen Y. Laser lipolysis used to treat localized adiposis: a preliminary report on experience with Asian patients. *Aesthetic Plast Surg.* 2009;33(5):701-705.

66. Swanson E. Prospective clinical study of 551 cases of liposuction and abdominoplasty performed individually and in combination. *Plastic and reconstructive surgery Global open*. 2013;1(5):e32.

67. Theodorou S, Chia C. Radiofrequency-assisted Liposuction for Arm Contouring: Technique under Local Anesthesia. *Plastic and reconstructive surgery Global open*. 2013;1(5):e37.
68. Trelles MA, Mordon SR, Bonanad E, et al. Laser-assisted lipolysis in the treatment of gynecomastia: a prospective study in 28 patients. *Lasers in medical science*. 2013;28(2):375-382.
69. Valizadeh N, Jalaly NY, Zarghampour M, Barikbin B, Haghighatkhah HR. Evaluation of safety and efficacy of 980-nm diode laser-assisted lipolysis versus traditional liposuction for submental rejuvenation: A randomized clinical trial. *Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology*. 2016;18(1):41-45.

70. Walden JL, Schmid RP, Blackwell SJ. Cross-chest lipoplasty and surgical excision for gynecomastia: a 10-year experience. *Aesthet Surg J.* 2004;24(3):216-223.

71. Wall SH, Jr., Lee MR. Separation, Aspiration, and Fat Equalization: SAFE Liposuction Concepts for Comprehensive Body Contouring. *Plast Reconstr Surg.* 2016;138(6):1192-1201.
72. Wang G, Cao WG, Zhao TL. Fluid management in extensive liposuction: A retrospective review of 83 consecutive patients. *Medicine.* 2018;97(41):e12655.

73. Zhang YX, Lazzeri D, Grassetti L, et al. Three-dimensional Superficial Liposculpture of the Hips, Flank, and Thighs. *Plastic and reconstructive surgery Global open*. 2015;3(1):e291.

74. Zoccali G, Orsini G, Scandura S, Cifone MG, Giuliani M. Multifrequency ultrasound-assisted liposuction: 5 years of experience. *Aesthetic Plast Surg.* 2012;36(5):1052-1061.
75. Rohrich RJ, Beran SJ. Is liposuction safe? *Plast Reconstr Surg.* 1999;104(3):819-822.
76. Ahmad J, Eaves FF, 3rd, Rohrich RJ, Kenkel JM. The American Society for Aesthetic Plastic Surgery (ASAPS) survey: current trends in liposuction. *Aesthet Surg J.* 2011;31(2):214-224.
77. Matarasso A, Swift RW, Rankin M. Abdominoplasty and abdominal contour surgery: a national plastic surgery survey. *Plast Reconstr Surg.* 2006;117(6):1797-1808.
78. Hanke CW, Bernstein G, Bullock S. Safety of tumescent liposuction in 15,336 patients.

National survey results. *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]*. 1995;21(5):459-462.

79. Guest RA, Amar D, Czerniak S, et al. Heterogeneity in Body Contouring Outcomes Based Research: The Pittsburgh Body Contouring Complication Reporting System. *Aesthet Surg J*. 2017;38(1):60-70.

Tables and Figures

Table 1 – Summary of inclusion and exclusion criteria for the systematic review and meta-analysis are presented herein.

Inclusion Criteria	Exclusion Criteria
Primary cohorts undergoing aesthetic	Case reports, database or survey inquiries,
liposuction (human subjects) only	and reviews
English language publications	Concomitant procedures performed
Publications in or following the year 2000	Pooled outcomes (with proportion of cohort
	undergoing non-liposuction procedures)
Sample size n=10 or larger	Studies prior to year 2000, or non-English
	Publications
Any invasive liposuction modality	Less than 1-month follow-up
Sufficient proportional data	Ambiguous data (incomplete, non-specific
	reporting)

Table 2 – Classification of complications, as either major or minor, is presented. Major complications were defined mainly as a systemic adverse event, potentially life-threatening or requiring urgent pharmaceutical or surgical intervention. Minor complications were defined as local adverse events, which may or may not require surgical intervention on a non-urgent basis. Pain, or "recurrence" of the condition was not considered a complication given the subjective nature of this outcome and heterogeneity in reporting strategies employed. Infections were considered minor if they were deemed localized and did not require surgical drainage of an abscess. A designation of overcorrection, as well as asymmetry was added to the contour irregularity category. Undesirable entry site complications site. Paresthesia was defined as any sensory change of the treated sites, including temporary changes. If complete sensory loss or pain was attributed to a direct nerve injury, this was considered a major complication. Skin loss was defined as tissue necrosis, not due to a thermal injury, that is directly associated with the procedure (i.e. separate from pressure-related ulceration).

Minor Complications	Major Complications
Contour irregularities (including over-	Overwhelming infection (e.g. sepsis,
resection, asymmetry)	Necrotizing fasciitis or toxic shock syndrome)
	or abscess formation
Seroma	Anesthesia related (cardiopulmonary or
	airway complications) including local
	anesthesia-related toxicity
Hematoma	Tumescent fluid-related fluid or electrolyte
	imbalance
Localized infection	Visceral structure or vital organ injury
	(including major nerve injury or
	inflammation)
Thermal injury	Deep venous thrombosis or embolism
Ecchymosis or Bruising	Significant Hypovolemia or Hypotension
Edema or swelling	Other embolic events (i.e. fat or microscopic
	fat embolism syndrome)

Pigmentary changes	Disseminated intravascular coagulation (DIC)
	or major hemorrhage
Entry site complications (aberrant scarring or	Pulmonary (including Pneumonia, and
dehiscence)	Pulmonary edema), cardiac or renal problems
Sensory changes	Hospital re-admission or emergency room
	visits
Minor allergic reactions	Death
Garment-related complications (e.g. ulcers)	-

Table 3 – Synthesis of studies and outline of study characteristics which met the inclusioncriteria for the meta-analysis.

Author	Year	Study Design	Country of	n	Type of	Sito
Author			Origin		liposuction	Site
Katz &	2008	Retrospective	USA	537	LAL	Not Specified
McBean ³⁵		Chart Review				
		Prospective			SAL vs.	
Duncan ²²	2012	Randomized	USA	12	SAL +	Abdomen
		Controlled trial			RFAL	
Giugliano et		Prospective				Variable:
	2004	Comparativa	Italy	60	SAL	Abdomen, Hips,
al.		Comparative			Thighs	
Roland ⁵⁶	2012	Prospective	Switzerland	320	SAL	Neck and Other
Kolanu	2012	Series				Sites
						Variable: Neck,
	2011	Prospective Series	Switzerland	4380	SAL	Arms, Female
Boeni ¹⁶						Breast, Abdomen,
Doom						Flanks, Back,
						Buttocks, Lower
						Extremity
	2016			18	LAL	Submental Region

Author	Year	Study Design	Country of	n	Type of liposuction	Site
Author			Origin			
Valizadeh et		Randomized	Iran	18	SAL	
al. ⁶⁹		Clinical Trial		10	SAL	
Keramidas &	2016	Prospective	Graaa	55	DEAI	Neck and Lower
Rodopoulou ³⁷	2010	Series	Uleece	55	N ^T A L	Face (Jowls)
Leclère et	2015	Prospective	Spain	10	TAT	Submental Region
al. ⁴⁴	2013	Series	Span	10		Submental Region
Hurwitz &	2012	Prospective	USA	17	DEVI	Variable: Arms,
Smith ³⁰	2012	Series	USA	1/	KFAL	Abdomen, Thighs
Moskovitz et	2007	Prospective	USA	20	ITAI	Female Breast
al. ⁴⁹	2007	Series	USA	20	UAL	Temale Dreast
Cohen et al ²⁰	2012	Prospective	USA	23	SAL	Abdomen
Conch et al.	2012	Series	USA	23	51 YL	
Habberna ²⁶	2009	Prospective	Netherlands	151	PAL	Female Breast
muooomu	2007	Series				
Boni ¹⁷	2006	Prospective	Switzerland	38	PAL	Male Breast
2011		Series				
						Variable: Face,
	2016	Retrospective Chart Review	USA	129	PAL	Neck, Upper
Wall & Lee ⁷¹						Extremity, Chest,
						Lower Extremity,
						Abdomen, Flanks
						Variable: Neck,
		Prospective Series			LAL	Upper Extremity,
Chia &						Male Breast,
Theodorou ¹⁹	2012		USA	581		Abdomen, Flanks,
						Back, Pubic
						Region, Lower
						Extremity

Author	Year	Study Design	Country of Origin	n	Type of liposuction	Site
Iacob et al ³⁴	2000	Retrospective	USA	20	SAL	Neck
Jucob et ul.	2000	Chart Review	OBR	20	57112	IVEEK
				682	PAL	
		Retrospective		884	PAL +	Variable;
Kim et al. ³⁸	2011	Chart Review	Korea		UAL	Not Specified in
				832	PAL +	Detail
					UAL	
Commons et		Retrospective		514	SAL	Variable;
al. ²¹	2001	Chart Review	USA	117	UAL	Not Specified in
						Detail
		Cross-				
Omranifard ⁵⁰	2003	Sectional	Iran	20	UAL	Abdomen
		Study				
						Variable: Neck,
		Retrospective Chart Review	Netherlands		SAL	Upper Extremity,
				3240		Male and Female
Habbema ²⁷	2009					Breast, Abdomen,
						Flanks, Back,
						Buttocks, Lower
						Extremity
						Variable:
Wang et al. ⁷²	2018	Retrospective Chart Review	China	83	SAL	Abdomen, Waist,
0.000						Flanks, Back,
						Lower Extremity
						Variable:
Roustaei et	2009	Prospective Series	Iran	609	UAL	Abdomen, Back,
al. ⁵⁷						Buttocks, Breast,
						Upper Extremity,
						Lower Extremity

Author	Vear	Study Design	Country of	n	Type of	Site	
Tution	I cui	Study Design	Origin		liposuction	Site	
Blugerman et	2010	Prospective	Argentina	23	REAL	Variable:	
al. ¹⁵	2010	Series	7 fi gentina	23		Abdomen, Hips	
		Retrospective				Variable;	
Katz et al. ³⁶	2003	Chart Review	USA	207	PAL	Not Specified in	
		Chart Review				Detail	
Innocenti et	2014	Retrospective	Italy	118	SAL	Neck	
al. ³¹	2014	Chart Review	Italy	110	SAL	INCCK	
						Variable: Chest,	
						Breast, Chin,	
Zoccali et	2012	Prospective	Italy	707	TIAT	Abdomen, Flanks,	
al. ⁷⁴	2012	Series	Italy	191	UAL	Hips, Gluteal,	
						Upper Extremity,	
						Lower Extremity	
						Variable:	
Perez &	2003	Retrospective	USA &	351	TIAT	Abdomen, Flank,	
Tetering ⁵³	2003	Chart Review	Netherlands	551	UAL	Back, Lower	
						Extremity, Face	
Mellul et al. ⁴⁷	2006	Case Series	USA	14	SAL	Female Breast	
		Prospective				Variable: Waist,	
Saleh et al. ⁶⁰	2009	Series	Egypt	60	SAL	Hips, Buttocks,	
						Lower Extremity	
		Retrospective				Variable: Hips,	
Zhang et al. ⁷³	2015	Chart Review Ch	China	4000	SAL	Flanks, Lower	
						Extremity	
Goldman ²⁵	2006	Prospective	Brazil	82	LAL	Submental Region	
	2000	Series					
Trelles et	2013	Prospective	France	28	LAL	Male Breast	
al. ⁶⁸	2010	Series	- 141100				
Author	Author Vear		Country of	Country of Type of		Site	
--------------------------	-------------	---------------	----------------	--------------------	-------------	---------------------	--
¹ uunoi	I Cal	Study Design	Origin		liposuction	Site	
Branas &	2013	Retrospective	Spain	330	LAL	Variable: Lower	
Moraga ¹⁸	2015	Chart Review	Span	100	SAL	Extremity, Hip	
		Prospective,		15	SAL		
Scuderi et	2000	Randomized	Itoly	15	UAL	Lower Extremity	
al. ⁶²	2000	Comparative	Italy	15	DAI	Lower Extremity	
		Series		13	PAL		
McBean &	2000	Prospective		20	TAT	Variable; Not	
Katz ⁴⁶	2009	Series	USA	20	LAL	Specified in Detail	
Hodgson et	2005	Retrospective	United	12	ITAT	Mala Proast	
al. ²⁸	2003	Chart Review	Kingdom 13 UAL		UAL	Male Dreast	
Leclère et	2014	Prospective	Franco	20	TAT	Neck and	
al. ⁴¹	2014	Series	Flance		LAL	Submental Region	
Leclère et	2014	Prospective	France			Lower Extremity	
al. ⁴²	2014	Series	Trance 50			Lower Extremity	
Walden et	2004	Retrospective	USA	12	SAT	Male Breast	
al. ⁷⁰	2004	Chart Review	0.5/1	12	SILL	Wate Dreast	
Theodorou &	2013	Prospective	USA	40	RFAI	Unner Extremity	
Chia ⁶⁷	2015	Series	0.011			oppor Extremity	
						Variable: Face,	
						Neck, Mental	
Sun et al. ⁶⁵	2009	Case series	China	35	LAL	Region, Upper	
						Extremity,	
						Abdomen	
						Variable: Chin,	
Reynaud et	2009	Retrospective	France	224	TAT	Abdomen, Hips,	
al. ⁵⁵	2007	Chart Review	1 101100	554		Flanks, Back,	
						Buttocks, Upper	

Author	Author Voor		Country of Type of			Sito	
Author	I Cal	Study Design	Origin	11	liposuction	Site	
						Extremity, Lower	
						Extremity	
Fulton et al. ²³	2001	Case Series	USA	15	SAL	Female Breast	
Moreno-		Prospective					
Moraga et	2012	Sorias	France	30	LAL	Lower Extremity	
al. ⁴⁸		Selles					
Saariniemi et		Prospective				Variable:	
al ⁵⁸	2015	Series	Finland	61	WJAL	Abdomen and	
<i>a</i> 1.		Series				Thigh	
Swanson ⁶⁶	2013	Prospective	LISA	ISA 384 I		Variable; Not	
Swanson	2015	Series	501	504	UAL	Specified in Detail	
Leclère et	2015	Prospective	Spain	45	TAT	Unner Extremity	
al. ³⁹	2013	Series	Span	7.7		Opper Extremity	
Sadove ⁵⁹	2005	Retrospective	Israel	25	SAT	Female Breast	
Sadove	2005	Chart Review	Israel 25 SAL Female Bre			Temale Dreast	
Sasaki ⁶¹	2012	Prospective	LISΔ	19	ΤΔΙ	Midface and Neck	
Sasaki	2012	Series	USA 19 LAL Midface		Whenace and Iveek		
Hong et al ²⁹	2012	Prospective	Korea	57	LAL	Unner Extremity	
filong et ui.	2012	Series	itorea	57		oppor Extremity	
Paul et al ⁵¹	2011	Prospective	USA	24	RFAL	Variable:	
i aui et ai.	2011	Series	0.571	27		Abdomen, Hips	
Duncan ²²	2012	Prospective	USA	11	RFAL	Unner Extremity	
Duncan	2012	Series	0.571	11		opper Extremity	
						Variable:	
Lop at $a1^{32}$ 201		Case Series	United	42	RFAL	Abdomen, Flanks,	
	2011		Kingdom			Cervicodorsal,	
						Breast	

Author	Vear	Study Design	Country of	Type of		Site	
Aution	1 Cal	Study Design	Origin		liposuction	Site	
						Variable: Hips,	
Doul &						Abdomen, Flanks,	
Faul & Mulhalland ⁵²	2009	Case Series	USA	20	RFAL	Male Breast,	
Wumonanu						Upper Extremity,	
						Lower Extremity	
Song at al 63	2014	Retrospective	China	221	SAL &	Mala Prosst	
Song et al.	2014	Chart Review	Ciiiia	551	UAL	Wale Diedst	
Petty et al ⁵⁴	2010	Retrospective	LISΔ	50	ITAI	Male Breast	
T only of al.	2010	Chart Review	0.571	50	OTTL	Whate Dreast	
						Variable: Neck,	
		Retrospective				Flanks, Hips, Male	
Licata et al.45	2013	Chart Review	Italy	230	LAL	Breast, Upper	
		Chart Review				Extremity, Lower	
						SiteVariable: Hips,Abdomen, Flanks,Male Breast,Upper Extremity,Lower ExtremityMale BreastMale BreastMale BreastVariable: Neck,Flanks, Hips, MaleBreast, UpperExtremity, LowerExtremity, LowerExtremity, Sack,Jowls, Abdomen,Flanks, Back,Buttocks, PubicRegion, MaleBreast, UpperExtremity, LowerExtremity, LowerRegion, MaleBreast, UpperExtremity, LowerExtremity, LowerExtremity, LowerExtremityVeriable: Neck, SubmentalRegion	
						Variable: Neck,	
					TAT	Jowls, Abdomen,	
						Flanks, Back,	
Leclère et	2012	Prospective	France	350		Buttocks, Pubic	
al. ⁴³	2012	Series	Tanee	557		Region, Male	
						Breast, Upper	
						Extremity, Lower	
						Extremity	
		Prospective,					
Alexiades-	2012	Randomized	USA	12	ΙΔΙ	Neck, Submental	
Armenakas ¹⁴	2012	Comparative	0.571	12		Region	
		Series				Variable: Hips, Abdomen, Flanks, Male Breast, Upper Extremity, Lower Extremity Male Breast Male Breast Variable: Neck, Flanks, Hips, Male Breast, Upper Extremity, Lower Extremity Variable: Neck, Jowls, Abdomen, Flanks, Back, Buttocks, Pubic Region, Male Breast, Upper Extremity, Lower Extremity, Lower Extremity, Lower Extremity, Lower Extremity, Lower Extremity, Lower Extremity, Lower Extremity, Lower Extremity, Lower Extremity Neck, Submental Region	
Leclère et	2016	Prospective	France	22	ΙΔΙ	Unner Extremity	
al. ⁴⁰	2010	Series				Spper Extremity	

Table 4 – Overall, major, minor, and individual complication rates, as identified and synthesized in the present meta-analysis using a random-effects model and meta-analysis of proportions, are presented herein.

Complication	Rate
Total (overall) complication rate	12%
Total complication rate*	5%
Major complication rate	1%
Minor complication rate*	5%
Ecchymosis	3%
Edema	2%
Contour irregularity	2%
Seroma	1%
Hematoma	1%
Surgical site infection	1%
Thermal injury	1%
Pigmentary changes	1%
Fibrosis or Induration	1%
Paresthesia	1%
Skin loss	1%
Undesirable entry site events	1%

Asterisk (*): excluding ecchymosis and edema

Table 5 – Incidence of infrequent complications identified in the present study from articlesmeeting the inclusion criteria

Complication	Total incidence (n)
Hypotension or orthostatic hypotension ^{50,57}	17
Garment-induced pressure necrosis ^{21,60}	9
Contact dermatitis or Urticaria ^{21,26,57,66}	8
Drug allergic reaction ^{16,27,66}	5
Pulmonary edema ^{21,66}	5
Pneumonia ²¹	1
Deep venous thrombosis ⁷⁴	1
Major mycobacterial infection ⁷³	1
Urinary retention ²⁷	1
Hemorrhage ³⁴	1
Globus pharyngeus ⁵⁶	1
Nerve inflammation ⁵⁶	1

Figure 1. Flowchart of the search strategy, conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, as well as the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.



Figure 2. Total complication rate, excluding ecchymosis and edema.

Study	Events Total	Proporti	on 95%-C	Weight Weight (fixed) (random)	
Katz & McBean (2008)	5 537		01 [0 00: 0 02]	0.7% 1.9%	6
Duncan (2013)	2 12	· · · · · · 0	17 [0.02: 0.48]	0.2% 1.6%	6
Giugliano et al. (2004)	0 60	0	00 [0.00; 0.06]	0.1% 1.0%	6
Roland (2012)	4 320	0	01 [0.00; 0.03]	0.6% 1.8%	6
Boeni (2011)	7 4380	0	00 [0.00; 0.00]	1.0% 2.0%	6
Valizaden et al.* (2016)	0 18	0.	00 [0.00; 0.19]	0.1% 1.0%	6
Keramidas & Rodopoulou (2016)	8 55	0	15 [0.06; 0.27]	1.0% 2.0%	'0 %
Leclère et al. (2015)	0 10	0	00 [0.00; 0.31]	0.1% 1.0%	%
Hurwitz & Smith (2012)	5 17	0	29 [0.10; 0.56]	0.5% 1.8%	6
Moskovitz et al. (2007)	0 20	0	00 [0.00; 0.17]	0.1% 1.0%	6
Cohen et al. (2012)	17 23	0	74 [0.52; 0.90]	0.6% 1.9%	6
Boni (2006)	0 39		09 [0.05; 0.14]	0.1% 2.07	'0 %
Wall & Lee(2016)	5 129	0	04 [0.01: 0.09]	0.7% 1.9%	6
Chia & Theodorou (2012)	6 581	0	01 [0.00; 0.02]	0.8% 1.9%	6
Jacob et al. (2000)	1 20	0	05 [0.00; 0.25]	0.1% 1.3%	6
Kim et al.* (2011)	83 682	0	12 [0.10; 0.15]	10.2% 2.1%	6
Kim et al.*** (2011)	63 833	U. 0	07 [0.05; 0.09]	7.8% 2.1%	6 6
Commons et al. (2001)	86 631	0	14 [0.11: 0.17]	10.4% 2.1%	%
Omranifard (2003)	20 20	1	00 [0.83; 1.00]	0.1% 1.0%	6
Habbema (2009)	9 3240	0	00 [0.00; 0.01]	1.3% 2.0%	6
Wang et al. (2018)	0 83	0	00 [0.00; 0.04]	0.1% 1.0%	6
Roustaei et al. (2009)	9 609	0	01 [0.01; 0.03]	1.2% 2.0%	6
Katz et al. (2003)	3 207	<u>.</u> 0.	00 [0.00; 0.15]	0.1% 1.0%	6 %
Innocenti et al. (2014)	17 118	0	14 [0.09: 0.22]	2.0% 2.0%	%
Zoccali et al. (2012)	106 797	0	13 [0.11; 0.16]	12.9% 2.1%	%
Perez & Tetering (2003)	10 351	- 0	03 [0.01; 0.05]	1.4% 2.0%	6
Mellul et al. (2006)	4 14	0	29 [0.08; 0.58]	0.4% 1.8%	6
Salen et al. (2009) Zhang et al. (2015)	30 60	0	50 [0.37; 0.63]	2.1% 2.0%	6
Goldman (2006)	97 4000	0.	02 [0.02; 0.03]	0.3% 2.17	'0 %
Trelles et al. (2013)	28 28	1	00 [0.88; 1.00]	0.1% 1.0%	%
Branas & Moraga* (2013)	143 330	0	43 [0.38; 0.49]	11.3% 2.1%	6
Branas & Moraga** (2013)	3 100		03 [0.01; 0.09]	0.4% 1.8%	6
Scuderi et al.* (2000)	0 15	0	00 [0.00; 0.22]	0.1% 1.0%	6
Scuderi et al *** (2000)	0 15	0.	27 [0.00; 0.22]	0.1% 1.0%	6 6
McBean & Katz (2009)	0 20	0	00 [0.00; 0.17]	0.1% 1.0%	%
Hodgson et al. (2005)	0 13	0	00 [0.00; 0.25]	0.1% 1.0%	6
Leclère et al. (2014)	3 30	0	10 [0.02; 0.27]	0.4% 1.7%	6
Leclère et al. (2013)	2 30	0	07 [0.01; 0.22]	0.3% 1.6%	6
Theodorou & Chia (2013)	0 12	0	00 [0.00; 0.26]	0.1% 1.0%	6
Sun et al. (2009)	0 35		00 [0.00: 0.10]	0.1% 1.0%	'0 %
Reynaud et al. (2009)	0 334	0	00 [0.00; 0.01]	0.1% 1.0%	%
Fulton et al. (2001)	2 15	0	13 [0.02; 0.40]	0.2% 1.6%	6
Moreno-Moraga et al. (2012)	1 30	0	03 [0.00; 0.17]	0.1% 1.3%	6
Swanson (2013)	1 61	0.	02 [0.00; 0.09]	U.1% 1.3%	6 6
Leclère et al. (2015)	10 384	U.	00 [0.00 0.081	2.0% 2.0%	'0 %
Sadove (2005)	1 25	0	04 [0.00; 0.20]	0.1% 1.3%	6
Sasaki (2012)	3 19	0	16 [0.03; 0.40]	0.4% 1.7%	6
Hong et al. (2012)	5 57	· · · · 0	09 [0.03; 0.19]	0.6% 1.9%	6
Paul et al. (2011)	1 24	0	04 [0.00; 0.21]	0.1% 1.3%	6
lon et al. (2011)	1 11	0.	09 [0.00; 0.41]	U.1% 1.3%	6 6
Paul & Mulholland (2009)	0 20	U	0. [0.00; 0.13]	0.1% 1.3%	.0 %
Song et al. (2014)	11 331	0	03 [0.02; 0.06]	1.5% 2.0%	6
Petty et al. (2010)	2 50	0	04 [0.00; 0.14]	0.3% 1.6%	6
Licata et al. (2013)	0 230	<u>.</u> 0	00 [0.00; 0.02]	0.1% 1.0%	6
Alexiades-Armenakas (2012)	0 359	0	00 [0.00; 0.01]	0.1% 1.0%	6
Leclère et al. (2016)	12 12	1.	00 [0.74; 1.00]	0.1% 1.0%	'0 %
	0 22	, 0.		0.170 1.07	-0
Fixed effectmodel	21776	0.	09 [0.08; 0.10]	100.0%	-
Random effects model		. 0	06 [0.04; 0.08]	100.0%	
Heterogeneity: $I^2 = 95\%$, $\tau^2 = 1.7853$, <i>p</i> < 0.01	20406081			
		0.20140.00.001			

Figure 3. Total major complication rate as determined using both the fixed-effects and randomeffects models for meta-analysis of articles meeting the inclusion criteria for review.

Study	Events	Total		Proportion	95%-CI (Weight fixed) (ra	Weight ndom)
Katz & McBean (2008)	0	537	t •••	0.00	[0: 0.01]	1.1%	1.3%
Duncan (2013)	0	12		0.00	[0; 0.26]	1.1%	1.3%
Giugliano et al. (2004)	0	60		0.00	[0; 0.06]	1.1%	1.3%
Roland (2012)	2	320	÷-	0.01	[0; 0.02]	4.6%	3.4%
Boeni (2011)	1	4380	-	0.00	[0; 0.00]	2.3%	2.2%
Valizadeh et al.* (2016)	0	18	•	0.00	[0; 0.19]	1.1%	1.3%
Keramidas & Rodopoulou (2016)	0	10	*	0.00	[0; 0.19]	1.1%	1.3%
Leclère et al. (2015)	0	10		0.00	[0, 0.00]	1.170	1.3%
Hurwitz & Smith (2012)	0	17		0.00	[0, 0.31]	1.1%	1.3%
Moskovitz et al. (2007)	0	20		0.00	[0; 0.17]	1.1%	1.3%
Cohen et al. (2012)	0	23		0.00	[0; 0.15]	1.1%	1.3%
Habbema (2009)	0	151		0.00	[0; 0.02]	1.1%	1.3%
Boni (2006)	0	38		0.00	[0; 0.09]	1.1%	1.3%
Wall & Lee(2016)	0	129		0.00	[0; 0.03]	1.1%	1.3%
Chia & Theodorou (2012)	0	581	-	0.00	[0; 0.01]	1.1%	1.3%
Jacob et al. (2000) Kim et al.* (2011)	0	20		0.00		1.1%	1.3%
Kim et al ** (2011)	0	884	ц 2	0.00	[0, 0.01]	1.170	1.3%
Kim et al. *** (2011)	0	832	•	0.00	[0, 0.00]	1.1%	1.3%
Commons et al. (2001)	5	631	-	0.01	[0: 0.02]	11.4%	4.9%
Omranifard (2003)	0	20	<u>≠</u>	0.00	[0; 0.17]	1.1%	1.3%
Habbema (2009)	1	3240	i i i i i i i i i i i i i i i i i i i	0.00	[0; 0.00]	2.3%	2.2%
Wang et al. (2018)	0	83		0.00	[0; 0.04]	1.1%	1.3%
Roustaei et al. (2009)	2	609	-	0.00	[0; 0.01]	4.6%	3.4%
Blugerman et al. (2010)	0	23	· · · · · · · · · · · · · · · · · · ·	0.00	[0; 0.15]	1.1%	1.3%
Katz et al. (2003)	0	207	∎ ∎	0.00	[0; 0.02]	1.1%	1.3%
Zoccali et al. (2012)	0	118		0.00	[0; 0.03]	1.1%	1.3%
Perez & Tetering (2003)	1	797		0.00		2.3%	2.2%
Mellul et al. (2006)	0	14	PL CONTRACTOR	0.00	[0, 0.01]	1.1%	1.3%
Saleh et al. (2009)	0	60		0.00	[0: 0.06]	1.1%	1.3%
Zhang et al. (2015)	1	4000		0.00	[0; 0.00]	2.3%	2.2%
Goldman (2006)	0	82	-	0.00	[0; 0.04]	1.1%	1.3%
Trelles et al. (2013)	0	28		0.00	[0; 0.12]	1.1%	1.3%
Branas & Moraga* (2013)	0	330		0.00	[0; 0.01]	1.1%	1.3%
Branas & Moraga** (2013)	0	100		0.00	[0; 0.04]	1.1%	1.3%
Scuderi et al.* (2000)	0	15		0.00	[0; 0.22]	1.1%	1.3%
Scuderi et al *** (2000)	0	15		0.00	[0; 0.22]	1.1%	1.3%
McBean & Katz (2009)	0	20		0.00	[0, 0.22]	1.1%	1.3%
Hodgson et al. (2005)	0	13	t 	0.00	[0: 0.25]	1.1%	1.3%
Leclère et al. (2014)	Ő	30		0.00	[0: 0.12]	1.1%	1.3%
Leclère et al. (2013)	0	30		0.00	[0; 0.12]	1.1%	1.3%
Walden et al. (2004)	0	12	• <u>•</u>	0.00	[0; 0.26]	1.1%	1.3%
Theodorou & Chia (2013)	0	40		0.00	[0; 0.09]	1.1%	1.3%
Sun et al. (2009)	0	35	t	0.00	[0; 0.10]	1.1%	1.3%
Reynaud et al. (2009)	0	334		0.00	[0; 0.01]	1.1%	1.3%
Moreno-Morana et al. (2012)	0	15	T i	0.00	[0; 0.22]	1.1%	1.3%
Saariniemi et al. (2015)	0	30		0.00	[0; 0.12]	1.1%	1.3%
Swanson (2013)	2	384		0.00	[0, 0.00]	4.6%	3.4%
Leclère et al. (2015)	0	45		0.01	[0, 0.02]	1.1%	1.3%
Sadove (2005)	0	25		0.00	[0; 0.14]	1.1%	1.3%
Sasaki (2012)	0	19		0.00	[0; 0.18]	1.1%	1.3%
Hong et al. (2012)	0	57		0.00	[0; 0.06]	1.1%	1.3%
Paul et al. (2011)	0	24		0.00	[0; 0.14]	1.1%	1.3%
Duncan (2012)	0	11		0.00	[0; 0.28]	1.1%	1.3%
Dri et al. (2011) Roul & Mulhollond (2000)	0	42		0.00	[0; 0.08]	1.1%	1.3%
Song et al. (2014)	0	20	<mark>*******</mark> *****************************	0.00	[0; 0.17]	1.1%	1.3%
Petty et al. (2010)	0	331	8	0.00	[0, 0.01]	1.1%	1.3%
Licata et al. (2013)	0	230		0.00	[0, 0.07]	1.1%	1.3%
Leclère et al. (2012)	0	359		0,00	[0: 0.01]	1.1%	1.3%
Alexiades-Armenakas (2012)	Ő	12	1 1	0.00	[0; 0.26]	1.1%	1.3%
Leclère et al. (2016)	0	22		0.00	[0; 0.15]	1.1%	1.3%
			•				
Fixed effectmodel		21776		0.01	[0; 0.01]	100.0%	
Random effects model			1	0.01	[0; 0.01]	·	100.0%
Heterogeneity: I ⁻ = 24%, τ ⁻ = 0.4756	, p = 0.05		0 05 0 1 0 15 0 2 0 25 0 2				
			ψ σ. σφ σ. τ μ. το μ. z σι z ο σ.ο η				

Figure 4. Total minor complication rate as determined using both the fixed-effects and randomeffects models for meta-analysis of articles meeting the inclusion criteria for review.

Study	Events -	Total	Proportion	95%-CI	Weight V (fixed) (ra	Veight andom)
Katz & MaBaan (2008)	-	527 . I	0.01	10 00: 0 021	0.7%	1.0%
Duncan (2013)	2	12	0.01	[0.00, 0.02] $[0.02 \cdot 0.48]$	0.7%	1.9%
Giugliano et al. (2004)	ō	60	0.00	[0.00: 0.06]	0.1%	1.0%
Roland (2012)	2	320 +	0.01	[0.00; 0.02]	0.3%	1.7%
Boeni (2011)	6	4380 -	0.00	[0.00; 0.00]	0.9%	1.9%
Valizadeh et al.* (2016)	0	18	0.00	[0.00; 0.19]	0.1%	1.0%
Valizadeh et al.** (2016)	0	18	0.00	[0.00; 0.19]	0.1%	1.0%
Keramidas & Rodopoulou (2016)	8	55	0.15	[0.06; 0.27]	1.0%	2.0%
Leciere et al. (2015) Hurwitz & Smith (2012)	5	17	0.00	[0.00; 0.31]	0.1%	1.0%
Moskovitz et al. (2007)	ő	20	0.00	[0.00: 0.17]	0.1%	1.0%
Cohen et al. (2012)	17	23	- 0.74	[0.52; 0.90]	0.6%	1.9%
Habbema (2009)	13	151	0.09	[0.05; 0.14]	1.7%	2.0%
Boni (2006)	0	38	0.00	[0.00; 0.09]	0.1%	1.0%
Wall & Lee(2016)	5	129 -	0.04	[0.01; 0.09]	0.7%	1.9%
Chia & Theodorou (2012)	6	581	0.01	[0.00; 0.02]	0.8%	1.9%
Kim et al * (2011)	83	682	0.05	[0.00, 0.25]	10.1%	2.1%
Kim et al.** (2011)	60	884	0.07	[0.05: 0.09]	8.0%	2.1%
Kim et al.*** (2011)	63	832	0.08	[0.06; 0.10]	8.3%	2.1%
Commons et al. (2001)	81	631	0.13	[0.10; 0.16]	10.1%	2.1%
Omranifard (2003)	20	20	1.00	[0.83; 1.00]	0.1%	1.0%
Habbema (2009)	8	3240	0.00	[0.00; 0.00]	1.1%	2.0%
Roustani et al. (2016)	0	83	0.00	[0.00; 0.04]	0.1%	1.0%
Blugerman et al. (2003)	0	23	0.01	[0.00, 0.02]	0.1%	2.0%
Katz et al. (2003)	3	207	0.01	[0.00; 0.04]	0.4%	1.8%
Innocenti et al. (2014)	17	118	0.14	[0.09; 0.22]	2.1%	2.0%
Zoccali et al. (2012)	105	797	0.13	[0.11; 0.16]	13.0%	2.1%
Perez & Tetering (2003)	10	351	0.03	[0.01; 0.05]	1.4%	2.0%
Mellul et al. (2006)	4	14	0.29	[0.08; 0.58]	0.4%	1.8%
Zhang et al. (2009)	30	4000	0.50	[0.37; 0.03]	2.1%	2.0%
Goldman (2006)	2	82	0.02	[0.02, 0.03]	0.3%	1.6%
Trelles et al. (2013)	28	28	1.00	[0.88; 1.00]	0.1%	1.0%
Branas & Moraga* (2013)	143	330	0.43	[0.38; 0.49]	11.5%	2.1%
Branas & Moraga** (2013)	3	100	0.03	[0.01; 0.09]	0.4%	1.8%
Scuderi et al.* (2000)	0	15	0.00	[0.00; 0.22]	0.1%	1.0%
Scuderi et al *** (2000)	0	15	0.00	[0.00; 0.22]	0.1%	1.0%
McBean & Katz (2009)	0	20	0.00	[0.00, 0.33]	0.4%	1.0%
Hodgson et al. (2005)	Ő	13	0.00	[0.00; 0.25]	0.1%	1.0%
Leclère et al. (2014)	3	30	0.10	[0.02; 0.27]	0.4%	1.8%
Leclère et al. (2013)	2	30	0.07	[0.01; 0.22]	0.3%	1.6%
Theodorou & Chia (2013)	0	12	0.00	[0.00; 0.26]	0.1%	1.0%
Sun et al. (2009)	2	35	0.05		0.3%	1.6%
Revnaud et al. (2009)	0	334	0.00	[0.00, 0.10]	0.1%	1.0%
Fulton et al. (2001)	2	15 •	0.13	[0.02; 0.40]	0.2%	1.6%
Moreno-Moraga et al. (2012)	1	30	0.03	[0.00; 0.17]	0.1%	1.3%
Saariniemi et al. (2015)	1	61	0.02	[0.00; 0.09]	0.1%	1.3%
Swanson (2013)	13	384 +	0.03	[0.02; 0.06]	1.8%	2.0%
Sadove (2005)	0	40 *	0.00	[0.00; 0.08]	0.1%	1.0%
Sasaki (2012)	3	19	0.04	[0.00, 0.20]	0.1%	1.3%
Hong et al. (2012)	5	57	0.09	[0.03; 0.19]	0.7%	1.9%
Paul et al. (2011)	1	24	0.04	[0.00; 0.21]	0.1%	1.3%
Duncan (2012)	1	11	0.09	[0.00; 0.41]	0.1%	1.3%
Ion et al. (2011) Paul & Mulholland (2000)	1	42	0.02	[0.00; 0.13]	0.1%	1.3%
Song et al. (2014)	11	20 +++	0.00	[0.00; 0.17]	0.1%	1.0%
Petty et al. (2010)	2	50	0.03	[0.00: 0.14]	0.3%	1.6%
Licata et al. (2013)	0	230	0.00	[0.00; 0.02]	0.1%	1.0%
Leclère et al. (2012)	0	359.	0.00	[0.00; 0.01]	0.1%	1.0%
Alexiades-Armenakas (2012)	12	12.	1.00	[0.74; 1.00]	0.1%	1.0%
Leciere et al. (2016)	0	22	0.00	[0.00; 0.15]	0.1%	1.0%
Fixed effectmodel		21776	0.09	[0.08; 0.10]	100.0%	
Random effects model			0.05	[0.04; 0.08]	1	00.0%
Heterogeneity: $I^2 = 95\%$, $\tau^2 = 1.7908$, <i>p</i> < 0.01					
		φ 0.20μ40.6ρ.81 μ				

Supplementary Figure 1 Total complication rate, according to definitions set by authors of the

primary studies included in the meta-analysis

Study.	Evente	Total				Proportion	05%-01	Weight	Weight
Study	Events	lotai				Proportion	95%-01	(fixed) (random)
Katz & McBean (2008)	5	537	•			0.01	[0.00; 0.02]	0.7%	1.9%
Duncan (2013)	2	12	_	•		0.17	[0.02; 0.48]	0.2%	1.5%
Giugliano et al. (2004)	2	60		-		0.03	[0.00; 0.12]	0.3%	1.6%
Roland (2012)	4	320	•			0.01	[0.00; 0.03]	0.6%	1.8%
Boeni (2011)	7	4380	•			0.00	[0.00; 0.00]	1.0%	1.9%
Valizadeh et al.* (2016)	0	18	-	-		0.00	[0.00; 0.19]	0.1%	0.9%
Valizadeh et al.** (2016)	7	18		·		0.39	[0.17; 0.64]	0.6%	1.8%
Keramidas & Rodopoulou (2016)	8	55				0.15	[0.06; 0.27]	1.0%	1.9%
Leciere et al. (2015)	2	10	_			0.20	[0.03; 0.56]	0.2%	1.5%
Moskovitz et al. (2007)	5	20		•		0.29	[0.10; 0.56]	0.5%	1.0%
Cohen et al. (2012)	17	20	-			0.00	[0.00, 0.17]	0.1%	1.9%
Habbema (2009)	13	151			•	0.74	[0.02, 0.30]	1 7%	2.0%
Boni (2006)	13	38	-			0.03	[0.03, 0.14]	0.1%	2.0 %
Wall & Lee(2016)	5	129				0.04	[0.01: 0.09]	0.7%	1.9%
Chia & Theodorou (2012)	6	581				0.01	[0.00: 0.02]	0.9%	1.9%
Jacob et al. (2000)	1	20	-			0.05	[0.00; 0.25]	0.1%	1.3%
Kim et al.* (2011)	83	682				0.12	[0.10; 0.15]	10.5%	2.1%
Kim et al.** (2011)	60	884				0.07	[0.05; 0.09]	8.0%	2.1%
Kim et al.*** (2011)	63	832	1			0.08	[0.06; 0.10]	8.3%	2.1%
Commons et al. (2001)	86	631				0.14	[0.11; 0.17]	10.7%	2.1%
Omranifard (2003)	20	20				1.00	[0.83; 1.00]	0.1%	0.9%
Habbema (2009)	9	3240				0.00	[0.00; 0.01]	1.3%	2.0%
Wang et al. (2018)	0	83	-			0.00	[0.00; 0.04]	0.1%	1.0%
Roustaei et al. (2009)	9	609				0.01	[0.01; 0.03]	1.3%	1.9%
Blugerman et al. (2010)	0	23				0.00	[0.00; 0.15]	0.1%	0.9%
Katz et al. (2003)	3	207	•			0.01	[0.00; 0.04]	0.4%	1.7%
Zoopoli et al. (2012)	22	118		- -		0.19	[0.12; 0.27]	2.6%	2.0%
Perez & Tetering (2003)	100	797				0.13	[0.11; 0.16]	13.2%	2.1%
Mellul et al. (2006)	10	351	٠			0.03	[0.01; 0.05]	0.4%	2.0%
Saleh et al. (2009)	30	60		• • • • • • • • • • • • • • • • • • • •		0.23	[0.00, 0.00]	2.2%	2.0%
Zhang et al. (2015)	97	4000				0.02	[0.02: 0.03]	13.6%	2.1%
Goldman (2006)	2	82				0.02	[0.00: 0.09]	0.3%	1.6%
Trelles et al. (2013)	28	28	+			1.00	[0.88; 1.00]	0.1%	0.9%
Branas & Moraga** (2013)	100	100				1.00	[0.96; 1.00]	0.1%	1.0%
Scuderi et al.* (2000)	3	15			-	0.20	[0.04; 0.48]	0.3%	1.7%
Scuderi et al.** (2000)	1	15				0.07	[0.00; 0.32]	0.1%	1.3%
Scuderi et al. (2000)	4	15	_			0.27	[0.08; 0.55]	0.4%	1.7%
Hodoson et al. (2005)	20	20				1.00	[0.83; 1.00]	0.1%	0.9%
Leclère et al. (2014)	0	20	-	<u> </u>		0.00	[0.00; 0.25]	0.1%	1 70/
Leclère et al. (2013)	30	30	_	•		1.00	[0.02, 0.27]	0.4%	0.0%
Walden et al. (2004)	0	12				. 0.00	[0.00; 0.26]	0.1%	0.9%
Theodorou & Chia (2013)	2	40	-			0.05	[0.01: 0.17]	0.3%	1.6%
Sun et al. (2009)	3	35	-+-	-		0.09	[0.02; 0.23]	0.4%	1.7%
Reynaud et al. (2009)	334	334	_			1.00	[0.99; 1.00]	0.1%	1.0%
Fulton et al. (2001)	2	15				0.13	[0.02; 0.40]	0.2%	1.6%
Moreno-Moraga et al. (2012)	1	30	-	÷		0.03	[0.00; 0.17]	0.1%	1.3%
Saariniemi et al. (2015)	1	61	+	+		0.02	[0.00; 0.09]	0.1%	1.3%
Swanson (2013)	15	384	•			0.04	[0.02; 0.06]	2.1%	2.0%
Leclere et al. (2015)	11	45	•			0.24	[0.13; 0.40]	1.2%	1.9%
Sauove (2005)	1	25				0.04	[U.00; 0.20]	0.1%	1.3%
Jasani (2012)	3	19				0.16	[U.U3; U.40]	0.4%	1.7%
Paul et al. (2011)	5	5/	-			0.09	[U.U3; U.19]	0.7%	1.8%
Duncan (2012)	1	24 11				0.04	[0.00; 0.21]	0.1%	1.3%
lon et al. (2011)	1	42	_			0.09	[0.00; 0.41]	0.1%	1.3%
Paul & Mulholland (2009)	20	20				1.00	[0.83: 1.00]	0.1%	0.9%
Song et al. (2014)	11	331				0.03	[0.02; 0.06]	1.5%	2.0%
Petty et al. (2010)	2	50				0.04	[0.00; 0.14]	0.3%	1.6%
Licata et al. (2013)	63	230	+	-		0.27	[0.22; 0.34]	6.6%	2.1%
Leclère et al. (2012)	359	359		- <mark></mark>		1.00	[0.99; 1.00]	0.1%	1.0%
Alexiades-Armenakas (2012)	12	12				1.00	[0.74; 1.00]	0.1%	0.9%
Leciere et al. (2016)	22	22				. 1.00	[0.85; 1.00]	0.1%	0.9%
Fine d offerstmendel							10 00.0 001	400.00	
Random effects model		21446				0.09	[0.00; 0.09]	100.0%	100 0%
Heterogeneity: $l^2 = 94\% + l^2 = 1,7000$	n < 0.01			1		0.12	[0.00, 0.10]		/0
			φo	2 0 ₁ 4 0.6 ρ.8 1 τ		1			

Supplementary Figure 2 *Rate of ecchymosis as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Katz & McBean (2008) 0 537	Study	Events	Total			Proportion	95%-CI	Weight (fixed) (Weight random)
Durcan (2013) 0 12 0.00 0.00 0.22 0.00	Katz & McBean (2008)	0	537	•	1	0.00	[0.00: 0.01]	0.5%	1.5%
Glugino et al. (2004) 0 60 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2016) 0 18 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2016) 0 18 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2017) 0 23 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2017) 0 23 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2017) 0 23 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2017) 0 23 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2009) 0 151 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 20 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 22 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 23 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 23 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 561 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 561 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 561 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 561 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 561 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 561 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 561 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2001) 0 561 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 1 6 20 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2003) 0 220 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2013) 0 30 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2014) 0 18 - 0.00 [0.00 0.01] 0.5% 1.5% Glugina et al. (2015) 0 4000 - 0.00 [0.00 0.02] 0.5% 1.5% Glugina et al. (2013) 0 30 - 0.00 [0.00 0.02] 0.5% 1.5% Glugina et al. (2013) 0 30 - 0.00 [0.00 0.02] 0.05% 1.5% Glugin et al. (2014) 0 13 - 0.00 [0.00 0.02] 0.05% 1.5% Glugin	Duncan (2013)	Ő	12	<u> </u>		0.00	[0.00; 0.26]	0.4%	1.5%
Roland (2012) 0 320 0.00 (0.00, 0.01) 0.5% 1.5% Valizadeh et al.* (2016) 1 1 0.00 (0.00, 0.01) 0.5% 1.5% Keramidas Acopoulou (2016) 0 55 0.00 (0.00, 0.01) 0.5% 1.5% Lacitre et al. (2017) 0 10 0.00 (0.00, 0.01) 0.5% 1.5% Meskovitz et al. (2007) 0 20 0.00 (0.00, 0.01) 0.5% 1.5% Meskovitz et al. (2000) 0 15 0.00 (0.00, 0.01) 0.5% 1.5% School (1.10, 0.01) 0.84 0.00 (0.00, 0.01) 0.5% 1.5% Mak Lee(2016) 1.29 0.00 (0.00, 0.01) 0.5% 1.5% Chao B at I.* (2011) 682 0.00 (0.00, 0.01) 0.5% 1.5% Commons et al. (2010) 117 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05% 1.5% Commons et al. (2010) 0.23 </td <td>Giugliano et al. (2004)</td> <td>0</td> <td>60</td> <td>÷</td> <td></td> <td>0.00</td> <td>[0.00; 0.06]</td> <td>0.5%</td> <td>1.5%</td>	Giugliano et al. (2004)	0	60	÷		0.00	[0.00; 0.06]	0.5%	1.5%
Valizade et al. (2016) 0 18 0.00 0.00, 0.17, 0.64 4.0% 1.8% Keramides & Rodopoluo (2016) 0 55 0.00 1.00, 0.01 0.00 0.00, 0.01 0.05% 1.5% Hurwitz & Smith (2012) 0 17 0.00 1.00, 0.01 0.00 0.00 0.00, 0.01 0.05% 1.5% Moskoviz et al. (2017) 0 22 0.00 1.00, 0.01 0.5% 1.5% Main (2000) 0 13 0.00 1.00, 0.01 0.5% 1.5% Yalia Lee (2016) 0 12 0.00 1.00, 0.01 0.5% 1.5% Yalia Lee (2016) 0 22 0.00 1.00, 0.00 0.05% 1.5% Commons et al. (2011) 0 542 0.00 1.00, 0.00 0.5% 1.5% Commons et al. (2011) 0 542 0.00 1.00, 0.00 0.5% 1.5% Commons et al. (2011) 0 53 0.00 1.00, 0.00 0.05% 1.5%	Roland (2012)	0	320	•		0.00	[0.00; 0.01]	0.5%	1.5%
Valizade et al. "(2016) 7 18	Valizadeh et al.* (2016)	0	18	·		0.00	[0.00; 0.19]	0.5%	1.5%
Keramidas & Rodopoulo (2016) 0 55 - 0.00 10.00: 0.00 0.05% 1.5% Hurwitz & Smith (2012) 0 17 - 0.00 10.00: 0.00 0.00 1.5% Cohen et al. (2017) 0 20 - 0.00 10.00: 0.01 0.5% 1.5% Mackoviz et al. (2017) 0 20 - 0.00 10.00: 0.01 0.5% 1.5% Main (2006) 13 - 0.00 10.00: 0.01 0.5% 1.5% Main (2010) 0 13 - 0.00 10.00: 0.001 0.5% 1.5% Main (2011) 0 884 0.00 10.00: 0.001 0.5% 1.5% Commons et al. '(2011) 0 544 - 0.00 10.00: 0.001 0.5% 1.5% Commons et al. (2010) 0 11 - 0.00 10.00: 0.001 0.5% 1.5% Commons et al. (2011) 0 63 - 0.00 1.00: 0.001 0.5% 1.5% Commons et al. (2010) 0 13 - 0.00 0.00:	Valizadeh et al.** (2016)	7	18		•	0.39	[0.17; 0.64]	4.0%	1.8%
Lebere et al. (2015) 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Keramidas & Rodopoulou (2016)	0	55	÷		0.00	[0.00; 0.06]	0.5%	1.5%
number 2 simil (2012) 0 17 000 10.00 20 000 10.00 20 000 10.00 15% 15% Cohen et al. (2012) 0 22 000 10.00 000 </td <td>Leciere et al. (2015)</td> <td>0</td> <td>10</td> <td></td> <td>J 1</td> <td>0.00</td> <td>[0.00; 0.31]</td> <td>0.4%</td> <td>1.5%</td>	Leciere et al. (2015)	0	10		J 1	0.00	[0.00; 0.31]	0.4%	1.5%
Cohere et al. (2012) 0 23 0.00 0.00 1.02 1.5% Habbems (2006) 0 38 0.00 0.00 0.02 0.5% 1.5% Kim (2006) 0 38 0.00 1.00 0.02 0.05 1.5% Chia A Theodorou (2012) 0 581 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.5% 1.5% Kim et al. *(2011) 0 682 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.5% 1.5% Commons et al. *(2011) 0 117 0.00 0.00 0.00 0.00 0.00 0.05% 1.5% Commons et al. *(2010) 0 117 0.00 0.00 0.00 0.00 0.05% 1.5% Routacit et al. (2014) 0 118 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05% <td< td=""><td>Hurwitz & Smith (2012) Moskovitz et al. (2007)</td><td>0</td><td>17</td><td>·</td><td></td><td>0.00</td><td>[0.00; 0.20]</td><td>0.5%</td><td>1.5%</td></td<>	Hurwitz & Smith (2012) Moskovitz et al. (2007)	0	17	·		0.00	[0.00; 0.20]	0.5%	1.5%
Habbema (2009) 0 151 0.00	Cohen et al. (2012)	0	20			0.00	[0.00, 0.17]	0.5%	1.5%
bion (2006) 0 38 0.00 1000 1000 0.03 0.5% 15% Chia A Theodorou (2012) 0 581 0.00 1000 0.00 1000 0.03 0.5% 15% Acob et al. (2000) 0 20 0.00 1000 0.0	Habbema (2009)	0	151	_		0.00	[0.00: 0.02]	0.5%	1.5%
Walk Lee(2016) 0 129 0.00	Boni (2006)	0	38	_		0.00	[0.00; 0.09]	0.5%	1.5%
Chia A Theodorou (2012) 0 581 0.00	Wall & Lee (2016)	0	129	-		0.00	[0.00; 0.03]	0.5%	1.5%
Jacob et al (2000) Kim et al.*(2011) 0 682 Kim et al.**(2011) 0 884 Commons et al.*(2011) 0 884 Commons et al.*(2001) 0 514 Commons et al.*(2001) 0 514 Commons et al.*(2001) 0 117 0 00 [0.00; 0.00] 0 0.5% 1.5% Commons et al.*(2001) 0 514 Ababema (2009) 0 3240 0 00 [0.00; 0.00] 0 0.00; 0.00; 0.00; 0.5% 1.5% Commons et al.*(2009) 0 3240 0 00 [0.00; 0.00] 0 0.00; 0.00; 0.00; 0.05% 1.5% Commons et al.(2009) 0 23 0 00 [0.00; 0.00] 0 0.00; 0.00; 0.00; 0.05% 1.5% Commons et al.(2010) 0 23 0 00 [0.00; 0.00] 0 0.00; 0.00; 0.00; 0.05% 1.5% Commons et al.(2010) 0 23 0 00 [0.00; 0.00; 0.00; 0.5% 1.5% Commons et al.(2011) 0 797 0 00 [0.00; 0.00; 0.00; 0.5% 1.5% Common et al.(2014) 0 118 Concell et al.(2014) 0 107 Concell et al.(2014) 0 107 Concell et al.(2013) 0 82 Concell et al.(2013) 0 82 Concell et al.(2013) 2 80 2 87 Concell et al.(2013) 2 80 2 90 0 100 0 100	Chia & Theodorou (2012)	0	581			0.00	[0.00; 0.01]	0.5%	1.5%
Kim et al.* (2011) 0 682 0.00 0.000 0.000 0.05% 1.5% Kim et al.** (2011) 0 832 0.00 0.000 0.05% 1.5% Commons et al.* (2001) 0 514 0.00 0.000 0.000 0.5% 1.5% Mabema (2009) 0 3240 0.00 0.000 0.000 0.5% 1.5% Roustael et al. (2010) 0 669 0.00 0.000 0.000 0.5% 1.5% Roustael et al. (2010) 0 23 0.00 0.000 0.000 0.5% 1.5% Innocenti et al. (2014) 0 118 0.00 0.000 0.000 0.5% 1.5% Zoccali et al. (2013) 0 351 0.00 0.000 0.000 0.5% 1.5% Mellui et al. (2013) 28 0.00 0.00 0.00 0.00 0.05% 1.5% Codiman (2006) 0 4000 0.00 0.00 0.00 0.00 0.05% 1.5% Coder et al. (2013) 28 0.00 0.00	Jacob et al. (2000)	0	20	<u> </u>		0.00	[0.00; 0.17]	0.5%	1.5%
Kim et al.** (2011) 0 884 0.00 0.00; 0.00; 0.5% 1.5% Commons et al.** (2001) 0 614 0.00 0.00; 0.00; 0.00; 0.5% 1.5% Commons et al.**(2001) 0 117 0.00 0.00;	Kim et al.* (2011)	0	682	•		0.00	[0.00; 0.01]	0.5%	1.5%
Kim et al.** (2011) 0 B32 0.00	Kim et al.** (2011)	0	884	•		0.00	[0.00; 0.00]	0.5%	1.5%
Commons et al. *(2001) 0 514 0.00 0	Kim et al.*** (2011)	0	832	4		0.00	[0.00; 0.00]	0.5%	1.5%
Commanifar (2003) 16 117 174 Habbema (2009) 0 3240 0.00 [0.00; 0.00] 0.5% [1.5% Wang et al. (2016) 0 609 0.00 [0.00; 0.00] 0.5% [1.5% Roustaei et al. (2010) 0 223 0.00 [0.00; 0.00] 0.5% [1.5% Innocenti et al. (2014) 0 118 0.00 [0.00; 0.00] 0.5% [1.5% Innocenti et al. (2014) 0 118 0.00 [0.00; 0.00] 0.5% [1.5% Zocali et al. (2013) 0 207 0.00 [0.00; 0.00] 0.5% [1.5% Salhe et al. (2013) 0 351 0.00 [0.00; 0.00] 0.5% [1.5% Scuderi et al. (2013) 280 330 - 0.00 [0.00; 0.00] 0.5% [1.5% Scuderi et al. (2013) 280 330 - 0.00 [0.00; 0.00] 0.5% [1.5% Scuderi et al. (2013) 280 330 - 0.00 [0.00; 0.22] 0.5% [1.5% Scuderi et al. (2014) 0 15 - 0.00 [0.00; 0.22] 0.5% [1.5% Scuderi et al. (2014) 0 0 0.00 [0.00; 0.22] 0.5% [1.5% Scuderi et al. (2014)	Commons et al.* (2001)	0	514	•		0.00	[0.00; 0.01]	0.5%	1.5%
Chinama (2009) 10 224 0.00 <td>Omrapifard (2003)</td> <td>16</td> <td>20</td> <td>H.</td> <td></td> <td>0.00</td> <td>[0.00, 0.03]</td> <td>2.0%</td> <td>1.5%</td>	Omrapifard (2003)	16	20	H.		0.00	[0.00, 0.03]	2.0%	1.5%
Wang et al. (2016) 0	Habberna (2009)	0	3240			0.80	[0.30, 0.94]	0.5%	1.7%
Rousizaei et al. (2009) 0 600 00	Wang et al. (2018)	0	83	1		0.00	[0.00; 0.00]	0.5%	1.5%
Blugernan et al. (2010) 0 22 0.00 0	Roustaei et al. (2009)	0	609	1		0.00	[0.00: 0.01]	0.5%	1.5%
kaiz et al. (2003) 0 207 0.00	Blugerman et al. (2010)	0	23	•		0.00	[0.00; 0.15]	0.5%	1.5%
Innocenti et al. (2014) 0 118 0 0 15% 2cocali et al. (2012) 0 787 0 0.00 0.00: 0.00: 0.03 0.5% 1.5% Perez & Tetering (2003) 0 351 0.00 0.00: 0.00: 0.03 0.5% 1.5% Salen et al. (2015) 0 4000 0.00 0.00: 0.00: 0.04 0.5% 1.5% Coldman (2006) 0 82 0.00 0.00: 0.00: 0.04 0.5% 1.5% Branas & Moraga* (2013) 280 330 0.05 0.00: 0.00: 0.22 0.5% 1.5% Scuder et al. *(2000) 3 15 0.00: 0.00: 0.22 0.5% 1.5% Scuder et al. *(2014) 0 30 0.00: 0.00: 0.22 0.5% 1.5% Lecker et al. (2013) 0 30 0.00: 0.00: 0.22 0.5% 1.5% Lecker et al. (2014) 0 30 0.00: 0.00: 0.22 0.5% 1.5% Lecker et al. (2013) 0 34 0.00: 0.00: 0.22 0.5% 1.5% Lecker et al. (2013) 0 34 0.00: 0.00: 0.22 0.5% <td< td=""><td>Katz et al. (2003)</td><td>0</td><td>207</td><td>-</td><td></td><td>0.00</td><td>[0.00; 0.02]</td><td>0.5%</td><td>1.5%</td></td<>	Katz et al. (2003)	0	207	-		0.00	[0.00; 0.02]	0.5%	1.5%
Zoccali et al. (2012) 0 737 0.00 0.	Innocenti et al. (2014)	0	118			0.00	[0.00; 0.03]	0.5%	1.5%
Perez & Tetering (2003) 0 351 0.00 0.000 0.001 0.5% 1.5% Saleh et al. (2006) 0 14 0.00 0.000 0.000 0.5% 1.5% Saleh et al. (2015) 0 4000 0.00 0.0	Zoccali et al. (2012)	0	797	3		0.00	[0.00; 0.00]	0.5%	1.5%
Melliul et al. (2009) 0 14 0.00 0.00 0.23 0.5% 1.5% Zhang et al. (2015) 0 4000 0.00	Perez & Tetering (2003)	0	351			0.00	[0.00; 0.01]	0.5%	1.5%
Saler et al. (2015) 0 60 0.00<	Mellul et al. (2006)	0	14			0.00	[0.00; 0.23]	0.5%	1.5%
Zhang et al. (2015) 0 4000 0.000	Salen et al. (2009) Zhong et al. (2015)	0	60	÷		0.00	[0.00; 0.06]	0.5%	1.5%
Outside (2013) 28 28 1.00 0.00 0.00 0.5% 1.5% Branas & Moraga* (2013) 280 330 100 0.68 1.00 0.5% 1.5% Branas & Moraga* (2013) 100 100 0.68 1.00 0.5% 1.5% Scuderi et al.* (2000) 3 15 0.00 </td <td>Goldman (2006)</td> <td>0</td> <td>4000</td> <td></td> <td></td> <td>0.00</td> <td>[0.00; 0.00]</td> <td>0.5%</td> <td>1.5%</td>	Goldman (2006)	0	4000			0.00	[0.00; 0.00]	0.5%	1.5%
Branas & Moraga* (2013) 280 330 0.85 (0.81, 0.89) 39.5% 1.8% Branas & Moraga* (2013) 100 100 0.85 (0.81, 0.89) 39.5% 1.8% Branas & Moraga* (2013) 100 100 0.85 (0.81, 0.89) 39.5% 1.8% Scuderi et al. **(2000) 0 15 0.00 (0.00, 0.22) 0.5% 1.5% Scuderi et al. **(2000) 0 15 0.00 (0.00, 0.22) 0.5% 1.5% Hodgson et al. (2005) 0 13 0.00 (0.00, 0.22) 0.5% 1.5% Leciere et al. (2014) 0 30 0.00 (0.00, 0.22) 0.5% 1.5% Validen et al. (2009) 34 35 0.00 (0.00, 0.22) 0.4% 1.5% Sun et al. (2001) 0 15 0.00 (0.00, 0.22) 0.5% 1.5% Gravin et al. (2011) 0 15 0.00 (0.00, 0.22) 0.5% 1.5% Lecière et al. (2015) 0 45 0.00 (0.00, 0.12) 0.5% 1.5% Swanson (2013) 0 384 0.00 (0.00, 0.02) 0.00 (0.00, 0.02) 0.00 (0.00, 0.02) 1.5%	Trelles et al. (2013)	28	28	÷		1.00	[0.88 1.00]	0.5%	1.5%
Branas & Moraga**(2013) 100 100 100 100 0.05% 1.5% Scuderi et al.**(2000) 3 15 0.00 <td>Branas & Moraga* (2013)</td> <td>280</td> <td>330</td> <td></td> <td>—</td> <td>- 1.00 - 0.85</td> <td>[0.80, 1.00]</td> <td>39.5%</td> <td>1.3%</td>	Branas & Moraga* (2013)	280	330		—	- 1.00 - 0.85	[0.80, 1.00]	39.5%	1.3%
Souderi et al. ** (2000) 3 15 0.20 0.04; 0.48] 2.2% 1.7% Scuderi et al. *** (2000) 0 15 0.00 0.00; 0.02, 22 0.5% 1.5% Scuderi et al. *** (2000) 0 15 0.00 0.00; 0.22 0.5% 1.5% McBean & Katz (2009) 20 20 0.00 0.00; 0.22 0.5% 1.5% Hodgson et al. (2013) 0 30 0.00 0.00; 0.22 0.5% 1.5% Leclère et al. (2014) 0 30 0.00 0.00; 0.02; 0.23 0.4% 1.5% Leclère et al. (2014) 0 30 0.00 0.00; 0.02; 0.23 2.6% 1.5% Validen et al. (2009) 334 334 0.00 0.00; 0.00; 0.22 0.5% 1.5% Fund et al. (2010) 0 15 0.00 0.00; 0.00; 0.22 0.5% 1.5% Moreno-Moraga et al. (2015) 0 61 0.00 0.00; 0.00; 0.12 0.5% 1.5% Swanson (2013) 0 384 0.00 0.00; 0.00; 0.13 0.5% 1.5% Sun et al. (2015	Branas & Moraga** (2013)	100	100			1.00	[0.96: 1.00]	0.5%	1.5%
Scuderi et al.***(2000) 0 15 0.00 0.00 0.221 0.5% 1.5% McBean & Katz (2009) 20 20 1.00 0.00	Scuderi et al.* (2000)	3	15		-	0.20	[0.04; 0.48]	2.2%	1.7%
Scuderi et al.*** (2000) 0 15 0.00 0.000 0.221 0.5% 1.5% Hodgson et al. (2005) 0 13 0.00 0.000 0.000 0.221 0.5% 1.5% Lecière et al. (2014) 0 30 0.00 0.000 0.000 0.121 0.5% 1.5% Uecière et al. (2013) 0 0.00 0.000	Scuderi et al.** (2000)	0	15			0.00	[0.00; 0.22]	0.5%	1.5%
McBean & Katz (2009) 20 20 1.00 [0.83; 1.00] 0.5% 1.5% Hodgson et al. (2015) 0 13 0.00 [0.00; 0.25] 0.4% 1.5% Lecière et al. (2014) 0 30 0.00 [0.00; 0.12] 0.5% 1.5% Lecière et al. (2014) 0 12 0.00 [0.00; 0.12] 0.5% 1.5% Validen et al. (2004) 12 0.00 [0.00; 0.22] 0.5% 1.5% Sun et al. (2009) 334 334 0.00 [0.00; 0.12] 0.5% 1.5% Fuiton et al. (2015) 0 15 0.00 [0.00; 0.12] 0.5% 1.5% Swanson (2013) 0 384 0.00 [0.00; 0.01] 0.5% 1.5% Saariniemi et al. (2015) 0 45 0.00 [0.00; 0.01] 0.5% 1.5% Saaki (2012) 0 19 0.00 [0.00; 0.01] 0.5% 1.5% Paul & Mulholland (2009) 20 57 0.00 [0.00; 0.02] 0.5% 1.5% Duncan (2012) 0 11 0.00 [0.00; 0.01] 0.5% 1.5% Paul & Mulholland (2009) 20 20 1.5% </td <td>Scuderi et al.*** (2000)</td> <td>0</td> <td>15</td> <td>· · · ·</td> <td></td> <td>0.00</td> <td>[0.00; 0.22]</td> <td>0.5%</td> <td>1.5%</td>	Scuderi et al.*** (2000)	0	15	· · · ·		0.00	[0.00; 0.22]	0.5%	1.5%
Hodgson et al. (2015) 0 13 0.00 [0.00; 0.25] 0.4% 1.5% Lecière et al. (2013) 0 30 0.00 [0.00; 0.12] 0.5% 1.5% Valden et al. (2004) 0 12 0.00 [0.00; 0.25] 0.4% 1.5% Sun et al. (2009) 33 35 0.00 [0.00; 0.22] 0.5% 1.5% Reynaud et al. (2009) 33 35 0.00 [0.00; 0.22] 0.5% 1.5% Sun et al. (2001) 0 15 0.00 [0.00; 0.22] 0.5% 1.5% Sarninemi et al. (2015) 0 61 0.00 [0.00; 0.02] 0.5% 1.5% Swanson (2013) 0 384 0.00 [0.00; 0.02] 0.5% 1.5% Lecière et al. (2011) 0 24 0.00 [0.00; 0.02] 0.5% 1.5% Paul et al. (2011) 0 24 0.00 [0.00; 0.02] 0.5% 1.5% Duncan (2012) 0 19 0.00 [0.00; 0.02] 0.5% 1.5% Duncan (2012) 0 11 0.00 [0.00; 0.02] 0.5% 1.5% Duncan (2014) 0 0.00 [0.00; 0.01] <t< td=""><td>McBean & Katz (2009)</td><td>20</td><td>20</td><td></td><td></td><td>1.00</td><td>[0.83; 1.00]</td><td>0.5%</td><td>1.5%</td></t<>	McBean & Katz (2009)	20	20			1.00	[0.83; 1.00]	0.5%	1.5%
Lectire et al. (2014) Lectire et al. (2013) Walden et al. (2004) Sun et al. (2004) Sun et al. (2003) Sun et al. (2009) Sun et al. (2010) Sun et al. (2011) Sun et al. (2012) Sun et al. (2012) Sun et al. (2015) Sun et al. (2012) Sun et al. (2012) Sun et al. (2012) Sun et al. (2011) Sun et al. (2012) Sun et al. (2012) Sun et al. (2011) Sun et al. (2012) Sun et al. (2012) Sun et al. (2011) Sun et al. (2011) Sun et al. (2012) Sun et al. (2012) Sun et al. (2011) Sun et al. (2011) Sun et al. (2012) Sun et al. (2011) Sun et al. (2012) Sun et al. (2011) Sun et al. (2012) Sun et al. (2014) Sun et al. (2014) Sun et al. (2014) Sun et al. (2015) Sun et al. (2014) Sun et al. (2015) Sun et al. (2014) Sun et al. (2016) Sun et al. (2016) Sun et al. (2017) Sun et al. (2017) Sun et al. (2018) Sun et al. (2018) Sun et al. (2019) Sun et al. (2019) Sun et al. (2019) Sun et al. (2014) Sun et al. (2016) Sun et al. (2016) Sun et al. (2017) Sun et al. (2016) Sun et al. (2017) Sun et al. (2018) Sun et al. (2018) Sun et al. (2019) Sun et al. (2016) Sun et al. (2016) Sun et al. (2017) Sun et al. (2018) Sun et al. (2018) Sun et al. (2019) Sun et al. (2019) Su	Hodgson et al. (2005)	0	13			- 0.00	[0.00; 0.25]	0.4%	1.5%
Lectore et al. (2013) 0 30 000 0.000	Leclere et al. (2014)	0	30			0.00	[0.00; 0.12]	0.5%	1.5%
Theodorou & Chia (2013) 0 12 0.00 0.00 0.02 0.05% 1.5% Sun et al. (2009) 3 35 0.00 0.00 0.09 1.02 2.6% 1.7% Futno et al. (2009) 34 334 1.00 0.00 0.00 0.5% 1.5% Futno et al. (2010) 0 15 0.00	Walden et al. (2013)	0	30	<u> </u>		0.00	[0.00; 0.12]	0.5%	1.5%
Sun et al. (2009) 3 35 0.08 10.00 10.00 17.3% Reynaud et al. (2009) 334 334 334 0.09 0.09 1.00 0.99 1.00 0.5% 1.5% Fulton et al. (2011) 0 15 0.00 0.000	Theodorou & Chia (2013)	0	40			0.00	[0.00, 0.20]	0.4%	1.5%
Reynaud et al. (2009) 334 334 100 0.99; 1.00 0.5% 1.5% Futton et al. (2011) 0 15 0.00 0.00; 0.12; 0.5% 1.5% Saariniemi et al. (2015) 0 61 0.00 0.00; 0.02; 0.5% 1.5% Swanson (2013) 0 384 0.00 0.00; 0.01; 0.5% 1.5% Saaki (2012) 0 19 0.00 0.00; 0.00; 0.12; 0.5% 1.5% Paul et al. (2011) 0 24 0.00 0.00; 0.02; 0.08; 0.5% 1.5% Duncan (2012) 0 11 0.00 0.00; 0.00; 0.12; 0.5% 1.5% Paul & Muiholland (2009) 20 20 1.5% 0.00 0.00; 0.00; 0.02; 0.5% 1.5% Paul & Muiholland (2009) 20 20 1.00 0.83; 1.00; 0.5% 1.5% Lecière et al. (2011) 0 42 0.00 0.00; 0.00; 0.00; 0.00; 0.00; 0.00; 1.5% Lecière et al. (2013) 20 20 20 1.5% 0.00; 0.00;	Sun et al. (2009)	3	35	÷		0.09	[0.02: 0.23]	2.6%	1.7%
Futon et al. (2011) 0 15 0.00 0.00 0.22 0.5% 1.5% Moreno-Moraga et al. (2012) 0 30 0.00 0.00 0.02 0.5% 1.5% Saariniemi et al. (2015) 0 45 0.00 0.00 0.00 0.00 0.5% 1.5% Swanson (2013) 0 384 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.5% 1.5% Leckere et al. (2012) 0 57 0.00 <	Reynaud et al. (2009)	334	334			1.00	[0.99; 1.00]	0.5%	1.5%
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Fulton et al. (2001)	0	15			• 0.00	[0.00; 0.22]	0.5%	1.5%
Saariniemi et al. (2015) 0 61 0.00 0.000 0.000 0.005 1.5% Swanson (2013) 0 384 0.00 0.000 0.000 0.5% 1.5% Lecker et al. (2015) 0 45 0.00 0.000 0.001 0.5% 1.5% Sasaki (2012) 0 19 0.00 0.000 0.000 0.000 0.5% 1.5% Paul et al. (2011) 0 24 0.00 0.000 0.000 0.5% 1.5% Duncan (2012) 0 11 0.00 0.000 0.000 0.000 0.000 0.5% 1.5% Paul & Muiholland (2009) 20 20 0.00 0.000<	Moreno-Moraga et al. (2012)	0	30	·		0.00	[0.00; 0.12]	0.5%	1.5%
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Saariniemi et al. (2015)	0	61	÷		0.00	[0.00; 0.06]	0.5%	1.5%
Lecier et al. (2015) 0 45 0.00 0.000 0.008 0.5% 1.5% Hong et al. (2012) 0 57 0.00 0.000 0.000 0.5% 1.5% Paul et al. (2011) 0 24 0.00 0.000 0.000 0.5% 1.5% Duncan (2012) 0 11 0.000 0.000 0.000 0.000 0.5% 1.5% Paul et al. (2011) 0 24 0.000	Swanson (2013)	0	384	+		0.00	[0.00; 0.01]	0.5%	1.5%
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Leclere et al. (2015)	0	45	•		0.00	[0.00; 0.08]	0.5%	1.5%
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Hong et al (2012)	0	19	-		0.00	[0.00; 0.18]	0.5%	1.5%
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Paul et al. (2011)	0	2/			0.00	[0.00; 0.06]	0.5%	1.5%
Ion et al. (2011) 0 11 0.00 0.03 0.00 0.03 0.00 0.05% 1.5% Paul & Mulholland (2009) 20 20 0.00 0.03 0.00 0.03 0.00 0.05% 1.5% Song et al. (2014) 0 331 0.00 0.00 0.05% 1.5% Lectar et al. (2013) 20 20 0.00	Duncan (2012)	0	24	T		0.00	[0.00, 0.14]	0.5%	1.5%
Paul & Mulholland (2009) 20 20 1.00 $[0.33; 1.00]$ 0.5% 1.5% Song et al. (2014) 0 331 1.00 $[0.00; 0.01]$ 0.5% 1.5% Petty et al. (2010) 0 50 0.00 $[0.00; 0.07]$ 0.5% 1.5% Licita et al. (2013) 20 230 0.09 $[0.05; 0.13]$ 17.0% 1.8% Lecière et al. (2016) 18 22 0.33 $[0.00; 0.07]$ 0.4% 1.7% Fixed effect model 17371 0.31 0.31 $[0.27; 0.35]$ 100.0% Heterogeneity: $l^2 = 93\%, \tau^2 = 10.5454, p < 0.01$ ψ <td< td=""><td>lon et al. (2011)</td><td>0</td><td>42</td><td></td><td></td><td>0.00</td><td>[0.00; 0.20]</td><td>0.4%</td><td>1.5%</td></td<>	lon et al. (2011)	0	42			0.00	[0.00; 0.20]	0.4%	1.5%
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Paul & Mulholland (2009)	20	20	_		1.00	[0.83: 1.00]	0.5%	1.5%
Petty et al. (2010) 0 50 \cdot 0.00 [0.00; 0.07] 0.5% 1.5% Licata et al. (2013) 20 230 \cdot 0.09 [0.05; 0.13] 17.0% 1.8% Alexiades-Armenakas (2012) 4 12 \cdot 0.03 [0.09; 1.00] 0.5% 1.5% Alexiades-Armenakas (2012) 4 12 \cdot 0.33 [0.10; 0.65] 2.5% 1.7% Leclère et al. (2016) 18 22 \cdot 0.33 [0.10; 0.65] 2.5% 1.7% Leclère et al. (2016) 18 22 \cdot 0.33 [0.10; 0.65] 2.5% 1.7% 0.82 [0.60; 0.95] 3.0% 1.7% 0.82 [0.60; 0.95] 3.0% \cdot 1.5% 0.33 [0.10; 0.65] 2.5% 1.7% 0.33 [0.10; 0.65] 2.5% 1.7% 0.33 [0.10; 0.65] 2.5% 1.7% 0.33 [0.00; 0.07] \cdot 100.0%	Song et al. (2014)	0	331			- 0.00	[0.00; 0.01]	0.5%	1.5%
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Petty et al. (2010)	0	50	•		0.00	[0.00; 0.07]	0.5%	1.5%
Leciere et al. (2012) 359 359 Alexiades-Armenakas (2012) 4 12 Lecière et al. (2016) 18 22 Fixed effect model 17371 Heterogeneity: $l^2 = 93\%$, $\tau^2 = 10.5454$, $p < 0.01$	Licata et al. (2013)	20	230	÷		0.09	[0.05; 0.13]	17.0%	1.8%
Alexiades-Armenakas (2012) 4 12 0.33 0.10: $(0.65]$ 2.5% 1.7% Lecière et al. (2016) 18 22 0.32 0.02: $(0.60; 0.25]$ 3.0% 1.7% Fixed effectmodel 17371 0.31 0.31 [0.27; 0.35] 100.0% Heterogeneity: $l^2 = 93\%$, $r^2 = 10.5454$, $p < 0.01$ 0.01 0.02 [0.01; 0.07] 100.0%	Leclere et al. (2012)	359	359	+		1.00	[0.99; 1.00]	0.5%	1.5%
Lectoric et al. (2010) 18 22 0.82	Alexiades-Armenakas (2012)	.4	12			. 0.33	[0.10; 0.65]	2.5%	1.7%
Fixed effect model 17371 0.31 [0.27; 0.35] 100.0% Random effects model 17371 0.33 [0.01; 0.07] 100.0% Heterogeneity: I ² = 93%, τ ² = 10.5454, p < 0.01	Leclere et al. (2016)	18	22			0.82	[0.60; 0.95]	3.0%	1.7%
Hot vice interval $(0.27, 0.33)$ $(0.07, 0.07)$ Random effects model Heterogeneity: $l^2 = 93\%$, $\tau^2 = 10.5454$, $p < 0.01$ 0.03 $[0.01; 0.07]$ 100.0%	Fixed effectmodel		17374			0.34	[0 27.0 25]	100.0%	
Heterogeneity: $J^2 = 93\%$, $\tau^2 = 10.5454$, $p < 0.01$	Random effects model				<u>i</u>	0.03	[0.01: 0.07]	.00.0%	100.0%
φ <mark>0.2 0₁4 0.6 ρ.8 1 γ γ γ</mark>	Heterogeneity: $l^2 = 93\%$, $\tau^2 = 10.545$	4, p < 0.01			-		,		
				0.2 0 4 ().6 ρ.8 1	Г			

Supplementary Figure 3 *Rate of edema as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Study	Events	Total	Proportio	n 95%-C	Weight ۱ I (fixed) (r	Neight andom)
Katz & McBean (2008)	0	537	0.0	0 [0.00; 0.01]	0.6%	1.5%
Duncan (2013)	0	12		0 [0.00; 0.26]	0.6%	1.5%
Giugliano et al. (2004) Belend (2012)	2	220	0.0	3 [0.00; 0.12]	2.3%	2.0%
Valizadab at al * (2016)	0	19	0.0	0 [0.00,0.01]	0.0%	1.5%
Valizadeh et al. ** (2016)	0	18	- 0.0	0 [0.00,0.19]	0.0%	1.5%
Keramidas & Rodopoulou (2016)	0	55	- 0.0	0 [0.00:0.06]	0.6%	1.5%
Leclère et al. (2015)	2	10	• 0.2	0 [0.03:0.56]	1.9%	1.9%
Hurwitz & Smith (2012)	0	17	_ 0.0	0 [0.00:0.20]	0.6%	1.5%
Moskovitz et al. (2007)	0	20	- 0.0	0 [0.00; 0.17]	0.6%	1.5%
Cohen et al. (2012)	0	23	0.0	0 [0.00; 0.15]	0.6%	1.5%
Habbema (2009)	0	151	0.0	0 [0.00; 0.02]	0.6%	1.5%
Boni (2006)	0	38	0.0	0 [0.00; 0.09]	0.6%	1.5%
Wall & Lee (2016)	0	129	0.0	0 [0.00;0.03]	0.6%	1.5%
Chia & Theodorou (2012)	0	581	0.0	0 [0.00;0.01]	0.6%	1.5%
Jacob et al. (2000)	0	20	. 0.0	0 [0.00;0.17]	0.6%	1.5%
Kim et al.** (2011)	0	884	0.0	0 [0.00; 0.00]	0.6%	1.5%
Kim et al.*** (2011)	0	832	0.0	0 [0.00;0.00]	0.6%	1.5%
Commons et al." (2001)	0	514	0.0		0.0%	1.5%
Commons et al. (2001)	0	20	0.0		0.6%	1.5%
Wang et al. (2018)	0	20	. 0.0		0.6%	1.5%
Reustani et al. (2000)	0	609	0.0	0 [0.00,0.04]	0.0%	1.5%
Blugerman et al. (2009)	ő	23	0.0	0 [0.00:0.15]	0.6%	1.5%
Katz et al. (2003)	ő	207	0.0	0 [0.00,0.10]	0.6%	1.5%
Innocenti et al. (2014)	5	118	0.0	4 [0.01:0.10]	5.7%	2.1%
Zoccali et al. (2012)	Ō	797	0.0	0 [0.00; 0.00]	0.6%	1.5%
Perez & Tetering (2003)	0	351	0.0	0 [0.00; 0.01]	0.6%	1.5%
Mellul et al. (2006)	0	14	0.0	0 [0.00; 0.23]	0.6%	1.5%
Saleh et al. (2009)	0	60	0.0	0 [0.00; 0.06]	0.6%	1.5%
Zhang et al. (2015)	0	4000	0.0	0 [0.00; 0.00]	0.6%	1.5%
Goldman (2006)	0	82	0.0	0 [0.00; 0.04]	0.6%	1.5%
Trelles et al. (2013)	0	28	0.0	0 [0.00; 0.12]	0.6%	1.5%
Branas & Moraga* (2013)	0	330	0.0	0 [0.00;0.01]	0.6%	1.5%
Branas & Moraga** (2013)	0	100	0.0	0 [0.00;0.04]	0.6%	1.5%
Scuderi et al.* (2000)	0	15	0.0	0 [0.00;0.22]	0.6%	1.5%
Scuderi et al.** (2000)	1	15	- 0.0	7 [0.00;0.32]	1.1%	1.8%
Scuderi et al.*** (2000)	0	15		0 [0.00; 0.22]	0.6%	1.5%
McBean & Katz (2009)	20	20	1.0		0.6%	1.5%
Hodgson et al. (2005)	0	13		0 [0.00;0.25]	0.6%	1.5%
Leciere et al. (2014)	30	30	0.0	0 [0.00,0.12]	0.6%	1.5%
Leciere et al. (2013)	50	12	0.0	0 [0.88, 1.00]	0.0%	1.5%
Theodorou & Chip (2012)	0	40		0 [0.00,0.20]	0.0%	1.5%
Sun et al. (2009)	ő	35	0.0	0 [0.00,0.00]	0.6%	1.5%
Revnaud et al. (2009)	Ő	334	0.0	0 [0.00:0.01]	0.6%	1.5%
Fulton et al. (2001)	0	15	0.0	0 [0.00:0.22]	0.6%	1.5%
Moreno-Moraga et al. (2012)	0	30	- 0.0	0 [0.00; 0.12]	0.6%	1.5%
Saariniemi et al. (2015)	0	61 🕂	0.0	0 [0.00;0.06]	0.6%	1.5%
Swanson (2013)	1	384	0.0	0 [0.00; 0.01]	1.2%	1.8%
Leclère et al. (2015)	11	45 •	0.2	4 [0.13;0.40]	9.8%	2.1%
Sadove (2005)	0	25 -	— <u>•</u> — 0.0	0 [0.00;0.14]	0.6%	1.5%
Sasaki (2012)	0	19	0.0	0 [0.00;0.18]	0.6%	1.5%
Hong et al. (2012)	0	57	- 0.0	0 [0.00;0.06]	0.6%	1.5%
Paul et al. (2011)	0	24 —	0.0	0 [0.00;0.14]	0.6%	1.5%
Duncan (2012)	0	11 ++	0.0	0 [0.00;0.28]	0.6%	1.5%
lon et al. (2011)	0	42	0.0	0 [0.00; 0.08]	0.6%	1.5%
Paul & Mulholland (2009)	20	20	1.0		0.6%	1.5%
Song et al. (2014)	0	50	0.0		0.0%	1.5%
Petty et al. (2010)	10	230	0.0	0 [0.00,0.07] 9 [0 14 · 0 241	0.0% 41 /%	1.5%
Licata et al. (2013)	43	350	0.1	0 [0.14,0.24]	41.4 % 0.6%	2.270
Aleviades – Armonakas (2012)	12	12		0 [0.74.1 00]	0.0%	1.5%
Leclère et al (2016)	4	22	. 0.1	8 [0.05:0.40]	3.9%	2.1%
LEGIERE EL dI. (2010)	-		0.1	5 [0.00, 0.40]	0.070	2.170
Fixed effect model		13474	0.0	7 [0.06; 0.09]	100.0%	
Random effects model			0.0	2 [0.01; 0.03]	I ·	00.0%
Heterogeneity: I ² = 82%, τ ² = 4.3249,	p < 0.01					
		¢ —	01 <u>2 014 016 018 1</u>			

Supplementary Figure 4 *Rate of contour irregularity as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

						Weight \	Neight
Study	Events	Total		Proportion	95%-CI	(fixed) (ra	andom)
Kata & MaDaara (2000)	•	507	1	0.00		0.00/	1 00/
Katz & McBean (2008)	0	537 +		0.00	[0.00; 0.01]	0.2%	1.2%
Giudiano et al. (2004)	0	12		0.00	[0.00; 0.26]	0.2%	1.2%
Boland (2012)	0	320		0.00		0.2%	1.2%
Valizadeh et al * (2016)	0	18		0.00	[0.00, 0.01]	0.2%	1.2%
Valizadeh et al ** (2016)	0	18		0.00	[0.00, 0.19]	0.2 %	1.2 %
Keramidas & Rodopoulou (2016)	Ő	55		0.00	[0.00: 0.06]	0.2%	1.2%
Leclère et al. (2015)	ŏ	10		0.00	[0.00: 0.31]	0.2%	1.2%
Hurwitz & Smith (2012)	0	17 ++		0.00	[0.00: 0.20]	0.2%	1.2%
Moskovitz et al. (2007)	0	20 +		0.00	[0.00; 0.17]	0.2%	1.2%
Cohen et al. (2012)	0	23 🛶		0.00	[0.00; 0.15]	0.2%	1.2%
Habbema (2009)	2	151 🛶	_	0.01	[0.00; 0.05]	0.7%	2.4%
Boni (2006)	0	38 🛶		0.00	[0.00; 0.09]	0.2%	1.2%
Wall & Lee(2016)	0	129		0.00	[0.00; 0.03]	0.2%	1.2%
Chia & Theodorou (2012)	0	581 📮		0.00	[0.00; 0.01]	0.2%	1.2%
Jacob et al. (2000)	0	20		0.00	[0.00; 0.17]	0.2%	1.2%
Kim et al.* (2011)	45	682		0.07	[0.05; 0.09]	14.2%	3.5%
Kim et al.^^ (2011)	21	884	-	0.02	[0.01; 0.04]	6.9%	3.4%
Commono et al. (2011)	23	632	F	0.03	[0.02; 0.04]	10.0%	3.4%
Commons et al. (2001)	63	20		0.10	[0.08; 0.13]	19.2%	3.5%
Wang et al. (2003)	0	20		0.00	[0.00, 0.17]	0.2 /0	1.2 /0
Roustaei et al. (2009)	0	600	-	0.00		0.2%	1.2%
Blugerman et al (2010)	0	23		0.00	[0.00; 0.01]	0.2%	1.2%
Katz et al. (2003)	0	207		0.00	[0.00; 0.02]	0.2%	1.2%
Innocenti et al. (2014)	Ō	118		0.00	[0.00: 0.03]	0.2%	1.2%
Zoccali et al. (2012)	76	797	_	0.10	[0.08; 0.12]	23.2%	3.5%
Perez & Tetering (2003)	0	351		0.00	[0.00; 0.01]	0.2%	1.2%
Mellul et al. (2006)	0	14		0.00	[0.00; 0.23]	0.2%	1.2%
Saleh et al. (2009)	12	60		0.20	[0.11; 0.32]	3.2%	3.2%
Zhang et al. (2015)	38	4000		0.01	[0.01; 0.01]	12.7%	3.5%
Goldman (2006)	2	82		0.02	[0.00; 0.09]	0.7%	2.4%
Trelles et al. (2013)	0	28		0.00	[0.00; 0.12]	0.2%	1.2%
Branas & Moraga* (2013)	4	330		0.01	[0.00; 0.03]	1.3%	2.9%
Branas & Moraga ^{**} (2013)	3	100		0.03	[0.01; 0.09]	1.0%	2.7%
Scuderi et al." (2000)	0	15		0.00	[0.00; 0.22]	0.2%	1.2%
Souderi et al. (2000)	0	15		0.00	[0.00; 0.22]	0.2%	1.2%
McBean & Katz (2000)	0	20 +		0.00	[0.00, 0.22]	0.2 /0	1.2 /0
Hodgson et al. (2005)	0	13		0.00	[0.00, 0.17]	0.2%	1.2%
Leclère et al. (2014)	0	30		0.00	[0.00; 0.23]	0.2%	1.2%
Leclère et al. (2013)	ő	30		0.00	[0.00; 0.12]	0.2%	1.2%
Walden et al. (2004)	õ	12		0.00	[0.00: 0.26]	0.2%	1.2%
Theodorou & Chia (2013)	Ō	40		0.00	[0.00; 0.09]	0.2%	1.2%
Sun et al. (2009)	0	35 🕂	<u>+</u>	0.00	[0.00; 0.10]	0.2%	1.2%
Reynaud et al. (2009)	0	334 🕂	<u>+</u>	0.00	[0.00; 0.01]	0.2%	1.2%
Fulton et al. (2001)	0	15 -		0.00	[0.00; 0.22]	0.2%	1.2%
Moreno-Moraga et al. (2012)	0	30 🕂		0.00	[0.00; 0.12]	0.2%	1.2%
Saariniemi et al. (2015)	0	61 🕂		0.00	[0.00; 0.06]	0.2%	1.2%
Swanson (2013)	0	384 🕂	+	0.00	[0.00; 0.01]	0.2%	1.2%
Leclère et al. (2015)	0	45 ⊷		0.00	[0.00; 0.08]	0.2%	1.2%
Sadove (2005)	0	25 ++	<u>+</u>	0.00	[0.00; 0.14]	0.2%	1.2%
Sasaki (2012)	0	19		0.00	[0.00; 0.18]	0.2%	1.2%
Hong et al. (2012)	2	5/		0.04	[0.00; 0.12]	0.7%	2.4%
Paul et al. (2011) Duncon (2012)	0	24 -	•	0.00	[0.00, 0.14]	0.2%	1.2%
lon et al. (2012)	0	11		0.00	[0.00, 0.28]	0.2 /0	1.2 /0
Paul & Mulholland (2009)	0	20		0.00	[0.00; 0.00]	0.2%	1.2%
Song et al. (2014)	0	331		0.00	[0.00.0.01]	0.2%	1.2%
Petty et al. (2010)	0 0	50		0.00	[0.00; 0.07]	0.2%	1.2%
Licata et al. (2013)	õ	230		0.00	[0.00; 0.02]	0.2%	1.2%
Leclère et al. (2012)	õ	359		0.00	[0.00; 0.01]	0.2%	1.2%
Alexiades-Armenakas (2012)	0	12		0.00	[0.00; 0.26]	0.2%	1.2%
Leclère et al. (2016)	Ō	22		0.00	[0.00; 0.15]	0.2%	1.2%
Fixed effectmodel		14156		0.05	[0.04;0.05]	100.0%	
Random effects model			•	0.02	[0.01; 0.02]	1	00.0%
Heterogeneity: $I^2 = 81\%$, $\tau^2 = 1.0674$,	p < 0.01		05 0 1 0 15 0 2 0 25 0 2				
		ψU	υφ υ . ηυ. τοιυ.2 ψ.25 ψ.3 η				

Supplementary Figure 5 *Rate of seroma as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

a				_			Weight	Weight
Study	Events	Total		Prop	ortion	95%-CI	(fixed) (random)
Katz & McBean (2008)	0	537	- 1		0.00	[0.00: 0.01]	0.3%	0.9%
Duncan (2013)	Ō	12	, <u>i</u>		0.00	[0.00; 0.26]	0.3%	0.9%
Giugliano et al. (2004)	0	60	-i		0.00	[0.00; 0.06]	0.3%	0.9%
Roland (2012)	0	320	-		0.00	[0.00; 0.01]	0.3%	0.9%
Boeni (2011)	0	4380			0.00	[0.00; 0.00]	0.3%	0.9%
Valizadeh et al.* (2016)	0	18		-	0.00	[0.00; 0.19]	0.3%	0.9%
Valizaden et al (2016) Koramidaa & Badapaulau (2016)	0	18	•	_	0.00	[0.00; 0.19]	0.3%	0.9%
Leclère et al. (2015)	0	10			0.00	[0.00, 0.00]	0.3%	0.9%
Hurwitz & Smith (2012)	1	17	1		0.06	[0.00; 0.01]	0.5%	1.5%
Moskovitz et al. (2007)	O	20	1		0.00	[0.00; 0.17]	0.3%	0.9%
Cohen et al. (2012)	0	23			0.00	[0.00; 0.15]	0.3%	0.9%
Habbema (2009)	0	151	4		0.00	[0.00; 0.02]	0.3%	0.9%
Boni (2006)	0	38			0.00	[0.00; 0.09]	0.3%	0.9%
Wall & Lee(2016)	5	129	3 .		0.04	[0.01; 0.09]	2.7%	3.6%
Chia & Theodorou (2012)	0	581	-1		0.00	[0.00; 0.01]	0.3%	0.9%
Jacob et al. (2000)	0	20			0.00	[0.00; 0.17]	0.3%	0.9%
Kim et al." (2011)	15	682	+		0.02	[0.01; 0.04]	8.2%	4.7%
Kim et al *** (2011)	10	004	÷		0.02	[0.01; 0.03]	9.9%	4.9%
Commons et al * (2001)	21	514	-		0.03	[0.02, 0.04]	2 20%	4.9%
Commons et al.**(2001)	0	117	•		0.01	[0.00, 0.02]	0.3%	0.9%
Omranifard (2003)	Ő	20	+		0.00	[0.00; 0.17]	0.3%	0.9%
Habbema (2009)	Ő	3240			0.00	[0.00; 0.00]	0.3%	0.9%
Wang et al. (2018)	0	83	1		0.00	[0.00; 0.04]	0.3%	0.9%
Roustaei et al. (2009)	3	609	3		0.00	[0.00; 0.01]	1.7%	3.0%
Blugerman et al. (2010)	0	23	<u> </u>		0.00	[0.00; 0.15]	0.3%	0.9%
Katz et al. (2003)	3	207	1		0.01	[0.00; 0.04]	1.7%	3.0%
Innocenti et al. (2014)	0	118	4		0.00	[0.00; 0.03]	0.3%	0.9%
Zoccali et al. (2012)	15	797			0.02	[0.01; 0.03]	8.3%	4.7%
Perez & Tetering (2003)	3	351	<u>.</u>		0.01	[0.00; 0.02]	1.7%	3.0%
Nellul et al. (2006)	0	14			0.00	[0.00; 0.23]	0.3%	0.9%
Zhang et al. (2009)	9	4000	· · · ·		0.15	[0.07; 0.27]	4.3%	4.2%
Goldman (2006)	50	4000	<u> </u>		0.01	[0.01; 0.02]	27.7%	0.0%
Trelles et al. (2013)	0	28	÷-		0.00	[0.00, 0.04]	0.3%	0.3%
Branas & Moraga* (2013)	0	330			0.00	[0.00; 0.12]	0.3%	0.3%
Branas & Moraga** (2013)	Ő	100	⊢;		0.00	[0.00; 0.04]	0.3%	0.9%
Scuderi et al.* (2000)	0	15	, 1		0.00	[0.00; 0.22]	0.3%	0.9%
Scuderi et al.** (2000)	0	15			0.00	[0.00; 0.22]	0.3%	0.9%
Scuderi et al.*** (2000)	0	15			0.00	[0.00; 0.22]	0.3%	0.9%
McBean & Katz (2009)	0	20			0.00	[0.00; 0.17]	0.3%	0.9%
Hodgson et al. (2005)	0	13			0.00	[0.00; 0.25]	0.3%	0.9%
Leciere et al. (2014)	0	30			0.00	[0.00; 0.12]	0.3%	0.9%
Walden et al. (2013)	0	30	2		0.00	[0.00; 0.12]	0.3%	0.9%
Theodorou & Chia (2013)	1	40	, <u>i</u>		0.00	[0.00, 0.20]	0.5%	1.5%
Sun et al. (2009)	0	35	- .		0.02	[0.00; 0.10]	0.3%	0.9%
Revnaud et al. (2009)	0	334	·		0.00	[0.00; 0.01]	0.3%	0.9%
Fulton et al. (2001)	0	15	⊢;		0.00	[0.00: 0.22]	0.3%	0.9%
Moreno-Moraga et al. (2012)	0	30			0.00	[0.00; 0.12]	0.3%	0.9%
Saariniemi et al. (2015)	0	61			0.00	[0.00; 0.06]	0.3%	0.9%
Swanson (2013)	0	384	<u>+</u>		0.00	[0.00; 0.01]	0.3%	0.9%
Leclère et al. (2015)	0	45	-j		0.00	[0.00; 0.08]	0.3%	0.9%
Sadove (2005)	0	25			0.00	[0.00; 0.14]	0.3%	0.9%
Sasaki (2012) Hong et al (2012)	0	19	·		0.00	[0.00; 0.18]	0.3%	0.9%
Poul et al. (2012)	0	57	1	-	0.00	[0.00; 0.06]	0.3%	0.9%
Duncan (2012)	1	24			0.04	[0.00; 0.21]	0.3%	1.5%
lon et al. (2011)	0	42			0.00	[0.00, 0.20]	0.3%	0.3%
Paul & Mulholland (2009)	ő	20			0.00	[0.00; 0.00]	0.3%	0.9%
Song et al. (2014)	7	331			0.02	[0.01; 0.04]	3.8%	4.0%
Petty et al. (2010)	1	50	4		0.02	[0.00; 0.11]	0.6%	1.5%
Licata et al. (2013)	0	230	4		0.00	[0.00; 0.02]	0.3%	0.9%
Leclère et al. (2012)	0	359	4		0.00	[0.00; 0.01]	0.3%	0.9%
Alexiades-Armenakas (2012)	0	12	⊢,		0.00	[0.00; 0.26]	0.3%	0.9%
Leciere et al. (2016)	0	22	. <u>.</u>		0.00	[0.00; 0.15]	0.3%	0.9%
Fined offerstmendel		04770				10 04 0 000	400.00	
Fixed effects model		21//6	1		0.02	[0.01; 0.02]	100.0%	100.0%
Heterogeneity: $l^2 = 48\%$ $\tau^2 = 0.3856$	n < 0.01		•		0.01	[0.01, 0.02]		100.070
	, 0.01		թ <mark>ծ.օ, օ.1 թ.15 թ.։</mark>	2 0 ₁ 25 0.3				

Supplementary Figure 6 *Rate of hematoma as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Study	Evonte Total	Proportion	W	/eight	Weight
Study	Events Total	Рюронной	95 %-CI (IIX	eu) (ran	uom)
Katz & McBean (2008)	0 537 -	0.00	[0; 0.01]	1.1%	1.3%
Duncan (2013)	0 12	0.00	[0; 0.26]	1.1%	1.3%
Giugliano et al. (2004)	0 60	0.00	[0; 0.06]	1.1%	1.3%
Roland (2012) Roopi (2011)	1 320 +-	0.00	[0; 0.02]	2.2%	2.1%
Valizadeb et al * (2016)	0 18		[0, 0.00]	1.1%	1.3%
Valizadeh et al.** (2016)	0 18	0.00	[0; 0, 19]	1.1%	1.3%
Keramidas & Rodopoulou (2016)	0 55	0.00	[0; 0.06]	1.1%	1.3%
Leclère et al. (2015)	0 10	0.00	[0; 0.31]	1.1%	1.3%
Hurwitz & Smith (2012)	0 17	0.00	[0; 0.20]	1.1%	1.3%
Moskovitz et al. (2007)	0 20		[0;0.17]	1.1%	1.3%
Conen et al. (2012)	0 23	- 0.00	[0; 0.15]	1.1%	1.3%
Boni (2006)	2 151 -	0.01	[0, 0.05]	4.4%	2.9%
Wall & Lee(2016)	0 129	0.00	[0; 0.03]	1.1%	1.3%
Chia & Theodorou (2012)	1 581	0.00	[0; 0.01]	2.2%	2.1%
Jacob et al. (2000)	0 20	0.00	[0; 0.17]	1.1%	1.3%
Kim et al.* (2011)	0 682	0.00	[0; 0.01]	1.1%	1.3%
Kim et al.** (2011)	0 884	0.00	[0; 0.00]	1.1%	1.3%
KIM et al. (2011)	0 832	0.00	[0; 0.00]	1.1%	1.3%
Commons et al.**(2001)	0 117	0.00	[0,0.01]	1.1%	1.3%
Omranifard (2003)	0 20	0.00	[0; 0.17]	1.1%	1.3%
Habbema (2009)	2 3240	0.00	[00.0]	4.5%	2.9%
Wang et al. (2018)	0 83	0.00	[0; 0.04]	1.1%	1.3%
Roustaei et al. (2009)	0 609	0.00	[0; 0.01]	1.1%	1.3%
Blugerman et al. (2010)	0 23	. 0.00	[0;0.15]	1.1%	1.3%
Raiz et al. (2003)	0 207	0.00	[0; 0.02]	1.1%	1.3%
Zoccali et al. (2012)	0 797	0.00	[0, 0.03]	1.1%	1.3%
Perez & Tetering (2003)	0 351	0.00	[0; 0.01]	1.1%	1.3%
Mellul et al. (2006)	0 14	0.00	[0; 0.23]	1.1%	1.3%
Saleh et al. (2009)	0 60	0.00	[0; 0.06]	1.1%	1.3%
Zhang et al. (2015)	0 4000	0.00	[0; 0.00]	1.1%	1.3%
Goldman (2006) Trollog et al. (2012)	0 82	0.00	[0; 0.04]	1.1%	1.3%
Branas & Moraga* (2013)	0 330	0.00		1.1%	1.3%
Branas & Moraga** (2013)	0 100	0.00	[0: 0.04]	1.1%	1.3%
Scuderi et al.* (2000)	0 15	0.00	[0; 0.22]	1.1%	1.3%
Scuderi et al.** (2000)	0 15	0.00	[0; 0.22]	1.1%	1.3%
Scuderi et al.*** (2000)	0 15	0.00	[0; 0.22]	1.1%	1.3%
McBean & Katz (2009) Hodgson et al. (2005)	0 20	0.00	[0; 0.17]	1.1%	1.3%
Leclère et al. (2003)	0 13	0.00	[0; 0.25]	1.1%	1.3%
Leclère et al. (2013)	0 30	0.00	[0, 0, 12]	1.1%	1.3%
Walden et al. (2004)	0 12	0.00	[0; 0.26]	1.1%	1.3%
Theodorou & Chia (2013)	0 40	0.00	[0; 0.09]	1.1%	1.3%
Sun et al. (2009)	0 35 -	0.00	[0; 0.10]	1.1%	1.3%
Reynaud et al. (2009)	0 334	0.00	[0; 0.01]	1.1%	1.3%
Fullon et al. (2001) Moreno-Morada et al. (2012)	0 20	0.00	[0; 0.22]	1.1%	1.3%
Saariniemi et al. (2015)		0.00	[0,0.12]	2.2%	2.1%
Swanson (2013)	0 384	0.00	[0; 0.01]	1.1%	1.3%
Leclère et al. (2015)	0 45 🕌	0.00	[0; 0.08]	1.1%	1.3%
Sadove (2005)	1 25	0.04	[0; 0.20]	2.2%	2.1%
Sasaki (2012)	0 19	0.00	[0;0.18]	1.1%	1.3%
Paul et al. (2012)	0 57	0.00	[0; 0.06]	1.1%	1.3%
Duncan (2012)	0 24	0.00	[0; 0, 14]	1.1%	1.3%
lon et al. (2011)	0 42		[0: 0.08]	1.1%	1.3%
Paul & Mulholland (2009)	0 20	0.00	[0; 0.17]	1.1%	1.3%
Song et al. (2014)	4 331 🙀	0.01	[0; 0.03]	8.9%	3.7%
Petty et al. (2010)	1 50 🛖	0.02	[0;0.11]	2.2%	2.1%
Licdla et al. (2013)	0 230	0.00	[0; 0.02]	1.1%	1.3%
Alexiades-Armenakas (2012)	0 12	0.00	[0; 0.01]	1.1%	1.3%
Leclère et al. (2016)	0 22	0.00	[0:0.15]	1.1%	1.3%
. /	· ·	0.00	[0, 0.10]		
Fixed effectmodel	21776	0.01	[0; 0.01] 10	10.0%	
Random effects model		0.01	[0; 0.01]	10	00.0%
neterogeneity: / = 33%, τ ⁻ = 0.7518	, p < 0.01	0.2 0.25 0.3			
	ψυ.υφυ.ιμ.το	P.= 0420 0.0			

Supplementary Figure 7 *Rate of surgical site infection as determined using both the fixedeffects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Study	Events Total	Proportion	95%-CI	Weight (fixed) (ra	Weight Indom)
Katz & McBean (2008)	1 537	0.00	[0.00; 0.01]	2.5%	1.8%
Giudiano et al. (2004)	0 60	- 0.00	[0.00; 0.26]	1.2%	1.5%
Roland (2012)	0 320	0.00	[0.00; 0.00]	1.2%	1.5%
Valizadeh et al.* (2016)	0 18	0.00	[0.00; 0.19]	1.2%	1.5%
Valizadeh et al.** (2016)	0 18 🖬		[0.00; 0.19]	1.2%	1.5%
Keramidas & Rodopoulou (2016)	0 55 🖌	- 0.00	[0.00; 0.06]	1.2%	1.5%
Leclère et al. (2015)	0 10	0.00	[0.00; 0.31]	1.2%	1.5%
Hurwitz & Smith (2012) Moskovitz et al. (2007)	0 17	0.00	[0.00; 0.20]	1.2%	1.5%
Cohen et al. (2012)	0 23	0.00	[0.00; 0.17]	1.2%	1.5%
Habbema (2009)	0 151	0.00	[0.00; 0.02]	1.2%	1.5%
Boni (2006)	0 38	0.00	[0.00; 0.09]	1.2%	1.5%
Wall & Lee(2016)	0 129 🖡	0.00	[0.00; 0.03]	1.2%	1.5%
Chia & Theodorou (2012)	2 581	0.00	[0.00; 0.01]	5.0%	2.1%
Jacob et al. (2000) Kim et al.* (2011)	1 682	0.00		1.2%	1.5%
Kim et al.** (2011)	1 884	0.00	[0.00; 0.01]	2.5%	1.8%
Kim et al.*** (2011)	0 832	0.00	[0.00; 0.00]	1.2%	1.5%
Commons et al.* (2001)	0 514	0.00	[0.00; 0.01]	1.2%	1.5%
Commons et al.**(2001)	0 117 🛓	0.00	[0.00; 0.03]	1.2%	1.5%
Omranifard (2003)	16 20	0.80	[0.56; 0.94]	8.0%	2.2%
Roustaei et al. (2018)	0 609	. 0.00	[0.00; 0.04]	1.2%	1.5%
Blugerman et al. (2010)	0 23	0.00	[0.00: 0.15]	1.2%	1.5%
Katz et al. (2003)	0 207	0.00	[0.00; 0.02]	1.2%	1.5%
Innocenti et al. (2014)	0 118	0.00	[0.00; 0.03]	1.2%	1.5%
Zoccali et al. (2012)	0 797	0.00	[0.00; 0.00]	1.2%	1.5%
Perez & Tetering (2003)	2 351	0.01	[0.00; 0.02]	5.0%	2.1%
Saleh et al. (2006)	0 14	0.00	[0.00; 0.23]	1.2%	1.5%
Zhang et al. (2015)	1 4000	- 0.00	[0.00; 0.00]	2.5%	1.8%
Goldman (2006)	0 82	0.00	[0.00; 0.04]	1.2%	1.5%
Trelles et al. (2013)	0 28	0.00	[0.00; 0.12]	1.2%	1.5%
Branas & Moraga* (2013)	0 330	0.00	[0.00; 0.01]	1.2%	1.5%
Branas & Moraga (2013) Scuderi et al * (2000)	0 100	0.00	[0.00; 0.04]	1.2%	1.5%
Scuderi et al ** (2000)	0 15	0.00	[0.00; 0.22]	1.2%	1.5%
Scuderi et al.*** (2000)	0 15	0.00	[0.00: 0.22]	1.2%	1.5%
McBean & Katz (2009)	0 20	0.00	[0.00; 0.17]	1.2%	1.5%
Hodgson et al. (2005)	0 13	0.00	[0.00; 0.25]	1.2%	1.5%
Leclère et al. (2014)	0 30	0.00	[0.00; 0.12]	1.2%	1.5%
Walden et al. (2013)	0 30	0.00	[0.00; 0.12]	1.2%	1.5%
Theodorou & Chia (2013)	0 40		[0.00, 0.20] [0.00 [,] 0.09]	1.2%	1.5%
Sun et al. (2009)	0 35	- 0.00	[0.00; 0.10]	1.2%	1.5%
Reynaud et al. (2009)	0 334 🗧	- 0.00	[0.00; 0.01]	1.2%	1.5%
Fulton et al. (2001)	0 15	0.00	[0.00; 0.22]	1.2%	1.5%
woreno-moraga et al. (2012) Saariniemi et al. (2015)	0 30	0.00	[U.00; 0.12]	1.2%	1.5%
Swanson (2013)	0 384	- 0.00	[0.00; 0.06] [0.00: 0.01]	1.2%	1.5%
Leclère et al. (2015)	0 45	0.00	[0.00; 0.08]	1.2%	1.5%
Sadove (2005)	0 25	- 0.00	[0.00; 0.14]	1.2%	1.5%
Sasaki (2012)	0 19 🛉	0.00	[0.00; 0.18]	1.2%	1.5%
Hong et al. (2012)	0 57 🛉	0.00	[0.00; 0.06]	1.2%	1.5%
Paul et al. (2011) Duncan (2012)	0 24	- 0.00	[0.00; 0.14]	1.2%	1.5%
lon et al. (2011)	0 42		[0.00, 0.28]	1.2%	1.5%
Paul & Mulholland (2009)	0 20	- 0.00	[0.00; 0.17]	1.2%	1.5%
Song et al. (2014)	0 331	0.00	[0.00; 0.01]	1.2%	1.5%
Petty et al. (2010)	0 50 🗖	0.00	[0.00; 0.07]	1.2%	1.5%
Licata et al. (2013)	0 230	- 0.00	[0.00; 0.02]	1.2%	1.5%
Alexiades-Armenakas (2012)	U 359	0.00	0.00; 0.01	1.2%	1.5%
Leclère et al. (2016)	0 22	0.00	[0.00: 0.15]	1.2%	1.5%
Fixed effectmodel	14156	0.01	[0.01; 0.02]	100.0%	
Random effects model		0.01 [0.01; 0.02]	1	00.0%
Heterogeneity: I = 66%, τ = 3.1886,	p < 0.01	012 0.4 0.6 0.8			
					

Supplementary Figure 8 *Rate of thermal injury as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

						Weight	Weight
Study	Events 1	Fotal	I	Proportion	95%-CI	(fixed)	(random)
Katz & McBean (2008)	4	537		0.01	[0.00; 0.02]	8.3%	6.6%
Valizadeh et al. (2016)	0	18	2	0.00	[0.00; 0.19]	1.0%	1.8%
Keramidas & Rodopoulou (2016)	2	55		0.04	[0.00; 0.13]	4.0%	4.7%
Leclère et al. (2015)	0	10		0.00	[0.00; 0.31]	1.0%	1.7%
Hurwitz & Smith (2012)	0	17	3	0.00	[0.00; 0.20]	1.0%	1.8%
Moskovitz et al. (2007)	0	20		0.00	[0.00; 0.17]	1.0%	1.8%
Chia & Theodorou (2012)	3	581	-	0.01	[0.00; 0.02]	6.2%	5.8%
Kim et al.* (2011)	0	884	. 0	0.00	[0.00; 0.00]	1.0%	1.8%
Kim et al.** (2011)	0	832		0.00	[0.00; 0.00]	1.0%	1.8%
Commons et al. (2011)	7	117	·	0.06	[0.02: 0.12]	13.7%	7.7%
Omranifard (2003)	0	20	a	0.00	[0.00: 0.17]	1.0%	1.8%
Roustaei et al. (2009)	0	609		0.00	[0.00: 0.01]	1.0%	1.8%
Blugerman et al. (2010)	0	23		0.00	[0.00: 0.15]	1.0%	1.8%
Zoccali et al. (2012)	14	797	3 	0.02	[0.01: 0.03]	28.7%	9.0%
Perez & Tetering (2003)	0	351		0.00	[0.00: 0.01]	1.0%	1.8%
Goldman (2006)	0	82	2	0.00	[0.00: 0.04]	1.0%	1.8%
Trelles et al. (2013)	0	28		0.00	[0.00: 0.12]	1.0%	1.8%
Branas & Moraga* (2013)	0	330	3	0.00	[0.00: 0.01]	1.0%	1.8%
Branas & Moraga** (2013)	0	15	1	0.00	[0 00 0 22]	1.0%	1.8%
McBean & Katz (2009)	Ő	20		0.00	[0.00; 0.17]	1.0%	1.8%
Hodgson et al. (2005)	Ő	13	3	0.00	[0.00; 0.25]	1.0%	1.8%
Leclère et al. (2014)	Ő	30	2	0.00	[0.00; 0.12]	1.0%	1.8%
Leclère et al. (2013)	Ő	30		0.00	[0.00; 0.12]	1.0%	1.8%
Theodorou & Chia (2013)	1	40	2	0.02	[0.00; 0.13]	2.0%	3.0%
Sun et al. (2009)	0	35	2	0.00	[0.00; 0.10]	1.0%	1.8%
Revnaud et al. (2009)	Ő	334		0.00	[0.00; 0.01]	1.0%	1.8%
Moreno-Moraga et al (2012)	Ő	30		0.00	[0.00; 0.12]	1.0%	1.8%
Swanson (2013)	1	384	3	0.00	[0.00; 0.01]	2.1%	3.1%
Leclère et al. (2015)	0	45	4	0.00	[0.00: 0.08]	1.0%	1.8%
Sasaki (2012)	Ő	19		0.00	[0.00; 0.18]	1.0%	1.8%
Hong et al (2012)	0	57	3	0.00	[0.00; 0.06]	1.0%	1.0%
Paul et al. (2011)	Ő	24		0.00	[0.00; 0.14]	1.0%	1.8%
Duncan (2012)	Ő	11		0.00	[0.00; 0.28]	1.0%	1.7%
lon et al. (2011)	1	42	<u>)</u>	0.00	[0.00; 0.20]	2.0%	3.0%
Paul & Mulholland (2009)	0	20		0.00	[0.00; 0.17]	1.0%	1.8%
Petty et al (2010)	Ő	50		0.00	[0.00; 0.07]	1.0%	1.8%
Licata et al. (2013)	0	230	<u> </u>	0.00	[0.00; 0.07]	1.0%	1.0%
Leclère et al (2012)	0	359		0.00	[0.00; 0.02]	1.0%	1.0%
Alexiades-Armenakas (2012)	0	12	1	0.00	[0.00; 0.01]	1.0%	1.0%
Leclère et al. (2016)	0	22		0.00	[0.00; 0.20]	1.0%	1.0%
Leciere et al. (2010)	0	22		0.00	[0.00, 0.15]	1.0 %	1.0 /0
Fixed effect model		7133	2	0.01	[0.01; 0.02]	100.0%	
Random effects model			<u>ب</u>	0.01	[0.01; 0.02]		100.0%
Heterogeneity: $I^2 = 31\%$, $\tau^2 = 0.4103$,	p = 0.04		•				
			0.05 0.1 0.15 0.2 0.25 0.3				

Supplementary Figure 9 *Rate of pigmentary changes as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Study	Events Total	Proportio	n 95%-Cl	Weight (fixed) (r	Weight andom)
Katz & McBean (2008)	0 537	0.0	0 [0.00: 0.01]	0.6%	1.2%
Duncan (2013)	0 12	0.0	0 [0.00: 0.26]	0.6%	1.2%
Giugliano et al. (2004)	0 60		0 [0.00; 0.06]	0.6%	1.2%
Roland (2012)	0 320	0.0	0 [0.00; 0.01]	0.6%	1.2%
Valizadeh et al.* (2016)	0 18	0.0	0 [0.00; 0.19]	0.6%	1.2%
Valizadeh et al.** (2016)	0 18	0.0	0 [0.00; 0.19]	0.6%	1.2%
Keramidas & Rodopoulou (2016)	0 55	0.0	0 [0.00; 0.06]	0.6%	1.2%
Leclère et al. (2015)	0 10	0.0	0 [0.00; 0.31]	0.6%	1.2%
Hurwitz & Smith (2012)	0 17	0.0	0 [0.00; 0.20]	0.6%	1.2%
Cohon of al. (2012)	0 20			0.6%	1.2%
Habberra (2009)	0 23	0.0	1 [0.00; 0.15]	0.0%	1.2%
Boni (2006)	2 131			2.5%	2.0%
Wall & Lee(2016)	0 129	- 0.0	0 [0.00; 0.03]	0.6%	1.2%
Chia & Theodorou (2012)	0 581	0.0	0 [0.00; 0.01]	0.6%	1.2%
Jacob et al. (2000)	0 20	0.0	0 [0.00; 0.17]	0.6%	1.2%
Kim et al.* (2011)	10 682	0.0	1 [0.01; 0.03]	12.4%	4.4%
Kim et al.** (2011)	14 884	0.0	2 [0.01; 0.03]	17.3%	4.6%
Kim et al.*** (2011)	12 832	0.0	1 [0.01; 0.03]	14.9%	4.5%
Commons et al.* (2001)	0 514	0.0	0 [0.00; 0.01]	0.6%	1.2%
Commons et al.** (2001)	0 117	_ 0.0	0 [0.00; 0.03]	0.6%	1.2%
Omranifard (2003)	0 20	0.0	0 [0.00; 0.17]	0.6%	1.2%
Habbema (2009) Wang et al. (2018)	1 3240	0.0	0 [0.00; 0.00]	1.3%	2.0%
Roustaei et al. (2010)	0 83	0.0	0 [0.00; 0.04]	0.6%	1.2%
Blugerman et al. (2000)	0 009	0.0		0.0%	1.2%
Katz et al. (2003)	0 207	0.0	0 [0.00, 0.13]	0.6%	1.2%
Innocenti et al. (2014)	0 118	0.0	0 [0.00: 0.03]	0.6%	1.2%
Zoccali et al. (2012)	0 797	- 0.0	0 [0.00: 0.00]	0.6%	1.2%
Perez & Tetering (2003)	0 351	0.0	0 [0.00; 0.01]	0.6%	1.2%
Mellul et al. (2006)	0 14	0.0	0 [0.00; 0.23]	0.6%	1.2%
Saleh et al. (2009)	3 60	0.0	5 [0.01; 0.14]	3.6%	3.3%
Zhang et al. (2015)	6 4000	0.0	0 [0.00; 0.00]	7.5%	4.1%
Goldman (2006)	0 82	0.0	0 [0.00; 0.04]	0.6%	1.2%
Trelles et al. (2013)	0 28	0.0	0 [0.00; 0.12]	0.6%	1.2%
Branas & Moraga" (2013)	0 330	0.0	0 [0.00; 0.01]	0.6%	1.2%
Scuderi et al * (2000)	0 100		0 [0.00; 0.04]	0.6%	1.2%
Scuderi et al ** (2000)	0 15		0 [0.00; 0.22]	0.6%	1.2%
Scuderi et al.*** (2000)	0 15		0 [0.00, 0.22]	0.0%	1.2%
McBean & Katz (2009)	0 20		0 [0.00: 0.17]	0.6%	1.2%
Hodgson et al. (2005)	0 13	0.0	0 [0.00: 0.25]	0.6%	1.2%
Leclère et al. (2014)	2 30	0.0	7 [0.01; 0.22]	2.3%	2.8%
Leclère et al. (2013)	2 30	0.0	7 [0.01; 0.22]	2.3%	2.8%
Theodorou & Chia (2013)	0 40	0.0	0 [0.00; 0.09]	0.6%	1.2%
Sun et al. (2009)	0 35	0.0	0 [0.00; 0.10]	0.6%	1.2%
Reynaud et al. (2009)	0 334	0.0	0 [0.00; 0.01]	0.6%	1.2%
Fullon et al. (2001) Merope-Merope et al. (2012)	0 15	0.0	U [0.00; 0.22]	0.6%	1.2%
Saariniemi et al. (2015)	1 30	0.0	3 [0.00; 0.17]	1.2%	1.9%
Swanson (2013)	0 61	- 0.0	0 [0.00; 0.06]	0.6%	1.2%
Leclère et al. (2015)	0 364			0.6%	1.2%
Sadove (2005)	0 45		0 [0.00; 0.00]	0.6%	1.2%
Sasaki (2012)	0 19		0 [0.00: 0.18]	0.6%	1.2%
Hong et al. (2012)	1 57	0.0	2 [0.00; 0.09]	1.2%	1.9%
Paul et al. (2011)	0 24	0.0	0 [0.00; 0.14]	0.6%	1.2%
Duncan (2012)	0 11	0.0	0 [0.00; 0.28]	0.6%	1.2%
lon et al. (2011)	0 42	0.0	0 [0.00; 0.08]	0.6%	1.2%
Paul & Mulholland (2009)	0 20	0.0	0 [0.00; 0.17]	0.6%	1.2%
Song et al. (2014)	0 331	0.0	0 [0.00; 0.01]	0.6%	1.2%
Petty et al. (2010)	0 50	0.0	U [0.00; 0.07]	0.6%	1.2%
Licala et al. (2013)	0 230	0.0	0 [0.00; 0.02]	0.6%	1.2%
Alexiades-Armenakas (2012)	U 359	0.0		0.6%	1.2%
Leclère et al (2016)	0 12	0.0		0.6%	1.2%
2000.0 01 01. (2010)	0 22	0.0	0 [0.00; 0.15]	0.0%	1.2%
Fixed effect model	17384	0.0	1 [0.01: 0.01]	100.0%	
Random effects model		0.0	1 [0.01; 0.01]	*	100.0%
Heterogeneity: $l^2 = 41\%$, $\tau^2 = 0.6144$	p < 0.01				
		0.05 0.1 0.15 0.2 0.25 0.3			

Supplementary Figure 10 *Rate of fibrosis as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Study	Events Total		Proportion	95%-CI	Weight (fixed) (ra	Weight andom)
Katz & McBean (2008)	0 53	e.	0.00	[0.00; 0.01]	1.0%	1.4%
Duncan (2013)	2 1		- 0.17	[0.02; 0.48]	3.3%	2.0%
Giugliano et al. (2004)	0 6	<u>■1</u>	0.00	[0.00; 0.06]	1.0%	1.4%
Roland (2012)	0 320	•	0.00	[0.00; 0.01]	1.0%	1.4%
Boeni (2011) Valizadeb et al * (2016)	0 438	••• 	0.00	[0.00; 0.00]	1.0%	1.4%
Valizadeh et al ** (2016)	0 1		0.00	[0.00, 0.19]	1.0%	1.4%
Keramidas & Rodopoulou (2016)	5 5		0.00	[0.03; 0.20]	9.0%	2.2%
Leclère et al. (2015)	0 1		0.00	[0.00; 0.31]	0.9%	1.4%
Hurwitz & Smith (2012)	4 1	·	- 0.24	[0.07; 0.50]	6.1%	2.2%
Moskovitz et al. (2007)	0 2	<u> </u>	0.00	[0.00; 0.17]	1.0%	1.4%
Cohen et al. (2012)	0 2	•	0.00	[0.00; 0.15]	1.0%	1.4%
Habbema (2009)	0 15		0.00	[0.00; 0.02]	1.0%	1.4%
Boni (2006)	0 3	-	0.00	[0.00; 0.09]	1.0%	1.4%
Chip & Theodorou (2012)	0 12	• <u>•</u> •	0.00	[0.00; 0.03]	1.0%	1.4%
Jacob et al. (2000)	0 38	••••••••••••••••••••••••••••••••••••••	0.00	[0.00, 0.01]	1.0%	1.4%
Kim et al.* (2011)	3 68		0.00	[0.00; 0.01]	5.9%	2.1%
Kim et al.** (2011)	2 884	2	0.00	[0.00; 0.01]	4.0%	2.0%
Kim et al.*** (2011)	1 83	2	0.00	[0.00; 0.01]	2.0%	1.8%
Commons et al.* (2001)	0 51	•	0.00	[0.00; 0.01]	1.0%	1.4%
Commons et al.**(2001)	0 11		0.00	[0.00; 0.03]	1.0%	1.4%
Omranifard (2003)	0 2	E	0.00	[0.00; 0.17]	1.0%	1.4%
Habbema (2009)	0 3240	-	0.00	[0.00; 0.00]	1.0%	1.4%
Roustani et al. (2010)	0 0	• <u>-</u>	0.00	[0.00; 0.04]	1.0%	1.4%
Blugerman et al. (2000)	0 00	•	0.00	[0.00; 0.01]	1.0%	1.4%
Katz et al. (2003)	0 20	• <u>•</u>	0.00	[0.00; 0.02]	1.0%	1.4%
Innocenti et al. (2014)	0 11	-	0.00	[0.00; 0.03]	1.0%	1.4%
Zoccali et al. (2012)	0 79	3	0.00	[0.00; 0.00]	1.0%	1.4%
Perez & Tetering (2003)	0 35	3	0.00	[0.00; 0.01]	1.0%	1.4%
Mellul et al. (2006)	3 1	· · · · ·	0.21	[0.05; 0.51]	4.7%	2.1%
Saleh et al. (2009)	0 6	-	0.00	[0.00; 0.06]	1.0%	1.4%
Znang et al. (2015) Goldman (2006)	0 400	-	0.00	[0.00; 0.00]	1.0%	1.4%
Trelles et al. (2013)	0 8	• <u>-</u>	0.00	[0.00; 0.04]	1.0%	1.4%
Branas & Moraga* (2013)	0 33	3 	0.00	[0.00, 0.12]	1.0%	1.4%
Branas & Moraga**(2013)	0 10	10 •••	0.00	[0.00; 0.04]	1.0%	1.4%
Scuderi et al.* (2000)	0 1		0.00	[0.00; 0.22]	1.0%	1.4%
Scuderi et al.** (2000)	0 1	• <u>1</u>	0.00	[0.00; 0.22]	1.0%	1.4%
Scuderi et al.*** (2000)	0 1	••••••••••••••••••••••••••••••••••••••	0.00	[0.00; 0.22]	1.0%	1.4%
McBean & Katz (2009)	0 2		0.00	[0.00; 0.17]	1.0%	1.4%
Hougson et al. (2005)	0 1		0.00	[0.00; 0.25]	1.0%	1.4%
Leclère et al. (2014)	0 3		0.00	[0.00; 0.12]	1.0%	1.4%
Walden et al. (2004)	0 1		0.00	[0.00, 0.12]	1.0%	1.4%
Theodorou & Chia (2013)	0 4	-	0.00	[0.00; 0.09]	1.0%	1.4%
Sun et al. (2009)	0 3		0.00	[0.00; 0.10]	1.0%	1.4%
Reynaud et al. (2009)	0 334		0.00	[0.00; 0.01]	1.0%	1.4%
Fulton et al. (2001)	2 1		0.13	[0.02; 0.40]	3.4%	2.0%
Moreno-Moraga et al. (2012)	0 3		0.00	[0.00; 0.12]	1.0%	1.4%
Saariniemi et al. (2015)	0 6	■ <u> </u> 	0.00	[0.00; 0.06]	1.0%	1.4%
Leclère et al. (2015)	0 384		0.00	[0.00; 0.01]	1.0%	1.4%
Sadove (2005)	0 4		0.00	[0.00, 0.00]	1.0%	1.4%
Sasaki (2012)	3 1	<u></u>	0.00	[0.03; 0.40]	5.0%	2.1%
Hong et al. (2012)	0 5		0.00	[0.00; 0.06]	1.0%	1.4%
Paul et al. (2011)	0 2	<u> </u>	0.00	[0.00; 0.14]	1.0%	1.4%
Duncan (2012)	0 1	•	0.00	[0.00; 0.28]	0.9%	1.4%
lon et al. (2011)	0 4		0.00	[0.00; 0.08]	1.0%	1.4%
Paul & Mulholland (2009) Song et al. (2014)	0 2		0.00	[U.00; 0.17]	1.0%	1.4%
Petty et al. (2010)	0 33	F	0.00	[U.UU; U.U1]	1.0%	1.4%
Licata et al. (2013)	0 5		0.00	[0.00; 0.07]	1.0%	1.4%
Leclère et al. (2012)	0 23	5	0.00	[0.00; 0.02]	1.0%	1.4%
Alexiades-Armenakas (2012)	0 1	5	0.00	[0.00; 0.26]	1.0%	1.4%
Leclère et al. (2016)	0 2		0.00	[0.00; 0.15]	1.0%	1.4%
		: 				
Fixed effectmodel	2177		0.02	[0.01; 0.02]	100.0%	
Hotorogonoity: 12 = 0.000	0 < 0.01	•	0.01	[0.01; 0.02]	1	00.0%
ποτει ogeneity. r = 00%, τ = 2.8595,	יט.ט <i>ר ק</i>	0.10.20.30.40.5	-			

Supplementary Figure 11 *Rate of paresthesia as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Study	Events To	otal	Proportior	95%-CI	Weight (fixed) (I	Weight andom)
Katz & McBean (2008)	0	537	0.00	IO 00· 0 01	0.4%	1.5%
Duncan (2013)	Ő	12	0.00	[0.00; 0.26]	0.4%	1.5%
Giugliano et al. (2004)	0	60 •	0.00	[0.00; 0.06]	0.4%	1.5%
Roland (2012)	2	320	0.01	[0.00; 0.02]	1.7%	1.8%
Boeni (2011)	0 4	4380	0.00	[0.00; 0.00]	0.4%	1.5%
Valizaden et al." (2016)	0	18 1	- 0.00	[0.00; 0.19]	0.4%	1.5%
Keramidas & Rodopoulou (2016)	1	55	- 0.00	[0.00, 0.19]	0.4%	1.5%
Leclère et al. (2015)	0	10	0.00	[0.00; 0.31]	0.4%	1.5%
Hurwitz & Smith (2012)	0	17	0.00	[0.00; 0.20]	0.4%	1.5%
Moskovitz et al. (2007)	0	20 .	_ 0.00	[0.00; 0.17]	0.4%	1.5%
Cohen et al. (2012)	0	23 .	- 0.00	[0.00; 0.15]	0.4%	1.5%
Boni (2006)	0	151	0.00	[0.00; 0.02]	0.4%	1.5%
Wall & Lee(2016)	0	129	0.00	[0.00, 0.09]	0.4%	1.5%
Chia & Theodorou (2012)	0	581	0.00	[0.00; 0.01]	0.4%	1.5%
Jacob et al. (2000)	0	20,	_ 0.00	[0.00; 0.17]	0.4%	1.5%
Kim et al.* (2011)	0	682 ,	0.00	[0.00; 0.01]	0.4%	1.5%
Kim et al.** (2011)	0	884,	0.00	[0.00; 0.00]	0.4%	1.5%
Commons et al * (2001)	0	514	0.00	[0.00, 0.00]	0.4%	1.5%
Commons et al.**(2001)	0	117	0.00	[0.00: 0.03]	0.4%	1.5%
Omranifard (2003)	0	20	0.00	[0.00; 0.17]	0.4%	1.5%
Habbema (2009)	0 3	3240	0.00	[0.00; 0.00]	0.4%	1.5%
Wang et al. (2018)	0	83	0.00	[0.00; 0.04]	0.4%	1.5%
Roustaei et al. (2009)	0	609	0.00	[0.00; 0.01]	0.4%	1.5%
Katz et al. (2003)	0	207		[0.00, 0.15]	0.4%	1.5%
Innocenti et al. (2014)	10	118	0.00	[0.04: 0.15]	8.0%	2.0%
Zoccali et al. (2012)	0	797	0.00	[0.00; 0.00]	0.4%	1.5%
Perez & Tetering (2003)	5	351	0.01	[0.00; 0.03]	4.3%	1.9%
Mellul et al. (2006)	1	14	0.07	[0.00; 0.34]	0.8%	1.7%
Salen et al. (2009) Zhong et al. (2015)	0	60	0.00	[0.00; 0.06]	0.4%	1.5%
Goldman (2006)	2 4	4000 82	0.00	[0.00; 0.00]	1.8%	1.8%
Trelles et al. (2013)	0	28	0.00	[0.00; 0.12]	0.4%	1.5%
Branas & Moraga* (2013)	89	330	0.27	[0.22; 0.32]	57.0%	2.0%
Branas & Moraga** (2013)	0	100		[0.00; 0.04]	0.4%	1.5%
Scuderi et al.* (2000)	0	15	0.00	[0.00; 0.22]	0.4%	1.5%
Scuderi et al.*** (2000)	0	15		[0.00; 0.22]	0.4%	1.5%
McBean & Katz (2009)	0	20		[0.00, 0.22]	0.4%	1.5%
Hodgson et al. (2005)	0	13	- 0.00	[0.00; 0.25]	0.4%	1.5%
Leclère et al. (2014)	0	30		[0.00; 0.12]	0.4%	1.5%
Leclère et al. (2013)	0	30 '	0.00	[0.00; 0.12]	0.4%	1.5%
Theodorou & Chia (2013)	0	12	0.00	[0.00; 0.26]	0.4%	1.5%
Sun et al. (2009)	0	40		[0.00; 0.09]	0.4%	1.5%
Reynaud et al. (2009)	0	334	0.00	[0.00: 0.01]	0.4%	1.5%
Fulton et al. (2001)	0	15	0.00	[0.00; 0.22]	0.4%	1.5%
Moreno-Moraga et al. (2012)	0	30 •	0.00	[0.00; 0.12]	0.4%	1.5%
Saariniemi et al. (2015)	0	61 •	0.00	[0.00; 0.06]	0.4%	1.5%
Leclère et al. (2015)	0	384	0.00	[0.00; 0.01]	0.4%	1.5%
Sasaki (2012)	0	45	0.00	[0.00, 0.08]	0.4%	1.5%
Hong et al. (2012)	Ő	57	- 0.00	[0.00; 0.06]	0.4%	1.5%
Paul et al. (2011)	0	24	0.00	[0.00; 0.14]	0.4%	1.5%
Duncan (2012)	0	11	- 0.00	[0.00; 0.28]	0.4%	1.5%
Ion et al. (2011) Raul & Mulholland (2009)	0	42 .	0.00	[0.00; 0.08]	0.4%	1.5%
Song et al. (2014)	0	20 +	0.00	[0.00; 0.17]	0.4%	1.5%
Petty et al. (2010)	0	50	0.00	[0.00: 0.07]	0.4%	1.5%
Licata et al. (2013)	õ	230	0.00	[0.00; 0.02]	0.4%	1.5%
Leclère et al. (2012)	0	359	0.00	[0.00; 0.01]	0.4%	1.5%
Alexiades-Armenakas (2012)	12	12 .	1.00	[0.74; 1.00]	0.4%	1.5%
Leciere et al. (2016)	0	22	0.00	[0.00; 0.15]	0.4%	1.5%
Fixed effectmodel	2	1751	- 0.08	[0.07: 0.09]	100.0%	
Random effects model	-		0.01	[0.00; 0.02]		100.0%
Heterogeneity: I ² = 87%, τ ² = 5.5215	, <i>p</i> < 0.01					
		¢	0µ40.6p.81			

Supplementary Figure 12 *Rate of skin loss as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Study	Events	Total	Proportion	95%-CI	Weight (fixed) (r	Weight andom)
Katz & McBean (2008)	0	537	0.00	[0.00; 0.01]	0.5%	1.4%
Duncan (2013)	0	12 -	0.00	[0.00; 0.26]	0.5%	1.4%
Giugliano et al. (2004)	0	60	0.00	[0.00; 0.06]	0.5%	1.4%
Roland (2012)	0	320 •	0.00	[0.00; 0.01]	0.5%	1.4%
Boeni (2011)	0	4380	0.00	[0.00; 0.00]	0.5%	1.4%
Valizadeh et al.* (2016)	0	18 -	0.00	[0.00; 0.19]	0.5%	1.4%
Valizadeh et al.** (2016)	0	18 -	0.00	[0.00; 0.19]	0.5%	1.4%
Keramidas & Rodopoulou (2016)	0	55 -	0.00	[0.00; 0.06]	0.5%	1.4%
Leclère et al. (2015)	0	10 -	0.00	[0.00; 0.31]	0.5%	1.4%
Hurwitz & Smith (2012)	0	17 -	0.00	[0.00; 0.20]	0.5%	1.4%
Moskovitz et al. (2007)	0	20			0.5%	1.4%
Conen et al. (2012)	0	23 -	0.00		0.5%	1.4%
Boni (2006)	0	38	. 0.04		0.5%	2.1%
Wall & Lee (2016)	0	129	0.00		0.5%	1.4%
Chia & Theodorou (2012)	0	581	0.00	[0.00: 0.01]	0.5%	1.4%
Jacob et al. (2000)	ő	20	0.00	0.00: 0.17	0.5%	1.4%
Kim et al.* (2011)	4	682	0.01	[0.00: 0.01]	4.4%	2.0%
Kim et al.** (2011)	0	884	0.00	[0.00; 0.00]	0.5%	1.4%
Kim et al.*** (2011)	0	832	0.00	[0.00; 0.00]	0.5%	1.4%
Commons et al.* (2001)	1	514	0.00	[0.00; 0.01]	1.1%	1.7%
Commons et al.**(2001)	0	117	0.00	[0.00; 0.03]	0.5%	1.4%
Omranifard (2003)	2	20	• 0.10	[0.01; 0.32]	2.0%	1.9%
Habbema (2009)	2	3240	0.00	[0.00; 0.00]	2.2%	1.9%
Wang et al. (2018)	0	83	0.00	[0.00; 0.04]	0.5%	1.4%
Roustaei et al. (2009)	0	609	0.00	[0.00; 0.01]	0.5%	1.4%
Biugerman et al. (2010)	0	23		0 [0.00; 0.15]	0.5%	1.4%
Raiz et al. (2003)	0	207	0.00	0 [0.00; 0.02]	0.5%	1.4%
Zoccali et al. (2014)	0	707	0.00		0.5%	1.4%
Perez & Tetering (2003)	0	351	0.00		0.5%	1.4 %
Mellul et al. (2006)	0	14	0.00		0.5%	1.4%
Saleh et al. (2009)	0	60		[0.00: 0.06]	0.5%	1.4%
Zhang et al. (2015)	0	4000	0.00	[0.00; 0.00]	0.5%	1.4%
Goldman (2006)	0	82	0.00	[0.00; 0.04]	0.5%	1.4%
Trelles et al. (2013)	0	28	0.00	[0.00; 0.12]	0.5%	1.4%
Branas & Moraga* (2013)	49	330	0.15	6 [0.11; 0.19]	45.9%	2.1%
Branas & Moraga** (2013)	0	100		[0.00; 0.04]	0.5%	1.4%
Scuderi et al.* (2000)	0	15	0.00	[0.00; 0.22]	0.5%	1.4%
Scuderi et al.*** (2000)	0	15	0.00	[0.00; 0.22]	0.5%	1.4%
McBoop & Kotz (2000)	4	15	0.2/		3.2%	2.0%
Hodgson et al. (2005)	0	20	- 0.00		0.5%	1.4%
Leclère et al. (2003)	0	20 6	0.00		0.5%	1.4%
Leclère et al. (2013)	0	30 -	- 0.00	0.00, 0.12	0.5%	1.49/
Walden et al. (2004)	0	12 •	- 0.00	0.00, 0.12	0.5%	1.4%
Theodorou & Chia (2013)	Ő	40		0.00:0.09	0.5%	1.4%
Sun et al. (2009)	0	35 -	- 0.00	[0.00; 0.10]	0.5%	1.4%
Reynaud et al. (2009)	0	334	- 0.00	[0.00; 0.01]	0.5%	1.4%
Fulton et al. (2001)	0	15 •	0.00	[0.00; 0.22]	0.5%	1.4%
Moreno-Moraga et al. (2012)	0	30 -	0.00	[0.00; 0.12]	0.5%	1.4%
Saariniemi et al. (2015)	0	61 -	- 0.00	[0.00; 0.06]	0.5%	1.4%
Swanson (2013)	0	384	0.00	[0.00; 0.01]	0.5%	1.4%
Leciere et al. (2015) Sadove (2005)	0	45 •	0.00	[0.00; 0.08]	0.5%	1.4%
Sadove (2005) Sasaki (2012)	0	25 -	0.00	[0.00; 0.14]	0.5%	1.4%
Hong et al (2012)	0	19 -	- 0.00	0 [0.00; 0.18]	0.5%	1.4%
Paul et al. (2011)	0	24	0.00		0.5%	1.4%
Duncan (2012)	0	11	0.00		0.5%	1.470
lon et al. (2011)	0	42			0.5%	1.4%
Paul & Mulholland (2009)	Ő	20	. 0.00	[0.00; 0.17]	0.5%	1.4%
Song et al. (2014)	Ő	331	0.00	[0.00; 0.01]	0.5%	1.4%
Petty et al. (2010)	0	50 .	0.00	[0.00; 0.07]	0.5%	1.4%
Licata et al. (2013)	0	230	0.00	[0.00; 0.02]	0.5%	1.4%
Leclère et al. (2012)	0	359	0.00	[0.00; 0.01]	0.5%	1.4%
Alexiades-Armenakas (2012)	8	12.	0.67	[0.35; 0.90]	2.9%	2.0%
Leclere et al. (2016)	0	22	0.00	[0.00; 0.15]	0.5%	1.4%
Fired offerst medal		04770	_	10 04 0 05	400.08/	
Fixed effects model		21//6	0.04	[U.U4; U.U5]	100.0%	100 0%
Heterogeneity: $l^2 = 81\%$, $\tau^2 = 4.0825$.	p < 0.01		0.0	[0.01, 0.02]		100.0 /0
	,	Ģ	012 0.4 0.6 0.8			

Supplementary Figure 13 *Rate of entry site complications, including aberrant scarring or dehiscence, as determined using both the fixed-effects and random-effects models for meta-analysis of articles meeting the inclusion criteria for review.*

Study	Events Total	Proportion	95%-CI (Weight (fixed) (ra	Weight Indom)
Katz & McRean (2008)	0 537	0.00	10 00: 0 011	1.0%	1 3%
Duncan (2013)	0 12		[0.00; 0.26]	1.0%	1.2%
Giugliano et al. (2004)	0 60	0.00	[0.00; 0.06]	1.0%	1.2%
Roland (2012)	0 320	0.00	[0.00; 0.01]	1.0%	1.3%
Boeni (2011)	0 4380 -	0.00	[0.00; 0.00]	1.0%	1.3%
Valizadeh et al.* (2016)	0 18	0.00	[0.00; 0.19]	1.0%	1.2%
Valizadeh et al.** (2016)	0 18	0.00	[0.00; 0.19]	1.0%	1.2%
Keramidas & Rodopoulou (2016)	0 55	0.00	[0.00; 0.06]	1.0%	1.2%
Leclere et al. (2015)	0 10	0.00	[0.00; 0.31]	0.9%	1.2%
Moskovitz et al. (2007)	0 20	0.00	[0.00, 0.20]	1.0%	1.2%
Cohen et al. (2012)	0 23	0.00	[0.00: 0.15]	1.0%	1.2%
Habbema (2009)	0 151	0.00	[0.00: 0.02]	1.0%	1.2%
Boni (2006)	0 38	0.00	[0.00; 0.09]	1.0%	1.2%
Wall & Lee(2016)	0 129	0.00	[0.00; 0.03]	1.0%	1.2%
Chia & Theodorou (2012)	0 581	0.00	[0.00; 0.01]	1.0%	1.3%
Jacob et al. (2000)	0 20	0.00	[0.00; 0.17]	1.0%	1.2%
Kim et al.* (2011)	5 682	0.01	[0.00; 0.02]	9.9%	5.4%
Kim et al *** (2011)	4 004	0.00	[0.00; 0.01]	7.9%	4.9%
Commons et al * (2001)	0 514	0.01	[0.00, 0.02]	1.0%	1.3%
Commons et al.** (2001)	0 117	0.00	[0.00; 0.01]	1.0%	1.3%
Habbema (2009)	0 3240	0.00	[0.00; 0.00]	1.0%	1.3%
Wang et al. (2018)	0 83	0.00	[0.00; 0.04]	1.0%	1.2%
Roustaei et al. (2009)	0 609	0.00	[0.00; 0.01]	1.0%	1.3%
Blugerman et al. (2010)	0 23	0.00	[0.00; 0.15]	1.0%	1.2%
Katz et al. (2003)	0 207	0.00	[0.00; 0.02]	1.0%	1.2%
Innocenti et al. (2014)	0 118	0.00	[0.00; 0.03]	1.0%	1.2%
Zoccall et al. (2012)	0 797	0.00	[0.00; 0.00]	1.0%	1.3%
Mellul et al. (2006)	0 351	0.00	[0.00; 0.01]	1.0%	1.3%
Saleh et al. (2009)	0 60	0.00	[0.00, 0.23]	1.0%	1.2%
Zhang et al. (2015)	0 4000	0.00	[0.00; 0.00]	1.0%	1.2 %
Goldman (2006)	0 82	0.00	[0.00; 0.04]	1.0%	1.2%
Trelles et al. (2013)	0 28	0.00	[0.00; 0.12]	1.0%	1.2%
Branas & Moraga* (2013)	0 330	0.00	[0.00; 0.01]	1.0%	1.3%
Branas & Moraga** (2013)	0 100	0.00	[0.00; 0.04]	1.0%	1.2%
Scuderi et al.* (2000)	0 15	0.00	[0.00; 0.22]	1.0%	1.2%
Scuderi et al.** (2000)	0 15	0.00	[0.00; 0.22]	1.0%	1.2%
McBean & Katz (2000)	0 15	0.00	[0.00; 0.22]	1.0%	1.2%
Hodgson et al. (2005)	0 13	0.00	[0.00, 0.17]	1.0%	1.2%
Leclère et al. (2014)	0 30	- 0.00	[0.00; 0.23]	1.0%	1.2 %
Leclère et al. (2013)	0 30	0.00	[0.00; 0.12]	1.0%	1.2%
Walden et al. (2004)	0 12	0.00	[0.00; 0.26]	1.0%	1.2%
Theodorou & Chia (2013)	0 40	0.00	[0.00; 0.09]	1.0%	1.2%
Sun et al. (2009)	0 35	0.00	[0.00; 0.10]	1.0%	1.2%
Reynaud et al. (2009)	0 334	0.00	[0.00; 0.01]	1.0%	1.3%
Fulton et al. (2001)	0 15	0.00	[0.00; 0.22]	1.0%	1.2%
Saariniemi et al. (2015)	0 30	0.00	[0.00; 0.12]	1.0%	1.2%
Swanson (2013)	2 284	0.00	[0.00; 0.06]	1.0% E 0%	1.2%
Leclère et al. (2015)	0 45	0.01	[0.00, 0.02]	1.0%	4.3%
Sadove (2005)	0 25	0.00	[0.00; 0.14]	1.0%	1.2%
Sasaki (2012)	0 19	0.00	[0.00: 0.18]	1.0%	1.2%
Hong et al. (2012)	2 57	0.04	[0.00; 0.12]	3.8%	3.4%
Paul et al. (2011)	0 24	0.00	[0.00; 0.14]	1.0%	1.2%
Duncan (2012)	1 11 🚽 🗕 🗕	0.09	[0.00; 0.41]	1.8%	2.0%
Ion et al. (2011)	0 42	0.00	[0.00; 0.08]	1.0%	1.2%
Paul & Mulholiand (2009) Song et al. (2014)	0 20	0.00	[0.00; 0.17]	1.0%	1.2%
Petty et al. (2014)		0.00	[U.UU; U.U1]	1.0%	1.3%
Licata et al. (2013)	0 230	0.00	[0.00; 0.07]	1.0%	1.2%
Leclère et al. (2012)	0 359	0.00	[0.00, 0.02] [0.00 [,] 0.011	1.0%	1.2%
Alexiades-Armenakas (2012)	0 12	0.00	[0.00; 0.26]	1.0%	1.2%
Leclère et al. (2016)	0 22	0.00	[0.00; 0.15]	1.0%	1.2%
Fixed effect model	21756	0.01	[0.01; 0.01]	100.0%	
Random effects model		0.01	[0.01; 0.01]	1	00.0%
Heterogeneity: / = 20%, τ ² = 0.3440	, p = 0.08	0.2 0.1			
	φ 011 012	013 014			

Bridging Text

The previous review and meta-analysis proves that contour irregularities is one of the most common complications following liposuction. When removing edema and ecchymosis, which are commonly seen as inevitable effects of most procedures as opposed to a proper complication, we may consider contour irregularity to be *the* most common complication following liposuction.

As the previous review deals with liposuction exclusively when not combined with another surgery, and as this may hinder proper appreciation of the caliber of this problem, we proceeded with studying the complication and revision rates of a common body contouring procedure that frequently employs liposuction as an adjunct, brachioplasty.

Complications in Brachioplasty: A Systematic Review and Meta-analysis

Author List:

Albaraa Aljerian (A.A), MD, MSc^{1,2}, Jad Abi-Rafeh (J.A.), MSc³, José Ramirez-GarciaLuna

(J.RGL.) MD, MSc, PhD², Thomas Hemmerling (T.H.), MD, MSc, DEAA^{2,4}, and Mirko S.

Gilardino (M.G.), MD, MSc, FACS, FRCSC^{1,3}

- Division of Plastic and Reconstructive Surgery, McGill University Health Center, Montreal, Quebec, Canada
- 2) Division of Experimental Surgery, McGill University, Montreal, Quebec, Canada
- 3) Faculty of Medicine, McGill University, Montreal, Quebec, Canada
- 4) Department of Anesthesia, McGill University, Montreal, Quebec, Canada

Corresponding Author:

Mirko S. Gilardino, MD, MSc, FACS, FRCSC Chief, Division of Plastic and Reconstructive Surgery Associate Professor of Surgery McGill University Health Centre Montreal General Hospital 1650 Cedar Avenue Montreal, Qc, Canada H3G 1A4

mirko.gilardino@muhc.mcgill.ca

ABSTRACT

Background: Brachioplasty procedures have experienced a surge in popularity over the past decade, mirroring the rise in bariatric procedures and growing population of massive weight loss patients. The purpose of this study is to estimate the incidence of associated complications and identify possible patient or procedure-related predictive factors.

Methods: A systematic review was performed using the Pubmed, Cochrane and Embase databases; extracted data was synthesized through a random-effects meta-analysis of proportions and a multivariate meta-regression.

Results: A total of 29 studies were included in the meta-analysis representing 1,578 patients; all studies followed an observational design. Incidence of adverse outcomes assessed included aberrant scarring at 9.9% [95%-CI 6.1%;15.6%]; ptosis or recurrence at 7.79% [95%-CI 4.8%;12.35%]; wound dehiscence at 6.81% [95%-CI 4.63%;9.90%]; seroma at 5.91% [95%-CI 3.75%;9.25%]; infection at 3.64% [95%-CI 2.38%;5.53%]; nerve-related complications at 2.47% [95%-CI 1.45%;4.18%]; lymphedema or lymphocele formation at 2.46% [95%-CI 1.55%;3.88%]; skin necrosis or delayed healing at 2.27% [95%-CI 1.37%;3.74%], and hematoma at 2.06% [95%-CI 1.38%;3.06%]. The operative reintervention rate for aesthetic purposes was 7.46% [95%-CI 5.05%;10.88%], while the operative reintervention rate for non-aesthetic purposes was 1.62% [95%-CI 1.00%;2.61%]. Multivariate meta-regression demonstrated that medial incision placement was associated with a higher risk of complications, while the incidence of certain complications was lowered with adjunctive liposuction (p<0.05).

Conclusion: In the absence of large clinical trials, the present meta-analysis can serve to provide plastic surgeons with an evidence-based reference to improve informed consent and guide procedure selection with respect to the complication profile of brachioplasty.

Introduction

Plastic surgery has experienced a surge in popularity of brachioplasty procedures over the past decade, mirroring the rise in bariatric procedures and the growing population of massive weight loss patients.¹ In response to the 5030% rise in brachioplasties performed over the past 2 decades, plastic surgeons continue to seek modifications and evolution of brachioplasty techniques in order to improve aesthetic outcomes and minimize complications.^{2,3} Several modifications have been proposed including limited incision brachioplasties³, adjunctive liposuction⁴, as well as a non-excisional brachioplasty approach.⁵ Despite these efforts, this procedure continues to be characterized by a relative lack of consensus on optimal surgical techniques as well as specific indications for the use of adjuncts.⁶ Whether indicated for senile elastosis, post-bariatric or 'natural' massive weight loss (MWL), patient selection and choice of the appropriate approach remains critical to achieve an aesthetically desirable outcome without undesirable cosmetic results or functional detriment.³

Multiple publications have discussed post-operative complications following brachioplasty.^{1,7-11} One literature review reported on a pooled overall complication rate of 28.9%.¹⁰, while another qualitative study reported on complication rates ranging from 25-40%, as well as revision rates ranging between 3-25%.¹¹ At present, the literature remains devoid of studies quantitatively synthesizing the available evidence to provide practitioners with an evidence-based reference to inform clinical guidelines and improve informed consent. The present article thus seeks to provide quantitative insight into the complication profile associated with brachioplasty, explore the prospect of identifying possible patient or procedure-related predictive factors, and serve as an elaboration on the heterogenous nature of this procedure and the state of available evidence.

Methods

Search strategy and Data Extraction:

A systematic review and subsequent meta-analysis was performed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions¹², as well as the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.¹³ The MEDLINE via Pubmed, Embase, and The Cochrane Central Register of Controlled Trials (CENTRAL) data bases were queried using the following search terms: ("brachioplasty" or "upper arm contouring" or "upper arm lift"), in combination with ("complications" or "adverse events"). A subsequent citation search was performed by screening references of retrieved articles as well as publications from key journals to supplement the initial protocolized search strategy.

Primary screening was conducted based on title and abstract review by two independent evaluators; strict inclusion and exclusion criteria were in place (see below). Relevant articles subsequently underwent full text analysis for relevance and data applicability; disagreements were resolved by means of consensus or discussion with the senior author. Data extraction comprised key data such as study design, intervention details (e.g. incision placement and adjunctive liposuction), sample size, as well as demographics. Where available, data on the proportion of patients with the adverse outcomes of interest were extracted; these included aberrant scarring, seroma, hematoma, infection, lymphedema or lymphocele formation, nerve-related complications, skin necrosis or delayed healing, ptosis/recurrence, as well as the need for operative reintervention.

Eligibility criteria:

Original primary research articles, both experimental and observational in design, containing patient cohorts that underwent brachioplasty by any described surgical technique (including non-excisional techniques, such as flap de-epithelialization), with sufficient, extractable, unambiguous reporting on complications, published in the English language, and available for full-text analysis, were included for review. Publications were excluded if substantial data was missing pertaining to follow-up and reporting on complications. Case-reports, reviews, survey studies, and database articles were excluded. If a study contained multiple study

populations, data from only those that fit the inclusion criteria was extracted and considered for analysis. Cohorts containing patients selected and reported on based on a specific outcome or complications were excluded in order to limit the over-estimation of complication rates, as were cohorts with less than 10 patients. (**Table 1**).

Defining complications:

Outcome incidence for select complications was recorded regardless of severity or rectifying steps taken. Incidence of residual ptosis or recurrence, as well as contour irregularities were grouped together, given that these are commonly reported collectively, thus it would not be feasible to extract the rates of each separately. Unless explicitly specified as present or absent, studies failing to report on this outcome were excluded from this specific subgroup analysis. Nerve-related complications include temporary or permanent dysethesia, paresthesia, or confirmed nerve sectioning or compression. Aberrant scarring included keloid, hypertrophic and widened scars. Lymphocele and lymphedema incidence were combined. Stitch abscesses were included in the infection category. Re-operation for aesthetic purposes included revision of scars, dog ears and residual laxity or ptosis, among others. This excludes non-invasive or minimally invasive modalities such as laser therapy or steroid injections. Reoperation for non-aesthetic purposes includes operative drainage of collections, nerve-related complications or wound dehiscence. Office-based drainage was not included in operative revision. Complication and revision rates were taken to be the same if only the revision rate, and not a complication rate, was specified for a particular adverse outcome.

Statistical analysis

Meta-analyses were performed using the aggregated data. Proportions were calculated as the ratio of the number of affected patients to the total sample size. Proportions are provided with the corresponding 95% confidence intervals (CI). For all studies, we performed a meta-analysis of each outcome. Combined with the inspection of forest plots, the I² index and the τ^2 statistic were utilized to investigate statistical heterogeneity. Heterogeneity based on the I² statistic was defined as: Low (25%), moderate (50%), and high (75%). Given the high degree of heterogeneity noted, the authors proceeded with a random-effects model for overall complications with a logit transformation. Using a random-effects model, meta-regressions were conducted to estimate the overall complication rates for each subgroup of interest by incision (medial vs. any other), age (<45 vs. \geq 45), Body Mass Index (BMI; <30 vs. \geq 30), and associated liposuction (Yes vs. No). Studies where a *specific* complication rate was not reported on adequately, or associated data not extractable with confidence, were excluded from subgroup analysis of that particular outcome. Publication bias was not statistically pursued given the substantial heterogeneity in addition to the authors choosing to pursue a meta-analysis of proportions. Meta-analyses and sub-analyses were performed using the R software (The R Project for Statistical Computing, R version 3.2.1), as previously described.¹⁴

Results

A total of 1524 papers were retrieved by the systemized search strategy and manual citation search, following the removal of duplicates. After title, abstract, and full-text review, 29 articles were included in the final analysis, representing a total of 1578 brachioplasty procedures with adequate reporting on outcomes and complications for inclusion in the meta-analysis. An elaboration on the search strategy, including the inclusion and exclusion process, can be found in **Figure 1**. **Table 2** provides a summary of all primary articles included in the meta-analysis.

All studies were of an observational design, with a retrospective review of 205 patients representing the largest cohort. Within the cohorts analyzed, the majority utilized a medial incision (n=22), four utilized a posterior incision, two utilized a posteromedial incision, one utilized a short-scar axillary 'mini-brachioplasty', while one cohort was unclear; keeping in mind that some studies used a combination of incision approaches. The majority of studies employed arm liposuction as an adjunct (n=24, 83%) either at the site of skin excision, or circumferentially. Among the studies that provided sufficient patient demographic data (54%), female patients constituted the vast majority of included subjects (97%). Fourteen studies (48%) distinctly specified using general anesthesia (GA), with or without local tumescent infiltration depending on the use of liposuction, while others used either local infiltration with sedation, or did not elaborate on anesthetic modalities (52%). Information pertaining to the indications for surgery (i.e. natural MWL, bariatric MWL, or Senile Elastosis), and the frequency or nature of combined procedures, if any, were generally lacking, preventing a quantitative estimate. Mean age and BMI measurements were not amenable to a weighted calculation given the lack of reporting as well.

Complication Rates:

Visual inspection of forest plots, the I^2 index, and the Q statistic was performed to investigate the statistical homogeneity of studies included; this analysis demonstrating high heterogeneity for most outcomes assessed. A random-effects meta-analysis model was thus pursued in the calculation of overall and specific complication rates from aggregated data collected. Publication bias was investigated graphically using funnel plots; however, this approach was complicated by the high degree of heterogeneity in studies assessed. (Supplementary Figures 1–12)

With regards to the incidence of specific brachioplasty complications in the population assessed, the rate of aberrant scarring was determined to be 9.9% [95%-CI 6.1%; 15.6%] (I²= 82%); ptosis or recurrence as 7.79% [95%-CI 4.82 %; 12.35%] (I²= 65%); dehiscence as 6.81% [95%-CI 4.63 %; 9.90%] (I²= 60%); seroma formation as 5.91% [95%-CI 3.75%; 9.25%] (I²= 69%); infection as 3.64% [95%-CI 2.38%; 5.53%] ($I^2 = 48\%$); nerve-related complications as 2.47% [95%-CI 1.45%; 4.18%] (I²=45%); lymphedema or lymphocele formation as 2.46% [95%-CI 1.55%; 3.88%] ($I^2 = 3\%$); skin necrosis or delayed healing as 2.27% [95%-CI 1.37%; 3.74%] $(I^2 = 13\%)$, and hematoma formation as 2.06% [95%-CI 1.38%; 3.06%] $(I^2 = 0\%)$. The operative intervention rate for aesthetic purposes was 7.46% [95%-CI 5.05%; 10.88%] (I^2 = 65%), and the intervention rate for non-aesthetic purposes was 1.62% [95%-CI 1.00%; 2.61%] (I²= 0%); (Figures 2-12; Table 3). With regards to major complications, no deaths were reported within the population assessed, however, one case of deep venous thrombosis and pulmonary embolism was described. The overall complication rate, including all individual complications described above, as well as any additional adverse sequelae considered as complications by the authors of the primary studies assessed, was determined to be 32.93% [95%-CI 19.91; 49.24] (I²= 92%) (Table 3, Figure 13). This number is to be interpreted with caution however given the disparity that exists across individual studies examined pertaining to what constitutes a true complication, and that some authors reported on complication rates according to adverse outcomes, rather than to the number of patients exhibiting complications, thus marginally overestimating complication rates, specifically for cohorts in which some patients exhibited more than one complication.

Procedural and Patient-Related Factors Predictive of Higher Complications

To investigate possible procedural or patient-related factors predictive of higher complication rates, a multivariate meta-regression was pursued using a random-effects model due to the high statistical heterogeneity. Procedure-related factors investigated included incision placement (medial, vs. other) as well as adjunctive liposuction of the arm (yes vs no). Patient-related predictive factors investigated included age (<45 vs. \geq 45) as well as BMI (<30 vs. \geq 30). Results of the meta-regression are presented in **Tables 4-7**, and **Supplementary Figures 1-2**.

A medial brachioplasty incision (n=1063 patients) was shown to statistically increase the overall complication rate (43.7% vs. 9.7%, p<0.05), as well as the incidence of individual complications examined including aberrant scarring (15.6% vs. 3.0%, p<0.01), dehiscence (8.7%) vs 3.1%, p<0.05), and seroma (8.4% vs. 1.4%, p<0.01). A medial incision placement was therefore associated with a greater operative reintervention rate (10.8% vs 3.7%, p<0.05), as well as specifically an increased rate of operative reintervention for aesthetic purposes (9.9% vs. 3.8%, p < 0.05) when compared to non-medial incisions collectively (n=465 patients). No statistically significant differences were observed for the incidence of residual ptosis, hematoma, infection, skin necrosis, lymphedema, or operative re-intervention for non-aesthetic purposes (p>0.05). With regards to the use of adjunctive liposuction in brachioplasty, either circumferential or at the site of skin excision, this was shown to significantly reduce the incidence of seroma (13.5% vs. 3.0%, p<0.01), lymphedema (6.5% vs. 1.6%, p<0.05), and nerve injury (5.5% vs. 1.5%, p<0.05). The overall complication rate was not significantly altered. No statistically significant differences were observed regarding patients' age or BMI as well; the latter analysis was however complicated by the paucity of data available due to incomplete reporting on patient demographics by the primary studies assessed.

Discussion

Since its inception in 1954, brachioplasty has evolved with numerous modifications to the original proposed technique.^{3,4} As is the case with all body contouring procedures, brachioplasty is tailored to the needs of the patient, magnitude of presentation, as well as the desired aesthetic evolution. Intervention can range from a limited axillary resection to a more invasive excisional pattern extending into the chest wall. The use of liposuction has also been adopted as a useful adjunct.^{1,4} Despite these advances, it remains evident that even in cases of similar presentation and operative goals, much variety exists across employed techniques, including excisional patterns, closure methods, scar placement, and the use of adjuvant liposuction. The objective of this study was to provide quantitative data regarding specific complication rates associated with this procedure, and to explore the analytical prospect of identifying procedure- and patient-specific factors associated with higher complications.

Poor visible scarring is a well-known consequence of brachioplasty. In the present metaanalysis, aberrant scarring was determined to be the most common adverse outcome, with an estimated incidence of 9.9%. Multiple published cohorts also make note of this sequela. Zomerlei et al.¹⁵ report on a poor scarring rate of 15.5% in a retrospective cohort of 96 patients, while Knoetgen and Moran⁸ note a 10% hypertrophic scar incidence in a review of 40 patients. A literature review pooling complication rates across 27 clinical studies reports a hypertrophic scaring incidence of 10.8%.¹⁰ Different techniques, each with their respective advocates and opponents, have been employed to preclude the formation of an unsightly or distinctly visible scar; these include modifications to closure techniques (i.e. multilayer or fascial closure), as well as modifications to scar position. Generally speaking, these modifications are yet to be widely adopted, with the present study demonstrating that 67% of cohorts examined were managed using a medial incision approach.

Complications such as wound dehiscence and seroma formation were shown to also rank high in this analysis. This is in concordance with previously published literature; qualitative estimates describe incidence rates of approximately 7 and 6 percent, respectively¹⁰, while two of the relatively larger brachioplasty studies examined establish these complications as highest within their cohorts.^{7,16} Besides re-intervention for minor or major non-cosmetic reasons, this study demonstrates a reintervention rate of 7.46% for aesthetic purposes. Variability is palpable between reported cohorts in this regard, with some authors describing revision rates of up to 23%. Aesthetic operative revisions were most often indicated for aberrant scarring and residual ptosis, the two individual adverse sequalae shown to have the highest incidence following brachioplasty in the present analysis. Infection, nerve-related complications, lymphedema, skin necrosis, and hematoma formation were found to be less common, which too seem to be in concordance with previous qualitative estimates.¹⁰ The rate of operative reintervention for non-aesthetic purposes was determined to be 1.62%.

Given the heterogenous nature of this procedure, coupled with the quality of the available evidence, optimal and accurate analysis of causative factors may be limited. Nonetheless, many authors have shed light on the culpability of specific elements in increasing or abating the likelihood of certain adverse events, including the use of / extent of adjunctive liposuction, the use

of drains, concomitant procedures performed, operative time, incision placement, as well as a history of bariatric surgery. One retrospective review of 144 patients compared the use of liposuction with brachioplasty at the site of excision to excision alone, demonstrating no detrimental effect of adjuvant liposuction¹⁶; while another study showed an increase risk of seroma formation with the use of liposuction.⁷ Zomerlei et al.'s cohort¹⁵ showed an increased risk of overall complications in patients with a history of surgical weight loss, while De Runz et al.¹⁷ demonstrated a significant association between complications and operative time in their review of 66 patients. In the present study, the authors performed a multivariate meta-regression in order to identify procedural- or patient-related factors associated with higher complications using the evidence assessed.

A medial incision approach was shown to be statistically associated with a higher complication rate relative to all other incisions, culminating predominantly in an increased risk of aberrant visible scarring as well as a higher incidence of wound dehiscence. Of note, the majority of patients assessed had a medial incision placement; it thus remains unclear the degree to which these findings are impacted upon by the present patient distribution. Additionally, a multivariate analysis controlling for BMI and/or age was not feasible, creating further potential bias. Higher revision rates were also observed in patients with a medial incision, performed predominantly for aesthetic purposes in order to rectify the aforementioned sequalae. Alternative brachioplasty techniques have been proposed to circumvent these challenges, including the S-brachioplasty¹⁸, Tbrachioplasty¹⁹, L-brachioplasty²⁰, J-brachioplasty²¹, Kris Knife technique²², fish-incision technique²³, and the triple vector brachial lifting technique.²⁴ Posterior²⁵, posteromedial²⁶, as well as axillary / short-scar brachioplasty incisions 4,27 have also been suggested for the same purpose. However, due to small sample sizes and a paucity of high-quality evidence, it remains unclear which combination of brachioplasty techniques and incision sites offer the best outcome. Adjuvant liposuction in brachioplasty procedures has been demonstrated to offer significant aesthetic and functional benefits.⁴ Impotantly, in the present analysis, liposuction use was also shown to significantly reduce the risk of seroma, lymphedema, and nerve injury. The authors acknowledge however that both cases of circumferential and excision-site liposuction were pooled for this analysis, which may impact interpretation of these findings. Due to limited reporting on patient demographics pertaining specifically to etiology of skin laxity (e.g., massive weight-loss vs. senile

elastosis), patient ages, as well as body mass index, the authors were unable to discern specific patient-related risk factors associated with higher complications, accentuating the need for more complete reporting in future works.

This study is not without its limitations. In order to appreciate and adequately infer the results of this study, a thorough elaboration of its limitations should be noted. Given the specific type of desired outcome investigated, specifically complications, and the paucity in experimental designs in this domain, it was not feasible to restrict study designs to only randomized control trials or case-control cohorts. The present data set was thus retrieved largely from observational studies, which carry biases inherent to their designs (e.g. under-reporting or information bias, and publication bias), besides the frequent occurrence of incomplete data. While the authors were prudent in only considering complete and unambiguous data across studies and within individual cohorts for the purpose of this meta-analysis, these limitations cannot be ignored. Other biases and limitations include restricting studies to the English language and the inconsistency and lack of consensus as to what defines a complication. While some authors may consider and report on edema as a "complication", others may consider this an inevitable outcome of any surgical intervention. Additionally, the overall complication rate presented in this study may be overestimated by studies in which authors considered a sub-optimal aesthetic result as a complication, rather than an undesirable outcome. Alternatively, some authors may consider a complication exclusively as an undesirable outcome that requires a corrective intervention, operative or otherwise, thus under-reporting on the incidence of other more benign complications. Owing to the method of calculation of proportions with the available data, a certain amount of inflation will likely occur, considering that while some patients will have more than one complication, the total number of complications was still calculated out of a proportion of the total sample size. Finally, the main source of heterogeneity rests in within-cohort and between-cohort differences including patient characteristics (e.g. age, body mass index, gender, method of weight loss), perioperative protocols and surgical technique; all of which, coalesce, culminating in a state of heterogeneity that cannot be ignored when interpreting the results of this study.

Conclusion

Brachioplasty continues to be refined and advanced to achieve improvements in function and aesthetics. Substantial heterogeneity in brachioplasty literature exists, which may limit reliable data synthesis and interpretation. Although wide variability in brachioplasty techniques is presently adopted, brachioplasty remains a safe procedure when appropriate judgment regarding patient selection, operative protocols, and appropriate techniques is employed. Patients seeking upper arm contouring should be informed about the estimated complication and reoperation rate profile of this procedure to improve informed consent and appropriately manage expectations.
References

- 1. Miotto G, Ortiz-Pomales Y. Arm Contouring: Review and Current Concepts. *Aesthet Surg J.* 2018;38(8):850-860.
- Surgeons ASoP. 2018 Plastic Surgery Procedural Statistics. <u>https://www.plasticsurgery.org/news/plastic-surgery-statistics</u>. Published 2018. Accessed November 16,2019.
- 3. Rohrich RJ, Mohan R, Durand PD. Brachioplasty Refinements: Limited-Incision Brachioplasty. *Plast Reconstr Surg.* 2020.
- 4. Hill S, Small KH, Pezeshk RA, Rohrich RJ. Liposuction-Assisted Short-Scar Brachioplasty: Technical Highlights. *Plast Reconstr Surg.* 2016;138(3):447e-450e.
- 5. Goddio AS. A new technique for brachioplasty. *Plast Reconstr Surg.* 1989;84(1):85-91.
- 6. Hurwitz D. Brachioplasty. *Clin Plast Surg.* 2014;41(4):745-751.
- Gusenoff JA, Coon D, Rubin JP. Brachioplasty and concomitant procedures after massive weight loss: a statistical analysis from a prospective registry. *Plast Reconstr Surg.* 2008;122(2):595-603.
- Knoetgen J, 3rd, Moran SL. Long-term outcomes and complications associated with brachioplasty: a retrospective review and cadaveric study. *Plast Reconstr Surg.* 2006;117(7):2219-2223.
- 9. Symbas JD, Losken A. An outcome analysis of brachioplasty techniques following massive weight loss. *Ann Plast Surg.* 2010;64(5):588-591.
- 10. Sisti A, Cuomo R, Milonia L, et al. Complications associated with brachioplasty: a literature review. *Acta Biomed.* 2018;88(4):393-402.
- 11. Shermak MA. Aesthetic refinements in body contouring in the massive weight loss patient: Part 2. Arms. *Plast Reconstr Surg.* 2014;134(5):726e-735e.
- 12. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: *The Cochrane Collaboration*.2011: www.handbook.cochrane.org.
- 13. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P)2015 statement. *SystRev*. 2015;4:1.

- 14. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing V, Austria. URL <u>http://www.R-project.org/</u>.
- 15. Zomerlei TA, Neaman KC, Armstrong SD, et al. Brachioplasty outcomes: a review of a multipractice cohort. *Plast Reconstr Surg.* 2013;131(4):883-889.
- BossertRP, Dreifuss S, Coon D, et al. Liposuction of the arm concurrent with brachioplasty in the massive weight loss patient: is it safe? *Plast Reconstr Surg.* 2013;131(2):357-365.
- 17. de Runz A, Colson T, Minetti C, et al. Liposuction-assisted medial brachioplasty after massive weight loss: an efficient procedure with a high functional benefit. *Plast Reconstr Surg.* 2015;135(1):74e-84e.
- 18. Aboul Wafa AM. S-shaped brachioplasty: an effective technique to correct excess skin and fat of the upper arm. *Plast Reconstr Surg.* 2013;131(4):661e-663e.
- 19. Wolf AM, Kuhlmann HW. Reconstructive procedures after massive weightloss. *Obes Surg.* 2007;17(3):355-360.
- Hurwitz DJ, Holland SW. The L brachioplasty: an innovative approach to correct excess tissue of the upper arm, axilla, and lateral chest. *Plast Reconstr Surg.* 2006;117(2):403-411; discussion 412-403.
- 21. Bocchiotti MA, Ruka E, Spaziante L, Morozzo U, Baglioni EA, Bruschi S. 'J' brachioplasty technique in massive weight loss patients. *J Plast Surg Hand Surg.* 2018;52(5):282-287.
- 22. Bracaglia R, D'Ettorre M, Gentileschi S, Mingrone G, Tambasco D. "Krisknife" brachioplasty after bariatric surgery and massive weight loss. *Aesthetic Plast Surg.* 2013;37(3):640-642.
- 23. Modolin ML, Cintra W, Jr., Faintuch J, et al. Improved double-fuse technique for postbariatric brachioplasty. *Rev Col Bras Cir.* 2011;38(4):217-222.
- 24. Fantozzi F. Brachial lifting using the balanced triple-vector (BTV) technique with dual opposing flaps. *Eur J Plast Surg.* 2014;37:95-102.
- 25. Elkhatib H. Posterior Scar Brachioplasty with Fascial Suspension: A Long-term Follow-up of a Modified Technique. *Plast Reconstr Surg Glob Open.* 2013;1(6):e38.

- Simone P, Carusi C, Segreto F, et al. Postbariatric Brachioplasty with Posteromedial Scar: Physical Model, Technical Refinements, and Clinical Outcomes. *Plast Reconstr Surg.* 2018;141(2):344-353.
- 27. Abramson DL. Minibrachioplasty: minimizing scars while maximizing results. *Plast Reconstr Surg.* 2004;114(6):1631-1634; discussion 1635-1637.
- Di Pietro V, Colicchia GM, Cervelli V, Gentile P. Arm Contouring After Massive Weight Loss: Liposuction-Assisted Brachioplasty Versus Standard Technique. J Cutan Aesthet Surg. 2018;11(2):73-78.
- 29. Boccara D, Petit A, Reinbold C, Chaouat M, Mimoun M, Serror K. The M-Y Axilloplasty After Massive Weight Loss: Analysis of 159 Consecutive Patients. *Aesthetic Plast Surg.* 2018;42(4):1059-1064.
- 30. Gentileschi S, Servillo M, Ferrandina G, Salgarello M. Lymphatic and Sensory Function of the Upper Limb After Brachioplasty in Post-Bariatric Massive WeightLoss Patients. *Aesthet Surg J.* 2017;37(9):1022-1031.
- 31. Ferraro GA, De Francesco F, Razzano S, D'Andrea F, Nicoletti G. Modified fish-incision technique in brachioplasty: a surgical approach to correct excess skin and fatof the upper arm (restoring the armpit contour). *Aesthetic Plast Surg.* 2015;39(2):203-208.
- 32. Knotts CD, Kortesis BG, Hunstad JP. Avulsion brachioplasty: technique overview and 5year experience. *Plast Reconstr Surg.* 2014;133(2):283-288.
- 33. Nguyen AT, Rohrich RJ. Liposuction-assisted posterior brachioplasty: technical refinements in upper arm contouring. *Plast Reconstr Surg.* 2010;126(4):1365-1369.
- Rivera Citarella E, Conde-Green A, Nakamura F, Pitanguy I. Plication of the brachial fascia: an important step in dermolipectomy procedures of the arm. *Aesthet Surg J*. 2010;30(1):66-70.
- 35. Hurwitz DJ, Jerrod K. L-brachioplasty: an adaptable technique for moderate to severe excess skin and fat of the arms. *Aesthet Surg J.* 2010;30(4):620-629.
- Bruschi S, Datta G, Bocchiotti MA, Boriani F, Obbialero FD, Fraccalvieri M. Limb contouring after massive weight loss: functional rather than aesthetic improvement. *Obes Surg.* 2009;19(4):407-411.

- 37. Migliori FC, Ghiglione M, D'Alessandro G, Serra Cervetti GG. Brachioplasty after bariatric surgery: personal technique. *Obes Surg.* 2008;18(9):1165-1169.
- 38. El Khatib HA. Classification of brachial ptosis: strategy for treatment. *Plast Reconstr Surg.* 2007;119(4):1337-1342.
- 39. Cannistra C, Valero R, Benelli C, Marmuse JP. Brachioplasty after massive weight loss: a simple algorithm for surgical plane. *Aesthetic Plast Surg.* 2007;31(1):6-9; discussion 10-11.
- 40. de Souza Pinto EB, Erazo PJ, Matsuda CA, et al. Brachioplasty technique with the use of molds. *Plast Reconstr Surg.* 2000;105(5):1854-1860; discussion 1861-1855.

Tables

Table 1 – Search Strategy: Summary of inclusion and exclusion criteria of primary articles
 evaluated for this systematic review and meta-analysis.

Inclusion Criteria	Exclusion Criteria
Primary cohorts undergoing brachioplasty	Case reports, database studies, survey
(human subjects only)	inquiries, or reviews
English language publications	Revision brachioplasties
Sample size of n=10 or larger	Ambiguous data (incomplete or non-specific
	reporting on complications)
Any incisional approach and any brachioplasty	Cohorts for which outcomes reporting is
technique	based only on specific outcomes or
	complication of interest
Any etiology (massive weight loss or senile	
elastosis)	
Sufficient proportional data	

Table 2 – Included Studies: Synthesis of studies and study characteristics for articles meeting

 the inclusion criteria for the meta-analysis. N.s.; not specified in detail.

Author	Year	Country	Study Design	N (% female)	Excisional Pattern (Scar Placement)	Adjunct Liposuction
Di Pietro et			Retrospective	20 (n.s.)	Swallowtail Pattern (Medial)	No
al. ²⁸	2018	Rome, Italy	Review	11	Elliptical Excision	Yes
				(n.s.)	(Medial)	
Bocchiotti et al. ²¹	2018	Turin, Italy	Retrospective Review	73 (82%)	J-brachioplasty (Medial)	Yes
Boccara et al. ²⁹	2018	Paris, France	Retrospective Review	159 (100%)	M-Y axilloplasty (Medial)	Yes
Simone et al. ²⁶	2018	Rome, Italy	Prospective Series	24 (n.s.)	Curvilear Pattern with Axillary Z- Plasty (Posteromedial)	Yes
Gentileschi et al. ³⁰	2017	Rome, Italy	Prospective Series	12 (100%)	Double Ellipse (Medial)	Yes
Hill et al. ⁴	2016	Dallas, Texas, USA	Retrospective Review	165 (n.s.)	Short Scar (Axilla)	Yes
Ferraro et al. ³¹	2015	Naples, Italy	Retrospective Review	30 (100%)	Modified Fish- Mouth (Medial)	No
De Runz et al. ¹⁷	2015	Nancy, France	Retrospective Review	66 (95%)	Elliptical with Axillary Z-Plasty (Medial)	Yes
El Khatib ²⁵	2013	Qatar	Retrospective Review	205 (n.s.)	n.s. (Posterior)	Yes

Knotts et al. ³²	2014	North Carolina, USA	Retrospective Review	44 (100%)	Elliptical (Posteromedial)	Yes
Fantozzi ²⁴	2014	Rome, Italy	Retrospective Review	23 (90%)	Semi-Sinusoidal (Medial)	Yes (7 cases)
Zomerlei et al. ¹⁵	2013	Michigan, USA	Retrospective Review	96 (99%)	Single Ellipse [n=75]; Fish Mouth [n=14], L-Pattern [n=5], Axillary Z- Plasty [n=2] (Medial)	Yes (51 cases)
Bracaglia et al. ²²	2013	Rome, Italy	Retrospective review	41 (100%)	"Kris Knife" (Medial)	Yes
Bossert et	2013	Pittsburgh, Pennsylvania	Retrospective Review of Prospective	80 (n.s.)	Anchor-Shaped" with Fascial Resuspension (Medial)	No
al. ¹⁶	_012	USA	Registry Entries	64 (n.s.)	"Anchor-Shaped" with Fascial Resuspension (Medial)	Yes
Modolin et al. ²³	2011	Sao Paolo, Brazil	Retrospective (Interviews)	18 (100%)	Fish-shaped (medial)	n.s.
Nguyen and Rohrich ³³	2010	Dallas, Texas, USA	Prospective Series	21 (100%)	Elliptical (Posterior)	Yes
Rivera Citarella et al. ³⁴	2010	Rio de Janeiro, Brazil	Retrospective Review	41 (100%)	Semi-Ellipse with Fascial Plication (Medial)	Yes
Hurwitz and Jerrod ³⁵	2010	Pittsburgh, Pennsylvania, USA	Prospective series	15 (87%)	L-Brachiolasty with Fascial Resuspension (Medial)	Yes

Symbas and Losken ⁹	2010	Atlanta, Georgia, USA	Retrospective Review	31 (100%)	Double Ellipse [n=16]; L-Shaped [n=15] (Medial)	n.s.
Bruschi et al. ³⁶	2009	Turin, Italy	Retrospective Review	13 (n.s.)	Z-Plasty in Axilla (Medial)	Yes (3 cases)
Gusenoff et al. ⁷	2008	Pittsburgh, Pennsylvania, USA	Retrospective Review of Prospective Registry	101 (96%)	n.s. (Medial)	Yes (24 cases)
Migliori et al. ³⁷	2008	Genoa, Italy	Retrospective Review	29 (100%)	n.s. (Medial)	n.s.
	2007	Doha, Qatar	Retrospective Review	29 (n.s.)	Short Scar (Posterior)	Yes
Elkhatib ³⁸				11 (n.s.)		No
Cannistra et al. ³⁹	2007	Paris, France	Retrospective Review	50 (n.s.)	Z-Plasty in Axilla (Medial n=10; Posterior n= 40)	Yes (40 cases preoperatively)
Hurwitz and Holland ²⁰	2006	Pittsburgh, Pennsylvania, USA	Retrospective Review	24 (100%)	L-Brachioplasty (Medial)	Yes (5 cases)

Abramson ²⁷	2004	New York, USA	Retrospective Review	10 (n.s.)	n=8 Short Scar (Axillary & Medial, n=8) "Traditional Pattern" (n.s., n=2)	Yes
De Souza Pinto et al. ⁴⁰	2000	Sao Paolo, Brazil	Retrospective Review	20 (100%)	Double S-Shaped Mold (Medial)	Yes (12 cases)
Goddio ⁵	1989	n.s.	Retrospective Review	12 (100%)	Non-Excisional Flap De- Epithelialization (Medial)	n.s.

Table 3 – **Complication Rates:** Overall and individual complication rates, as identified and synthesized in the present meta-analysis using a random-effects model and meta-analysis of proportions. Revision rates and specific indications also presented.

**including all complications reported on in primary articles, not restricted to the individual complications presented herein, and according to definitions set by authors of the primary studies.*

		n Studies	Incidence	95%	т2
		(n Patients)	Incluence	Confidence Interval	1-
Complica	ation Rates				
	Overall Complication	32	22.020/	10.01.40.24	020/
	Rate*	(1578)	32.9370	19.91, 49.24	9270
	Aberrant Scarring				
	(including keloid,	29	0.00/	(10/. 15 (0/	0.20/
	hypertrophic and widened	(1333)	9.9%	0.1%; 15.0%	82%
	scars)				
	Residual Ptosis,	14			
	Recurrence (including	g 14 7.79		4.82 %; 12.35%	65%
	contour irregularities)	(773)			
	Dehiseenee	32	6.81%	1 63 % 9 90%	60%
	Demseence	(1578)	0.0170	4.05 /0, 9.9070	0070
	Seroma Formation	32	5 01%	2 759/ • 0 259/	60%
	Scrollia Pormation	(1578)	5.7170	5.7570, 9.2570	0770
	Infection (including stitch	32	3 61%	2 380% · 5 530%	28%
	abscess)	(1578)	5.0470	2.3670, 3.3370	2070
	Nerve-Related				
	Complications (including				
	temporary or permanent	37			
	dysesthesia, paresthesia,	(1578)	2.47%	1.45%; 4.18%	45%
	or confirmed nerve	(1370)			
	sectioning or				
	compression)				

	Lymphedema or	32	2 460/	1 550/ . 2 990/	20/
	Lymphocele Formation	(1578)	2.40%	1.33%, 3.88%	3%0
	Skin Necrosis or Delayed	32	2 270/	1 270/. 2 7/0/	120/
	Healing	(1578)	2.2770	1.5770, 5.7470	1370
	Hematoma Formation	32	2.06%	1 38% 3 06%	0%
	riematoma i ormation	(1578)	2.0070	1.5670, 5.0070	070
Revision Rate	S				
	Overall Operative Re-	25	7 120/	5 01% · 10 86%	680/
	Intervention	(1426)	/.4270	5.0176, 10.8076	0870
	Operative Re-Intervention				
	for Aesthetic Purposes				
	(including revision of				
	scars, dog ears and residual ptosis; excluding				
		24	7 160/	5 050/ • 10 000/	650/
	non-invasive or	(1402)	/.4070	5.0570, 10.8870	0370
	minimally invasive				
	interventions such as laser				
	therapy or steroid				
	injections)				
	Operative Re-Intervention				
	for Non-Aesthetic				
	Purposes (including				
	operative drainage of	25			
	collections, repair of	23 (1426)	1.62%	1.00%; 2.61%	0%
	nerve-related	(1420)			
	complications, or wound				
	dehiscence; excluding				
	office-based drainage)				

Table 4 – Impact of Incision Placement on Complications and Reoperations: *Multivariate meta-regression demonstrated that medial incision placement significantly increased the* complication rate in brachioplasty, as well as the specific incidence of aberrant scarring, dehiscence, and seroma. A medial incision placement thus culminated in an increased operative *reintervention rate, specifically for aesthetic purposes.*

Outcome		Subg	roup Analys	is	
	Medial incision Other incision				
	Incidence (%)	95%CI	Incidence (%)	95%CI	p-value
Overall Complications	43.7	32.0 - 56.1	9.7	3.7 - 22.8	0.021
Aberrant scarring	15.6	10.5 - 22.6	2.98	1.2 – 7.3	0.002
Dehiscence	8.7	6.0 - 12.4	3.1	1.26 - 5.5	0.038
Seroma	8.41	5.5 - 12.6	1.4	0.4 - 4.5	0.005
Ptosis	9.44	2.8 - 26.9	5.84	1.2 – 24.2	0.31
Infection	4.02	0.8 - 16.7	3.65	2.3 - 5.6	0.33
Skin necrosis	3.13	1.2 - 7.5	3.72	1.8 – 7.4	0.17
Lymphedema	3.11	1.6 - 5.9	3.34	2.3 – 4.7	0.42
Nerve injury	2.89	1.5 - 5.2	1.39	0.4 - 4.8	0.28
Hematoma	2.25	1.4 - 3.5	2.09	1.4 – 3.1	0.41
Overall Operative Reintervention	10.8	8.7 - 14.1	3.7	1.7 – 7.9	0.027
Operative Reintervention for Aesthetic Purposes	9.9	6.9 - 14.0	3.8	1.7 - 8.3	0.035
Operative Reintervention for Non-Aesthetic Purposes	1.72	0.9 – 2.9	2.49	0.8-6.7	0.66

Table 5 – Impact of Liposuction on Complications and Reoperations: Multivariate meta-

regression demonstrated that adjunctive arm liposuction, either at the excision cite or circumferentially, reduced the incidence of seroma, lymphedema, and nerve injury, but did not significantly alter the overall complication or reoperation rate.

Outcome		Subg	roup Analys	is	
	No Lip	osuction	Lipos	suction	
	Incidence (%)	95%CI	Incidence (%)	95%CI	p-value
Overall complications	35.49	11.9 - 69.1	29.50	16.3 – 47.3	0.84
Seroma	13.53	7.5 – 29.6	3.0	1.6 – 4.9	0.007
Lymphedema	6.5	3.2 - 12.9	1.6	0.9 – 2.9	0.012
Nerve injury	5.5	2.5 – 11.7	1.5	0.8 - 2.8	0.013
Aberrant scarring	20.08	6.5 - 47.6	7.55	3.8 -14.3	0.12
Ptosis	6.16	2.5 - 14.3	8.23	5.3 - 12.6	0.09
Dehiscence	5.56	1.9 – 15.0	7.53	4.3 - 12.7	0.61
Infection	5.03	2.5 - 9.7	2.63	1.6 – 4.2	0.88
Skin necrosis	1.99	0.6 - 6.5	2.38	1.2 – 4.5	0.93
Hematoma	1.90	0.6 - 6.0	1.7	0.9 – 2.9	0.82
Overall Operative Reintervention	6.41	3.7 - 10.8	7.89	2.5 - 21.7	0.73
Operative Reintervention for Aesthetic Purposes	6.54	3.7 - 11.2	7.90	2.6 - 21.7	0.76
Operative Reintervention for Non-Aesthetic Purposes	1.48	0.7 – 2.8	1.99	0.5 - 7.6	0.70

Table 6 – Impact of BMI on Complications and Reoperations: Multivariate meta-regressiondemonstrated no statistically significant differences in complication or reoperation ratesbetween patients according to body mass index.

Outcome	Subgroup Analysis				
	BN	[] <30	BM		
	Incidence (%)	95%CI	Incidence (%)	95%CI	p-value
Overall complications	35.55	22.0 - 51.9	54.47	31.0 - 76.1	0.35
Aberrant scarring	14.25	6.6 - 27.9	16.98	5.4 - 42.1	0.80
Dehiscence	10.10	5.9 - 16.5	7.10	3.0 - 15.7	0.47
Seroma	8.51	3.9 - 17.5	5.51	5.5 - 18.3	0.58
Ptosis	8.02	1.9 – 28.1	9.25	1.8 - 35.8	0.88
Infection	3.48	2.1 - 5.6	4.13	2.0-8.2	0.69
Hematoma	1.95	1.0 - 3.7	2.75	1.0 - 7.4	0.56
Nerve injury	1.58	0.7 - 3.6	1.98	0.7 - 5.5	0.73
Lymphedema	1.38	0.6 -3.1	3.26	1.3 – 7.6	0.16
Skin necrosis	1.30	0.5 - 3.0	1.47	0.4 - 4.9	0.86
Overall Operative Reintervention	6.80	3.7 – 12.1	13.44	6.8 - 24.5	0.14
Operative Reintervention for Aesthetic Purposes	7.26	3.8 - 13.4	12.38	6.2 - 23.0	0.26
Operative Reintervention for Non-Aesthetic Purposes	1.46	0.6 - 3.5	1.67	0.5 - 5.0	0.85

Table 7 – Impact of Age on Complications and Reoperations: Multivariate meta-regressiondemonstrated no statistically significant differences in complication or reoperation ratesbetween patients according to age.

Outcome		Subg	group Analys	is	
	Ag	e <45	Age	e ≥45	
	Incidence (%)	95%CI	Incidence (%)	95%CI	p-value
Overall complications	38.42	24.7 - 54.1	64.21	35.4 - 85.5	0.33
Aberrant scarring	15.41	8.7 - 25.8	20.63	9.0 - 40.5	0.59
Seroma	9.23	5.5 - 15.1	4.11	1.5 – 10.6	0.19
Ptosis	9.01	4.5 - 17.3	8.60	2.3 - 27.1	0.94
Dehiscence	7.25	4.7 – 10.9	10.79	5.3 - 20.6	0.35
Infection	4.03	2.5 - 6.3	9.35	4.4 - 18.8	0.26
Skin necrosis	2.69	1.5 – 4.7	1.18	0.3 - 3.9	0.47
Lymphedema	2.67	1.4 - 5.0	2.41	0.7 - 7.4	0.89
Nerve injury	2.23	1.0 - 4.8	4.03	1.0 - 14.1	0.45
Hematoma	2.15	1.2 – 3.6	1.74	0.6 - 4.5	0.70
Overall Operative Reintervention	8.56	5.3 - 13.5	13.08	6.6 - 14.2	0.33
Operative Reintervention for Aesthetic Purposes	8.82	5.5 - 13.8	13.00	6.9 - 23.8	0.32
Operative Reintervention for Non-Aesthetic Purposes	1.57	0.7 - 3.2	1.74	0.6 - 4.5	0.86

FIGURES

Figure 1 Figure 1. Flowchart of the search strategy, conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, as well as the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

PRISMA flowchart



Figure 2. Incidence of aberrant scarring determined using a random effects model and metaanalysis of proportions.



Figure 3. Incidence of ptosis or recurrence determined using a random effects model and metaanalysis of proportions.



Figure 4. Incidence of wound dehiscence determined using a random effects model and metaanalysis of proportions.

Study	Events	Total	Incidence (%)	95% C.I.	Weight
El Khatib 2013	0	205 🖛	0.00	[0.02; 3.76]	1.6%
Hill et al. 2016	2	165 🗖	1.21	[0.30; 4.71]	3.7%
Boccara et al. 2018	16	159	10.06	[6.26; 15.79]	5.8%
Gusenoff et al. 2008	9	101	8.91	[4.70; 16.25]	5.4%
Zomerlei et al. 2013	7	96 -	7.29	[3.52; 14.51]	5.2%
Bossert et al. 2013	2	80 🛨	- 2.50	[0.63; 9.45]	3.6%
Bocchiotti et al. 2017	4	73 -		[2.07; 13.71]	4.6%
De Runz et al 2015	6	66	9.09	[4.14; 18.80]	5.0%
Bossert et al. 2013	5	64 -	7.81	[3.29; 17.43]	4.8%
Cannistra et al. 2007	0	50 💻	0.00	[0.06; 13.83]	1.6%
Knotts et al. 2014	14	44	31.82	[19.84; 46.81]	5.5%
Bracaglia et al. 2013	0	41 🖛	0.00	[0.07; 16.38]	1.6%
Rivera Citarella et al. 2010	3	41 -	7.32	[2.38; 20.37]	4.2%
Knoetgen and Moran 2006	3	40 -	7.50	[2.44; 20.82]	4.2%
Symbas and Losken 2010	0	31 💻	0.00	[0.10; 20.60]	1.6%
Ferraro et al. 2015	0	30 🗖	0.00	[0.10; 21.14]	1.6%
Migliori et al. 2008	1	29 🚽	3.45	[0.48; 20.79]	2.5%
El Khatib 2007	0	29 🗖	0.00	[0.10; 21.72]	1.6%
Simone et al. 2018	1	24 –	4.17	[0.58; 24.35]	2.5%
Hurwitz and Holland 2006	0	24 🛏	0.00	[0.12; 25.13]	1.6%
Fantozzi 2014	0	23 🛏	0.00	[0.13; 25.94]	1.6%
Nguyen and Rohrich 2006	2	21 -	9.52	[2.39; 31.13]	3.5%
Di Pietro et al. 2018	5	20		[10.81; 47.84]	4.6%
De Souza Pinto et al. 2004	0	20 🛏	0.00	[0.15; 28.74]	1.6%
Modolin et al. 2011	0	18 💻	0.00	[0.16; 30.96]	1.6%
Hurwitz and Jerrod 2010	5	15	33.33	[14.60; 59.40]	4.4%
Bruschi et al. 2009	3	13	23.08	[7.63; 52.15]	3.9%
Gentileschi et al. 2017	1	12 -	8.33	[1.16; 41.32]	2.4%
Goddio 1989	0	12 🖛	0.00	[0.24; 40.32]	1.6%
Di Pietro et al. 2018	1	11 -	9.09	[1.26; 43.86]	2.4%
El Khatib 2007	0	11 💻	0.00	[0.26; 42.46]	1.6%
Abramson 2004	1	10 —	10.00	[1.39; 46.72]	2.4%
Random effects model	91	1578	6.81	[4.63; 9.90]	100.0%
Heterogeneity: $I^2 = 60\%$, $\tau^2 =$	= 0.6780, <i>p</i>	< 0.01			
		U Inci	ence of Wound Dehiscence		

Figure 5. Incidence of seroma formation determined using a random effects model and metaanalysis of proportions.

Study	Events	Total		Incidence (%)	95% C.I.	Weight
El Khatib 2013	0	205 🖛		0.00	[0.02: 3.76]	2.0%
Hill et al. 2016	0	165 💻		0.00	[0.02; 4.63]	2.0%
Boccara et al. 2018	6	159 🛨	-	3.77	[1.71; 8.14]	5.0%
Gusenoff et al. 2008	24	101	_	23.76	[16.47; 33.01]	5.6%
Zomerlei et al. 2013	6	96 -	H-	6.25	[2.83; 13.22]	5.0%
Bossert et al. 2013	19	80		23.75	[15.69; 34.27]	5.5%
Bocchiotti et al. 2017	1	73 🗖	-	1.37	[0.19; 9.09]	3.0%
De Runz et al 2015	0	66 💻		0.00	[0.05; 10.83]	2.0%
Bossert et al. 2013	12	64		18.75	[10.97; 30.18]	5.3%
Cannistra et al. 2007	0	50 💻		0.00	[0.06; 13.83]	2.0%
Knotts et al. 2014	1	44 🛨		2.27	[0.32; 14.45]	3.0%
Bracaglia et al. 2013	1	41 🛨		2.44	[0.34; 15.39]	3.0%
Rivera Citarella et al. 2010	2	41 -		4.88	[1.22; 17.52]	3.9%
Knoetgen and Moran 2006	4	40 -		10.00	[3.80; 23.79]	4.6%
Symbas and Losken 2010	0	31 💻		0.00	[0.10; 20.60]	2.0%
Ferraro et al. 2015	0	30 🗖		0.00	[0.10; 21.14]	2.0%
Migliori et al. 2008	3	29 -		10.34	[3.37; 27.60]	4.3%
El Khatib 2007	0	29		0.00	[0.10; 21.72]	2.0%
Simone et al. 2018	0	24	_	0.00	[0.12; 25.13]	2.0%
Hurwitz and Holland 2006	4	24		16.67	[6.40; 36.91]	4.5%
Fantozzi 2014	1	23 -		4.35	[0.61; 25.22]	2.9%
Nguyen and Rohrich 2006	0	21		0.00	[0.14; 27.74]	2.0%
Di Pietro et al. 2018	1	20		35.00	[17.68; 57.44]	4.8%
De Souza Pinto et al. 2004	0	20		0.00	[0.15; 28.74]	2.0%
Modolin et al. 2011	1	18 -		5.56	[0.78; 30.65]	2.9%
Hurwitz and Jerrod 2010	1	15 -		6.67	[0.93; 35.20]	2.9%
Bruschi et al. 2009	3	13		23.08	[7.63; 52.15]	4.1%
Gentileschi et al. 2017	0	12		0.00	[0.24; 40.32]	2.0%
Goddio 1989	0	12		0.00	[0.24, 40.32]	2.0%
DI Pletro et al. 2018	0	11		0.00	[0.26; 42.46]	1.9%
El Khatib 2007	0	11		0.00	[0.26; 42.46]	1.9%
Abramson 2004	0	10		0.00	[0.28; 44.83]	1.9%
Random effects model	96	1578 🔄	•	5.91	[3.73; 9.25]	100.0%
Heterogeneity: $I^2 = 69\%$, $\tau^2 =$	= 1.0402, <i>p</i>	< 0.01 ¹	10 20 20 40 50 6	1 20		
		U	Incidence of Seroma	U		

Figure 6. Incidence of infection determined using a random effects model and meta-analysis of proportions.

Study	Events	Total					Ir	ncidence (%)	95% C.I.	Weight
El Khatib 2013	0	205 🖛	4					0.00	[0.02: 3.76]	2.0%
Hill et al. 2016	0	165 🖛	÷					0.00	[0.02; 4.63]	2.0%
Boccara et al. 2018	5	159	<u> </u>					3.14	[1.31; 7.33]	7.1%
Gusenoff et al. 2008	3	101 -	<u> </u>					2.97	[0.96; 8.81]	5.9%
Zomerlei et al. 2013	19	96		-				19.79	[12.99; 28.96]	8.8%
Bossert et al. 2013	5	80	-					6.25	[2.63; 14.15]	7.0%
Bocchiotti et al. 2017	0	73 🖛	<u> </u>					0.00	[0.04; 9.89]	2.0%
De Runz et al 2015	2	66 -	÷					3.03	[0.76; 11.32]	4.9%
Bossert et al. 2013	3	64 -	in					4.69	[1.52; 13.55]	5.9%
Cannistra et al. 2007	0	50 🗖	<u> </u>					0.00	[0.06; 13.83]	2.0%
Knotts et al. 2014	0	44 🖛		-				0.00	[0.07; 15.43]	2.0%
Bracaglia et al. 2013	0	41 🖛		-				0.00	[0.07; 16.38]	2.0%
Rivera Citarella et al. 2010	0	41 🛏		_				0.00	[0.07; 16.38]	2.0%
Knoetgen and Moran 2006	4	40						10.00	[3.80; 23.79]	6.4%
Symbas and Losken 2010	2	31 -	-					6.45	[1.62; 22.42]	4.8%
Ferraro et al. 2015	0	30 🖛						0.00	[0.10; 21.14]	2.0%
Migliori et al. 2008	0	29 🗖						0.00	[0.10; 21.72]	2.0%
El Khatib 2007	0	29 🗖						0.00	[0.10; 21.72]	2.0%
Simone et al. 2018	0	24 🖬						0.00	[0.12; 25.13]	2.0%
Hurwitz and Holland 2006	0	24 🖛						0.00	[0.12; 25.13]	2.0%
Fantozzi 2014	0	23 🖛	-		-			0.00	[0.13; 25.94]	2.0%
Nguyen and Rohrich 2006	0	21 🖛	-		_			0.00	[0.14; 27.74]	2.0%
Di Pietro et al. 2018	0	20 🛏	-					0.00	[0.15; 28.74]	2.0%
De Souza Pinto et al. 2004	0	20 🗖						0.00	[0.15; 28.74]	2.0%
Modolin et al. 2011	0	18 🖛						0.00	[0.16; 30.96]	1.9%
Hurwitz and Jerrod 2010	0	15 🖿						0.00	[0.19; 35.03]	1.9%
Bruschi et al. 2009	0	13 🖛						0.00	[0.22; 38.39]	1.9%
Gentileschi et al. 2017	0	12 🛏	-					0.00	[0.24; 40.32]	1.9%
Goddio 1989	0	12 🛏						0.00	[0.24; 40.32]	1.9%
Di Pietro et al. 2018	0	11 🖛						0.00	[0.26; 42.46]	1.9%
El Khatib 2007	1	11 -	-					9.09	[1.26; 43.86]	3.1%
Abramson 2004	1	10 -	-				_	10.00	[1.39; 46.72]	3.1%
Random effects model	45	1578 _	•					3.64	[2.38; 5.53]	100.0%
Heterogeneity: $I^2 = 48\%$, $\tau^2 =$	0.4983, p	< 0.01 ¹	1	1	1	1	I			
		0	10	20	30	40	50			
			Incide	ence o	f Infe	ction				

Figure 7. Incidence of nerve injury or nerve-related complications determined using a random effects model and meta-analysis of proportions.



Figure 8. Incidence of lymphedema determined using a random effects model and meta-analysis of proportions.



Figure 9. Incidence of skin necrosis determined using a random effects model and meta-analysis of proportions.



Figure 10. Incidence of hematoma determined using a random effects model and meta-analysis of proportions.



Figure 11. *Reintervention rate for aesthetic purposes, determined using a random effects model and meta-analysis of proportions.*



Figure 12. *Reintervention rate for non-aesthetic purposes, determined using a random effects model and meta-analysis of proportions.*

Study	Events	Total					Ir	ncidence (%) 95% C.I.	Weight
El Khatib 2013	0	205 🛋						0.0	0 [0.02; 3.76]	3.1%
Hill et al. 2016	0	165 🖷						0.0	0 [0.02; 4.63]	3.1%
Boccara et al. 2018	0	159 💻						0.0	0 [0.02; 4.79]	3.1%
Gusenoff et al. 2008	0	101 🖷	_					0.0	0 [0.03; 7.35]	3.1%
Zomerlei et al. 2013	2	96 👥	_					2.0	3 [0.52; 7.95]	12.1%
Bossert et al. 2013	0	80 -						0.0	0 [0.04; 9.10]	3.1%
Bocchiotti et al. 2017	2	73 🛨						2.7	4 [0.69; 10.30]	12.0%
De Runz et al 2015	1	66 📫						1.5	2 [0.21; 9.98]	6.1%
Bossert et al. 2013	0	64 🗖						0.0	0 [0.05; 11.13]	3.1%
Cannistra et al. 2007	0	50 🖷						0.0	0 [0.06; 13.83]	3.1%
Knotts et al. 2014	0	44 📑		-				0.0	0 [0.07; 15.43]	3.1%
Rivera Citarella et al. 2010	0	41 🖷		_				0.0	0 [0.07; 16.38]	3.1%
Knoetgen and Moran 2006	0	40 🗖		_				0.0	0 [0.08; 16.72]	3.1%
Symbas and Losken 2010	1	31 🛨						3.2	3 [0.45; 19.64]	6.0%
Ferraro et al. 2015	0	30 🗖						0.0	0 [0.10; 21.14]	3.0%
El Khatib 2007	0	29 📑						0.0	0 [0.10; 21.72]	3.0%
Simone et al. 2018	0	24 📑			-			0.0	0 [0.12; 25.13]	3.0%
Hurwitz and Holland 2006	0	24 🖷			-			0.0	0 [0.12; 25.13]	3.0%
Fantozzi 2014	0	23			-			0.0	0 [0.13; 25.94]	3.0%
Nguyen and Rohrich 2006	0	21 📑			_			0.0	0 [0.14; 27.74]	3.0%
Hurwitz and Jerrod 2010	0	15 🖷						0.0	0 [0.19; 35.03]	3.0%
Gentileschi et al. 2017	0	12 📑						0.0	0 [0.24; 40.32]	3.0%
Goddio 1989	0	12 📑						0.0	0 [0.24; 40.32]	3.0%
El Khatib 2007	0	11 🖷						0.0	0 [0.26; 42.46]	3.0%
Abramson 2004	0	10 🗖						0.0	0 [0.28; 44.83]	3.0%
Random effects model	6	1426 🔺						1.6	2 [1.00; 2.61]	100.0%
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$), <i>p</i> = 1.0) '	1	I	I	I	I			
		0	10	20	30	40	50			

Reintervention Rate for Non-Aesthetic Purposes

Figure 13. Overall complication rate determined using a random effects model and meta-analysis of proportions, based on specific definitions set by primary studies assessed for as to what constitutes a complication.



Supplementary Figure 1 Meta-regression forest plots demonstrating that medial incision placement significantly increased the complication rate in brachioplasty (a), as well as the specific incidence of aberrant scarring (b), dehiscence (c), and seroma (d). A medial incision placement thus culminated in an increased operative reintervention rate (e), specifically for aesthetic purposes (f).

Supplementary Figure 1a



Supplementary Figure 1b



Supplementary Figure 1c



Supplementary Figure 1d

Study	Events Total	Incidence (%) 98	5% C.I. Weight
Incision = Medial		_	
Di Pietro et al. 2018	7 20 -	35.00 [17.68;	57.44] 5.4%
Di Pietro et al. 2018	0 11	0.00 [0.26;	42.46] 1.7%
Bocchiotti et al. 2017	1 73	1.37 [0.19	; 9.09] 2.8%
Boccara et al. 2018	6 159	3.77 [1.71	; 8.14] 5.7%
Gentileschi et al. 2017	0 12	0.00 [0.24;	40.32] 1.7%
Ferraro et al. 2015	0 30	0.00 [0.10;	21.14] 1.7%
De Runz et al 2015	0 66	0.00 [0.05;	10.83] 1.8%
Knotts et al. 2014	1 44	2.27 [0.32]	14.45] 2.8%
Fantozzi 2014	1 23	- 4.35 [0.61;	25.22] 2.8%
Zomerlei et al. 2013	6 96 -	6.25 [2.83;	13.22] 5.7%
Bracaglia et al. 2013	1 41	2.44 [0.34;	15.39] 2.8%
Bossert et al. 2013	19 80 -	23.75 [15.69;	34.27] 6.6%
Bossert et al. 2013	12 64 -	18.75 [10.97;	30.18] 6.3%
Modolin et al. 2011	1 18 🗕	5.56 [0.78;	30.65] 2.7%
Hurwitz and Jerrod 2010	1 15 🚽	6.67 [0.93]	35.20] 2.7%
Hurwitz and Holland 2006	4 24	16.67 [6.40]	36.91] 4.9%
Symbas and Losken 2010	0 31	0.00 [0.10;	20.60] 1.7%
Gusenoff et al. 2008	24 101 -	23.76 [16.47]	33.01] 6.7%
Migliori et al. 2008	3 29		27.60] 4.6%
Goddio 1989	0 12	0.00 [0.24]	40.32] 1.7%
De Souza Pinto et al. 2004	0 20	0.00 [0.15]	28.74] 1.7%
Knoetgen and Moran 2006	4 40	10.00 [3.80;	23.79] 5.1%
Bruschi et al. 2009	3 13	23.08 [7.63]	52.15] 4.3%
Rivera Citarella et al. 2010	2 41	4.88 [1.22]	17.52] 4.0%
Combined Incidence	96 1063 🔶	8.41 [5.53;	12.60] 87.9%
Heterogeneity: $I^2 = 68\%$, $\tau^2 =$	0.6406, <i>p</i> < 0.01		
Incision = Other			
Simone et al. 2018	0 24	- 0.00 [0.12;	25.13] 1.7%
Hill et al. 2016	0 165 -	0.00 [0.02	; 4.63] 1.8%
El Khatib 2013	0 205 -	0.00 [0.02	; 3.76] 1.8%
Nguyen and Rohrich 2006	0 21	0.00 [0.14;	27.74] 1.7%
El Khatib 2007	0 29	- 0.00 [0.10;	21.72] 1.7%
El Khatib 2007	0 11	0.00 [0.26;	42.46] 1.7%
Abramson 2004	0 10	0.00 [0.28]	44.83] 1.7%
Combined Incidence	0 465 🍉	1.39 [0.42	: 4.54] 12.1%
Heterogeneity: $I^2 = 0\%$, $\tau^2 =$	0.6406, p = 0.64		
Combined Incidence	96 1528 🔶	6.82 [4.58;	10.05] 100.0%
Heterogeneity: $I^2 = 69\%$, $\tau^2 = Residual heterogeneity: I^2 =$	= 0.6406, p < 0.01 62%, p < 0.01 0 10 2	0 30 40 50 60	
	Incidenc	e of Seroma (%)	

Supplementary Figure 1e

Study	Events	Total						Incidend	ce (%)	95	5% <mark>C.I</mark> .	Weight
Incision = Medial			1									
Bocchiotti et al. 2017	2	73 🕇	H+						2.74	[0.69;	10.30]	3.9%
Boccara et al. 2018	11	159	-						6.92	[3.87;	12.06]	7.2%
Gentileschi et al. 2017	0	12 -				_			0.00	[0.24;	40.32]	1.4%
Ferraro et al. 2015	0	30 -		-					0.00	[0.10;	21.14]	1.5%
De Runz et al 2015	14	66	-						21.21	[12.98;	32.69]	7.3%
Knotts et al. 2014	9	44	1 -		_				20.45	[11.00;	34.85]	6.6%
Fantozzi 2014	2	23 -	-		1				8.70	[2.18;	28.88]	3.8%
Zomerlei et al. 2013	22	96		-	-				22.92	[15.59;	32.36]	7.8%
Bossert et al. 2013	7	80	-						8.75	[4.23;	17.24]	6.4%
Bossert et al. 2013	6	64	-						9.38	[4.27;	19.34]	6.1%
Hurwitz and Jerrod 2010	2	15	-	-		_			13.33	[3.36;	40.54]	3.7%
Hurwitz and Holland 2006	1	24 -	-						4.17	[0.58;	24.35]	2.5%
Symbas and Losken 2010	6	31		-		-			19.35	[8.96;	36.91]	5.9%
Gusenoff et al. 2008	3	101	H÷ –						2.97	[0.96	; 8.81]	4.8%
Goddio 1989	0	12 -							0.00	[0.24;	40.32]	1.4%
Knoetgen and Moran 2006	4	40	-						10.00	[3.80;	23.79]	5.3%
Rivera Citarella et al. 2010	2	41 -		-					4.88	[1.22;	17.52]	3.9%
Combined Incidence	91	911	-						9.78	[6.69;	14.09]	79.5%
Heterogeneity: $I^2 = 63\%$, $\tau^2 =$	= 0.3938, /	0 < 0.01										
Incision = Other												
Simone et al. 2018	0	24 -	-						0.00	[0.12;	25.13]	1.5%
Hill et al. 2016	2	165 🗖	- 1						1.21	[0.30	; 4.71]	3.9%
El Khatib 2013	6	205	H						2.93	[1.32	6.36]	6.3%
Nguyen and Rohrich 2006	0	21 -							0.00	[0.14;	27.74]	1.5%
El Khatib 2007	0	29 -							0.00	[0.10;	21.72]	1.5%
El Khatib 2007	2	11		-			_		18.18	[4.58;	50.70]	3.5%
Abramson 2004	1	10 -		204			-12		10.00	[1.39;	46.72]	2.4%
Combined Incidence	11	465 <							3.67	[1.66;	7.93]	20.5%
Heterogeneity: $I^2 = 37\%$, $\tau^2 =$	= 0.3938, /	0 = 0.14										
Combined Incidence	102	1376	-						8.05	[5.71;	11.24]	100.0%
Heterogeneity: $I^2 = 68\%$, $\tau^2 =$	0.3938.	o < 0.01	1		1	1						
Residual heterogeneity: $I^2 =$	58%, p <	0.01 0	10	20	30	40	50					
3,		Ov	erall F	Reinter	ventio	on Ra	te	(%)				

Supplementary Figure 1f

Study	Events	Total					Incidence	(%)	95% C.I.	Weight
Incision = Medial			1							
Bocchiotti et al. 2017	2	73 🗖	-					2.74	[0.69; 10.30]	3.9%
Boccara et al. 2018	11	159						6.92	[3.87; 12.06]	7.5%
Gentileschi et al. 2017	0	12	-			-		0.00	[0.24; 40.32]	1.4%
Ferraro et al. 2015	0	30 -						0.00	[0.10; 21.14]	1.4%
De Runz et al 2015	14	66			-			21.21	[12.98; 32.69]	7.7%
Knotts et al. 2014	9	44			-			20.45	[11.00; 34.85]	6.9%
Fantozzi 2014	2	23 -		-	-			8.70	[2.18; 28.88]	3.7%
Zomerlei et al. 2013	22	96			-			22.92	[15.59; 32.36]	8.3%
Bossert et al. 2013	7	80		-				8.75	[4.23; 17.24]	6.6%
Bossert et al. 2013	6	64						9.38	[4.27; 19.34]	6.3%
Hurwitz and Jerrod 2010	2	15 -	-	-				13.33	[3.36; 40.54]	3.6%
Hurwitz and Holland 2006	1	24 -	-	1 - 1				4.17	[0.58; 24.35]	2.4%
Symbas and Losken 2010	6	31	-					19.35	[8.96; 36.91]	6.0%
Gusenoff et al. 2008	3	101	+					2.97	[0.96; 8.81]	4.8%
Goddio 1989	0	12 -	-					0.00	[0.24; 40.32]	1.4%
Knoetgen and Moran 2006	4	40 -	-	10				10.00	[3.80; 23.79]	5.3%
Rivera Citarella et al. 2010	2	41 -		-				4.88	[1.22; 17.52]	3.8%
Combined Incidence	91	911	-					9.92	[6.89; 14.06]	81.1%
Heterogeneity: $I^2 = 63\%$, τ^2 :	= 0.3434, p	< 0.01								
Incision = Other										
Hill et al. 2016	2	165 🗖						1.21	[0.30; 4.71]	3.9%
El Khatib 2013	6	205	- 1					2.93	[1.32; 6.36]	6.5%
Nguyen and Rohrich 2006	0	21 -			-			0.00	[0.14; 27.74]	1.4%
El Khatib 2007	0	29 -						0.00	[0.10; 21.72]	1.4%
El Khatib 2007	2	11					-	18.18	[4.58; 50.70]	3.5%
Abramson 2004	1	10 -	-					10.00	[1.39; 46.72]	2.3%
Combined Incidence	11	441 <						3.83	[1.72; 8.30]	18.9%
Heterogeneity: $I^2 = 47\%$, $\tau^2 =$	= 0.3434, <i>p</i>	= 0.09								
Combined Incidence	102	1352	-				-0	8.32	[5.97; 11.49]	100.0%
Heterogeneity: $I^2 = 69\%$, $\tau^2 =$	0.3434, p	< 0.01		1		1	1			
Residual heterogeneity: 12 =	60%, p < 0	.01 0	10	20	30	40 5	50			
	0.0	Aest	hetic	Reinte	rventi	on Rate	e (%)			

Supplementary Figure 2 *Meta-regression forest plots demonstrating that adjunctive arm liposuction, either at the excision cite or circumferentially, reduced the incidence of seroma (a), lymphedema (b), and nerve injury (c), but did not significantly alter the overall complication or reoperation rate.*

Supplementary Figure 2a

Study	Events	Total		Incidence	(%)	95% C.I.	Weight
No Liposuction							
Di Pietro et al. 2018	7	20		_	35 00	[17 68: 57 44]	7.9%
Ferraro et al. 2015	0	30			0.00	[0.10:21.14]	2.9%
Bossert et al. 2013	19	80			23.75	[15.69: 34.27]	9.2%
Migliori et al. 2008	3	29			10.34	[3.37:27.60]	6.9%
Goddio 1989	0	12			0.00	[0.24, 40.32]	2.9%
El Khatib 2007	0	11			0.00	[0.26; 42.46]	2.9%
Combined Incidence	29	182	- Contraction		13.49	[5.47; 29.58]	32.7%
Heterogeneity: $I^2 = 57\%$, τ^2	= 0.8363, p	= 0.04					
Liposuction							
Di Pietro et al. 2018	0	11			0.00	[0.26; 42.46]	2.9%
Bocchiotti et al. 2017	1	73			1.37	[0.19; 9.09]	4.5%
Boccara et al. 2018	6	159	-		3.77	[1.71; 8.14]	8.3%
Simone et al. 2018	0	24			0.00	[0.12; 25.13]	2.9%
Gentileschi et al. 2017	0	12			0.00	[0.24; 40.32]	2.9%
Hill et al. 2016	0	165			0.00	[0.02; 4.63]	2.9%
De Runz et al 2015	0	66 -	<u> </u>		0.00	[0.05; 10.83]	2.9%
El Khatib 2013	0	205			0.00	[0.02; 3.76]	2.9%
Knotts et al. 2014	1	44			2.27	[0.32; 14.45]	4.5%
Bracaglia et al. 2013	1	41	and a second		2.44	[0.34; 15.39]	4.5%
Bossert et al. 2013	12	64			18.75	[10.97; 30.18]	8.9%
Nguyen and Rohrich 2006	0	21	1.00		0.00	[0.14; 27.74]	2.9%
Hurwitz and Jerrod 2010	1	15 -			6.67	[0.93; 35.20]	4.4%
El Khatib 2007	0	29			0.00	[0.10; 21.72]	2.9%
Abramson 2004	0	10			0.00	[0.28; 44.83]	2.9%
Rivera Citarella et al. 2010) 2	41 -			4.88	[1.22; 17.52]	6.1%
Combined Incidence	24	980			3.06	[1.56; 5.93]	67.3%
Heterogeneity: $I^2 = 59\%$, τ^2	= 0.8363, p	< 0.01					
Combined Incidence	53	1162	►		5.06	[2.93; 8.58]	100.0%
Heterogeneity: $I^2 = 71\%$, τ^2	= 0.8363, p	< 0.01					
Residual heterogeneity: 12 =	58%, p < 1	0.01 0	10 20 30 40 50	60			
		Ir	idence of Seroma (%	6)			

Supplementary Figure 2b

Study	Events Total	Incidence	(%)	95% C.I.	Weight
No Liposuction					
Di Pietro et al. 2018	0 20	0	0.00	[0.15; 28.74]	2.9%
Ferraro et al. 2015	0 30 -	0	0.00	[0.10; 21.14]	2.9%
Bossert et al. 2013	1 80	1	.25	[0.18; 8.34]	5.8%
Migliori et al. 2008	4 29	13	3.79	[5.27; 31.49]	20.2%
Goddio 1989	0 12	— 0	0.00	[0.24; 40.32]	2.8%
El Khatib 2007	1 11 🕂 🗖	g	9.09	[1.26; 43.86]	5.3%
Combined Incidence	6 182	6	5.53	[3.19; 12.90]	39.9%
Heterogeneity: $I^2 = 29\%$, τ^2	= 0, <i>p</i> = 0.21				
Liposuction					
Di Pietro et al. 2018	0 11	0	0.00	[0.26; 42.46]	2.8%
Bocchiotti et al. 2017	0 73	0	0.00	[0.04; 9.89]	2.9%
Boccara et al. 2018	0 159	0	0.00	[0.02; 4.79]	2.9%
Simone et al. 2018	0 24	0	0.00	[0.12; 25.13]	2.9%
Gentileschi et al. 2017	0 12	- 0	0.00	[0.24; 40.32]	2.8%
Hill et al. 2016	1 165	0).61	[0.09; 4.17]	5.8%
De Runz et al 2015	0 66	0	0.00	[0.05; 10.83]	2.9%
El Khatib 2013	0 205	0	0.00	[0.02; 3.76]	2.9%
Knotts et al. 2014	0 44	0	0.00	[0.07; 15.43]	2.9%
Bracaglia et al. 2013	0 41	0	0.00	[0.07; 16.38]	2.9%
Bossert et al. 2013	2 64	3	3.12	[0.78; 11.65]	11.3%
Nguyen and Rohrich 2006	0 21	0	0.00	[0.14; 27.74]	2.9%
Hurwitz and Jerrod 2010	0 15	0	0.00	[0.19; 35.03]	2.8%
El Khatib 2007	1 29	3	3.45	[0.48; 20.79]	5.7%
Abramson 2004	0 10		0.00	[0.28; 44.83]	2.8%
Rivera Citarella et al. 2010		0	0.00	[0.07; 16.38]	2.9%
Laters result. $l^2 = 000^{-2}$	4 980	1	.01	[0.88; 2.93]	60.1%
Heterogeneity: $T = 0\%$, $\tau =$	- 0, <i>p</i> = 0.92				
Combined Incidence	10 1162 🔶	2	2.84	[1.79; 4.48]	100.0%
Heterogeneity: $I^2 = 12\%$, τ^2	= 0, p = 0.30				
Residual heterogeneity: 1 ² =	= 0%, p = 0.76 0 10 20 30	40 50			
	Incidence of Lymphe	dema (%)			

Supplementary Figure 2c

Study	Events Total	Incidence (%)	95% C.I. Weight
No Liposuction			
Di Pietro et al. 2018	0 20	0.00	[0.15; 28.74] 3.3%
Ferraro et al. 2015	0 30 -	0.00	[0.10; 21.14] 3.3%
Bossert et al. 2013	0 80	0.00	[0.04; 9.10] 3.3%
Migliori et al. 2008	3 29	10.34	[3.37; 27.60] 18.1%
Goddio 1989	1 12	- 8.33	[1.16; 41.32] 6.2%
El Khatib 2007	0 11	- 0.00	[0.26; 42.46] 3.2%
Combined Incidence	4 182 🖝	5.45	[2.45; 11.69] 37.4%
Heterogeneity: $I^2 = 3\%$, $\tau^2 =$	0, <i>p</i> = 0.40		
Liposuction			
Di Pietro et al. 2018	0 11	- 0.00	[0.26; 42.46] 3.2%
Bocchiotti et al. 2017	0 73	0.00	[0.04; 9.89] 3.3%
Boccara et al. 2018	0 159	0.00	[0.02: 4.79] 3.4%
Simone et al. 2018	0 24	0.00	[0.12; 25.13] 3.3%
Gentileschi et al. 2017	0 12	0.00	[0.24; 40.32] 3.2%
Hill et al. 2016	0 165	0.00	[0.02; 4.63] 3.4%
De Runz et al 2015	2 66 💻	3.03	[0.76; 11.32] 13.0%
El Khatib 2013	0 205	0.00	[0.02; 3.76] 3.4%
Knotts et al. 2014	0 44	0.00	[0.07; 15.43] 3.3%
Bracaglia et al. 2013	0 41	0.00	[0.07; 16.38] 3.3%
Bossert et al. 2013	0 64	0.00	[0.05; 11.13] 3.3%
Nguyen and Rohrich 2006	0 21	0.00	[0.14; 27.74] 3.3%
Hurwitz and Jerrod 2010	0 15	0.00	[0.19; 35.03] 3.3%
El Khatib 2007	0 29	0.00	[0.10; 21.72] 3.3%
Abramson 2004	0 10		[0.28; 44.83] 3.2%
Rivera Citarella et al. 2010	0 41	0.00	[0.07; 16.38] 3.3%
Combined Incidence	2 980 🕊	1.51	[0.80; 2.83] 62.6%
Heterogeneity: $I^2 = 0\%$, $\tau^2 =$	0, <i>p</i> = 0.93		
Combined Incidence	6 1162 🔶	2.45	[1.49; 4.01] 100.0%
Heterogeneity: $I^2 = 0\%$, $\tau^2 =$	0, p = 0.58		
Residual heterogeneity: $I^2 =$	0%, p = 0.88 0 10 20 30 4	40 50 60	
•	Incidence of Nerve I	njury (%)	
Discussion

The previous two analyses demonstrate that contour irregularity plays a role in both the complication and revision rates of commonly performed body contouring procedures. Although heterogeneity is present, owing to the underlying study designs and other factors noted, these serve as the first quantitative synthesis of complication rates of liposuction and brachioplasty in the literature. Furthermore, they provide a valuable reflection and an elaboration on the state of current body of research and outcome reporting, which will hopefully serve to further improve our efforts as we move towards a well-founded evidence-based practice as a community. More importantly, the results emphasize the need for a sound, safe and reliable method of perioperative subcutaneous adipose tissue measurement and distribution in an objective manner. As in the example of contour irregularities, and given the nature of this complication, such a method may be instrumental in providing insight to the surgeon and allowing for improved patient outcomes.

While this work sheds light on a particular set of procedures the realm of adipose tissue manipulation to specifically underscore the need for more refined and objective methods of assessment, this does not, in any way, preclude the utility of an ultrasound-based evaluation in reconstructive surgery applications. Indeed, the potential benefit of this assessment tool in addressing donor sites in tissue flap-based reconstruction following cancer extirpation or trauma can be critical.

Conclusion and future directions

Objective quantification of subcutaneous adipose tissue has a potentially considerable role to play in the plastic and reconstructive surgeon's armamentarium. The synthesized data provided highlights the necessity and possible avenues of application of an ultrasound-based assessment tool, a subset of the larger role it can assume in this discipline. By automating the method ultrasound is used to provide volume and distribution of underlying adipose stores, we pave the way towards improving patient outcomes. The next steps of our study will address utilizing and further calibrating and refining our analysis software and assessment protocol in the clinical setting. The software developed in our lab processes input measurements (depth of adipose tissue) within an area of interest and subsequently produces a volumetric estimate, and a representative diagram of the subcutaneous adipose tissue stores (i.e. "heat map" of fat distribution). We aim to begin clinical testing as a proof of concept and pilot study to gauge its precision and effects on patient care. Ultimately, the prospect of developing real-time, intraoperative, assessment of fat tissue distribution can produce a paradigm shift in the way certain procedures are performed.

References

- Macadam SA, Bovill ES, Buchel EW, et al. Evidence-Based Medicine: Autologous Breast Reconstruction. *Plast Reconstr Surg.* 2017 Jan;139(1):204e-229e.
- Chia CT, Neinstein RM, Theodorou SJ. Evidence-Based Medicine: Liposuction. *Plast Reconstr Surg.* 2017;139(1):267e-274e.
- Khouri RK Jr, Khouri RK. Current Clinical Applications of Fat Grafting. *Plast Reconstr* Surg. 2017 Sep;140(3):466e-486e.
- Azzi AJ, Lafrenière AS, Gilardino M, et al. Ultrasonography Technique in Abdominal Subcutaneous Adipose Tissue Measurement: A Systematic Review. *J Ultrasound Med.* 2019 Apr;38(4):877-888.
- Azzi AJ, Lafrenière AS, Viezel-Mathieu A, et al. Objective Quantification of Liposuction Results. *J Cutan Aesthet Surg.* 2018 Jul-Sep;11(3):105-109.
- Shermak MA. Aesthetic refinements in body contouring in the massive weight loss patient: Part 2. Arms. *Plast Reconstr Surg.* 2014;134(5):726e-735e.